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The overall objectives of this work are to develop methods for the quality 
control of Panax notoginseng, and to study the effects of processing on the chemical 
and biological differences between raw and steamed P. notoginseng.  
A new HPLC-DAD method has been developed and validated for the analysis 
of saponins in raw and steamed P. notoginseng roots, and in products from various 
sources. P. ginseng and P. quinquefolium were also compared to P. notoginseng. 
Simultaneous quantification of six saponins (R1, Rg1, Re, Rb1, Rc and Rd) in P. 
notoginseng showed that the concentrations of these saponins decreased significantly 
upon steam processing. A chromatographic pattern matching analysis tool was 
employed, optimised and successfully applied to the differentiation of the roots and 
products, showing that it is a useful tool in assessing the quality of herbal products. 
Key marker compounds in the extract of steamed P. notoginseng which 
differentiate the two forms were isolated and identified. Their identities were 20S-
ginsenoside Rh1, 20R-ginsenoside Rh1, 20S-ginsenoside Rg3, 20R-ginsenoside Rg3, 
ginsenosides Rk3, Rh4, Rk1 and Rg5. This is the first report of isolation of 
ginsenosides Rk1 and Rk3 from P. notoginseng roots. 
Besides saponins, P. notoginseng is known to contain dencichine, a bioactive 
polar amino acid derivative with haemostatic activities. In this work, a novel 
HILIC/ESI-MS/MS method was successfully developed and validated for the analysis 
of underivatised dencichine in Panax species, providing rapid analysis in five minutes, 
high selectivity and sensitivity without the need for sample derivatisation. Raw P. 
notoginseng samples were found to have significantly higher quantities of dencichine 
than steamed samples, and the concentrations of dencichine in P. ginseng and P. 
 x
quinquefolium were significantly lower than those in raw P. notoginseng, thereby 
explaining their different indications.  
Haematological activities (platelet aggregation and blood coagulation 
activities) of the raw and steamed samples and their key chemical components were 
investigated in vitro and ex vivo. Steamed samples resulted in significantly greater 
inhibition of platelet aggregations and longer coagulation times than raw samples. P. 
ginseng and P. quinquefolium generally exhibited lower activities. Ginsenoside Rg5 
(98 µM) and 20S-ginsenoside Rg3 (92 µM) have better antiplatelet activities 
compared to aspirin (131 µM), indicating that they are potential leads for antiplatelet 
drugs. In vivo tail bleeding time (haemostatic) assays further showed that both forms 
of P. notoginseng have anti-haemostatic activities, with the steamed form being 
significantly more effective than the raw form. 
In conclusion, the results support the hypothesis that steaming of raw P. 
notoginseng roots changes the concentration and composition of chemical 
components in P. notoginseng. The two forms and its related species have been 
successfully differentiated. In addition, the chemical changes upon steam processing 
have an important impact on their activities, with the steamed form and some of its 
components having potentially good antithrombotic activities. The methods 
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1.1 Herbal medicines 
1.1.1 Importance of herbal medicines  
Traditional medicine, as defined by the World Health Organisation (WHO), 
refers to health practices, approaches, knowledge and beliefs incorporating plant, 
animal and mineral based medicines, spiritual therapies, manual techniques and 
exercises, applied singularly or in combination to treat, diagnose and prevent illnesses 
or maintain well-being [WHO, 2003a]. In industrialised countries, adaptations of 
traditional medicine are termed complementary and alternative medicine (CAM), and 
it is often used interchangeably with traditional medicine. CAM is also broadly 
defined by National Center for Complementary and Alternative Medicine (NCCAM) 
as a group of diverse medical and health care systems, practices, and products that are 
not presently considered to be part of conventional medicine [NCCAM, 2006; Barnes 
et al., 2004]. Herbal medicines (also known as botanical medicines, phytomedicines, 
natural products), which is a part of traditional medicine or CAM, refers to any herbs, 
herbal materials, herbal preparations and finished herbal products [WHO, 2002]. 
According to World Health Organisation [WHO, 2003a], the global market for 
herbal medicines currently stands at over US$60 billion annually and this figure is 
growing steadily, with a projected US$400 billion market by 2010 [Wang and Ren, 
2002]. It is estimated that 65-80% of the world’s population use traditional medicine 
as the primary form of healthcare [WHO, 2003a]. Traditional herbal preparations 
account for 30-50% of the total medicinal consumption in China. In the United States, 
158 million of the adult population use complementary medicines and according to 
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the USA Commission for Alternative and Complementary medicines, US$17 billion 
was spent on traditional remedies in 2000 [WHO, 2003a]. In one of the most 
comprehensive updated survey on CAM [Barnes et al., 2004], 62% of U.S. adults 
used some form of CAM and natural products is among the top three most prevalent 
types of CAM used by about 19% of the population. In the United Kingdom, annual 
expenditure on alternative medicines is US$230 million [WHO, 2003a]. These 
statistics showed the growing worldwide importance of herbal medicines in both 
developing and industrialised countries. In developing countries, the broad use of 
herbal medicines is often attributed to its accessibility, affordability and their cultural 
beliefs. While in many developed countries, the increasing use of herbal medicines is 
often fuelled by concerns regarding adverse effects and unsatisfactory treatments from 
modern western drugs, the need for apparently milder treatments for chronic 
debilitating diseases, and greater public access to health information [WHO, 2002].  
In response to the widespread use of herbal medicines, there is growing 
awareness of its safety, efficacy, quality and regulatory control by healthcare 
professionals, regulatory authorities of different countries and the public. Policy 
makers are faced with these challenges and are developing various strategies for 
ensuring good practices of herbal medicines and its integration into modern medicine. 
Western medicine emphasises the use of a rigorous scientific approach. However, for 
herbal medicine, such scientific evidences are still far from sufficient to meet the 
criteria needed to support its worldwide use. Fortunately, research on herbal 
medicines has been increasing over the years and these can be seen by the increase in 
funding and establishment of CAM research and research units in both developed and 
developing countries [WHO, 2002; NCCAM, 2004]. 
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1.1.2 Safety of herbal medicines 
1.1.2.1 Incidences of adverse effects 
Despite the common belief that natural herbal medicines are safer than 
western medicine, there are risks and adverse effects associated with herbal medicines. 
Due to inadequate documentations, at present, there is still limited data to indicate 
reliable incidence figures for adverse events related to herbal medicines. In an active 
adverse drug reaction reporting programme in a Taiwan hospital, Chinese crude drugs 
were responsible for 22% of hospital admissions and 12% of all adverse effects [Ernst, 
2004]. In two general wards of a Hong Kong hospital, 0.2% of cases were due to 
adverse reactions to traditional Chinese herbal medicines [Ernst, 2004]. Australian 
practitioners of traditional Chinese medicine estimated an average of 1.4 adverse 
events during each year of full-time practice.  
 
1.1.2.2 Intrinsic adverse effects 
The adverse effects or toxicities resulting from herbal medicines can be 
classified into two main categories. The first category is the intrinsic or plant-
associated health risks due to active ingredients in the plant. These can be predictable, 
dose-dependent reactions due to their pharmacological effects (Type A) or 
idiosyncratic reactions not predictable from their pharmacology (Type B), such as 
allergy and anaphylaxis. For herbal medicines, Type C adverse reactions involve 
those that are pharmacologically predictable and develop gradually during long-term 
use (e.g. slowed bowel function upon long term use of stimulant herbal laxatives), 
while Type D reactions are effects with a latency period of months or years (e.g. 
mutagenic effects) [Ernst, 2005a]. Type A dose-dependent reactions with herbal 
preparations will also include effects with deliberate overdose or accidental poisoning 
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and interactions with pharmaceuticals [Drew and Myers, 1997; Pinn, 2001, Myers and 
Cheras, 2004]. As herbal medicines are often taken complementarily with therapeutic 
drugs, drug-herb interactions have been a major safety concern, especially when 
healthcare professionals are often unaware of the type of herbal medicines that 
patients have been self-administering. These interactions may increase or decrease the 
pharmacological or toxicological effects of the drugs or herbs. Some of the well-
known interactions with clinical significance have been extensively reviewed [Fugh-
Berman, 2000; Hu et al., 2005; Tirona and Bailey, 2006]. Therefore, to ensure the 
safety of complementary medicines, the Australia New Zealand Therapeutic Products 
Authority [ANZTPA, 2006] has recently recommended a two-tier regulatory system 
based on the level of risk of the medicine. 
 
1.1.2.3 Extrinsic adverse effects 
The second category is extrinsic or non-plant-associated adverse effects, 
which include factors such as contamination (with heavy metals, pesticides, micro-
organisms, microbial toxins, radioactive substances etc), adulteration (accidental or 
intentional), misidentification, substitution, lack of standardisation, incorrect 
preparation/ dosage, and inappropriate labelling/ advertising [Drew and Myers, 1997]. 
These additional extrinsic factors make it more complicated for health professionals 
to assess the adverse effects of herbal preparations, as compared to conventional 
pharmaceuticals. Heavy metals are sometimes added intentionally for traditional uses, 
or it can arise unintentionally from environmental, cultivation and manufacturing 
processes. The levels of contamination have to be controlled to prevent heavy metal 
toxicities. Adulteration with synthetic drugs is a problem which may result in serious 
adverse effects in patients. For example, the addition of steroids, tranquillisers, non-
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steroidal anti-inflammatory drugs (NSAIDs) or phosphodiesterase-5 inhibitors, into 
Chinese herbal preparations increases the likelihood of effectiveness but may place 
patients at risk of their adverse effects, and over-dosage of the drugs (if they are 
already taking these prescribed drugs). In fact, several herbal products have caused 
toxicity and have been withdrawn from the market due to the presence of these 
synthetic drugs, and toxic heavy metals such as mercury, arsenic, lead and copper 
[Ernst, 2004; Koh and Woo, 2000]. This issue is further discussed in Section 1.1.4.3. 
Misidentification often occurs when the plant species look similar or when several 
similar but confusing names are used. This may result in erroneous usage, with 
potential clinical implications. Toxic reactions have been reported when the plants 
have been substituted with another similar but toxic plant. One classic example is 
Stephania tetrandra (Fen fangji), a traditional diuretic, anti-rheumatic and pain 
reliever, which have been mistakenly substituted with Aristolochia fangchi (Guang 
fangji). Both herbs have rather similar external morphology and Chinese names. The 
latter contain nephrotoxic components, the aristolochic acids, which result in many 
cases of serious renal failure [Pinn, 2001]. Furthermore, substitution with inferior 
commercial varieties by unethical practices may result in potential inefficacy and 
adverse effects. The different preparation or processing methods for herbal medicines 
can also increase the efficacy or reduce the toxicity of some herbs, so incorrect 
preparation methods may result in adverse effects. Similar to western medicines, 
correct labelling is also important to provide the right information and it should not 
mislead patients. In view of this problem, some countries (e.g. Singapore, Hong Kong) 
have regulations to control the label contents of herbal products. To add on to the 
complexity, the therapeutic and toxic components of plants may vary due to many 
environmental factors, cultivation and post-harvesting conditions, so these variations 
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in their components due to lack of standardisation may lead to inefficacy or potential 
adverse effects in some cases.  
From the above intrinsic and extrinsic factors, it can be seen that naturally 
occurring herbs are not necessarily harmless despite being natural. Long traditional 
history of usage is not a guarantee for its safety and the risks of herbal medicines need 
to be evaluated systematically with safety and toxicological studies, as well as post 
marketing surveillance studies [WHO, 2004]. These problems of herbal medicines 
highlighted the importance of implementing good quality control, standardisation and 
improved regulations/ policies to ensure their safety.  
 
1.1.3 Efficacy of herbal medicines 
The efficacy of herbal medicines is often based on traditional uses and claims. 
Although several herbal medicines have a long history of use, this does not guarantee 
their efficacy. Healthcare professionals practice modern medicine, which is based on 
evidence-based medical science, so it is difficult for them to accept treatments that 
lacked sound scientific data to support its efficacy claims [Mahady et al., 2001]. 
Furthermore, practitioners may not be able to recommend and advise patients on 
herbal medicines accurately without well-established efficacy data. Therefore, there is 
a need for rigorous scientific investigations in order to prove and explain the uses, 
discover new uses, understand the mechanisms of actions and finally, to bring herbal 
medicines into mainstream medicine. Similar to western medicine, in vitro and in vivo 
studies are often used to first test its efficacy in the initial preclinical stages. Well-
designed, multi-centred, randomised, double-blind, placebo-controlled clinical studies 
involving significant number of human subjects are then needed to prove the efficacy 
of herbal medicines in humans. Although anecdotal reports of utility are of interest, 
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particularly in giving indications of the herbal medicines worthy of intensive study, 
they may not be viewed as a substitute for detailed scientific studies and clinical trials. 
In recent years, there are increasing numbers of randomised clinical trials of herbal 
medicines being published and systematic reviews/ meta-analyses of these studies 
have become increasingly available [Ernst, 2005b].  
However, the evaluation of pre-clinical and clinical efficacy of herbal 
medicines is a more challenging and complicated process than synthetic medicines 
[Fong et al., 2006]. Some traditional effects or terms used in traditional medicine (e.g. 
yin and yang) are difficult to prove using modern scientific methods. Furthermore, 
herbal medicines contain a range of pharmacologically active compounds and it is 
usually not known which compounds are important for therapeutic effects. Isolated 
components may have different effects from the whole plant extracts. According to 
traditional practice, efficacy is often attributed to multiple components in the extracts 
and this concept is increasingly being accepted by many countries and the WHO [Xie 
and Wong, 2005]. The different components may have synergistic, cumulative, 
complementary effects or even antagonistic effects. This is an area where there is 
much speculation but relatively little concrete knowledge to date. These multi-
component characteristics of herbal medicines render efficacy testing more complex 
[Ernst, 2005b]. The current methods of standardisation of a few components may not 
be sufficient to ensure consistencies of the whole herbal extracts, as variation of other 
components may still remain. As a result of such lack of quality control, 
reproducibility of efficacy studies may be affected. Therefore, the key challenges to 
efficacy and safety assessments, as summarised by Fong et al. [2006], are the quality 
of raw materials, appropriateness of the activity assessment, data interpretation, 
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standardisation methodology, pharmacokinetics and bioavailability of the active 
components, dosage formulation, clinical study designs and outcome measures.  
 
1.1.4 Quality of herbal medicines 
Safety, efficacy and quality are three inter-related factors which are essential 
for all synthetic medicines. As both the safety and efficacy are mainly affected by the 
type and amount of chemical constituents and contaminations present, quality 
assurance of herbal medicines is critical and proper regulations are needed to ensure 
compliance to the quality standards. 
 
1.1.4.1 Factors affecting quality 
Unlike synthetic drugs, herbal medicines present a set of unique problems 
when quality aspects are considered. The variations of botanicals are due to several 
factors such as strains and species differences, organ specificity, climate, geography, 
seasonal variation, cultivation, harvesting, storage, transportation, post-harvest 
treatment, manufacturing practices, adulteration, substitution and contamination 
[Mahady et al., 2001].  
Botanicals of the same species may have different genetic makeup or belong 
to different strains or varieties. For example, the accumulation of hypericin in 
Hypericum perforatum is greater in the narrow leafed populations than the broader 
leafed varieties. It is also known that closely related species in the same family differ 
in their contents. Therefore, it is necessary that the starting material is accurately 
identified by their Latin scientific names and authenticated. The use of common 
names is inadequate as they may refer to more than one species. The site of chemical 
biosynthesis, accumulation and storage are also different in different plant parts, e.g., 
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the ginsenosides content in Panax ginseng leaves and roots are different, and hence it 
is important that the right plant part is used.  
Seasonal variation is an important factor affecting chemical accumulation. 
Depending on the plant, accumulation of chemical constituents can occur at any time 
during the various stages of their growth. Different times of the same day may even 
influence the chemical contents for some plants such as Ginkgo biloba [Scholten, 
2003]. Therefore, plants may need to be harvested during specific periods. The 
cultivation methods, climate and conditions such as soil, light, water, temperature, 
nutrients further complicate the phytochemical accumulation. The physical 
appearance and chemical quality of botanicals can also be influenced by methods 
employed in field collection, harvesting, post-harvesting and manufacturing methods, 
shipping and storage. Moreover, contaminations by micro-organisms, fungi, 
aflatoxins, chemical agents (pesticides, herbicides, heavy metals), inorganic matters, 
as well as by foreign organic matters such as other plant parts, insect parts, animal 
parts and excreta during any stages of plant material production can affect its quality 
and lead to unsafe products [Mahady et al., 2001]. In view of the numerous 
influencing factors, it is difficult to obtain standardised extracts and consistent 
qualities, so quality assurance of herbal medicines is definitely a complex problem 
that needs to be addressed. 
 
1.1.4.2 Good Practices for total quality assurance 
The current lack of uniform quality among herbal medicines and cases of 
adverse effects undermine consumers’ and healthcare professionals’ confidence. 
Herbal medicines are often marketed as dietary supplements, so their qualities are 
largely unregulated as compared to the stringent requirements necessary for synthetic 
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drugs. Fortunately, there are growing worldwide awareness and emphasis to regulate 
herbal medicines to ensure batch to batch consistency. To address the problems of 
variation in herbal medicines, a good total quality assurance system using a multi-
pronged approach is needed. The quality assurance of synthetic drugs is mainly 
affected through production under good manufacturing practices (GMP) which is 
mandated by Food and Drug Administration (FDA). Similar to synthetic drugs, GMP 
regulations should also be imposed on botanical drugs [WHO, 2005]. However, GMP 
alone will not be sufficient to assure quality, due to the numerous factors and 
processes which can affect the chemical composition of botanicals.  
The quality control measures should ideally start from the point of cultivation 
with good agricultural practices (GAP). GAP is a set of guidelines that requires 
botanical identification and regulation/ standardisation of every step involved in the 
cultivation process from field collection to post-harvesting processing, storage and 
transportation. The standards are not easily attainable as there are many steps to 
control. However, this is the first important step to ensure the quality of raw materials. 
GMP procedures employed for botanical products are similar to those used for the 
manufacturing of synthetic drugs, except for some special procedures and precautions 
specific for botanical products. In fact, there is increasing emphasis to ensure quality 
as WHO has published some general guidelines for GAP and GMP production of 
botanical products [WHO, 2003b; WHO, 2005a]. Besides GAP and GMP, good 
laboratory practices (GLP), good clinical practices (GCP), and good supply/ selling 
practices (GSP) are also needed [Cheng et al., 2006; Chan, 2005]. These are the broad 
guidelines for total quality assurance and the whole development process of herbal 
medicines into good quality products for patients’ use. 
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1.1.4.3 Detection of contamination and identification of herbal medicines by 
chemical analyses 
One aspect of quality control of herbal medicines includes testing for the 
presence of various contaminants such as micro-organisms, toxins, heavy metals, 
pesticides and synthetic drugs [Koh and Woo, 2000; Zou et al., 2006; Lau et al., 
2003]. Regulatory control and guidelines on the analysis of some of these 
contaminants in botanical medicines/ Chinese Proprietary Medicines (CPMs) are 
available [Yee et al., 2005; Health Sciences Authority, 2006; WHO, 2005b].  
Besides detection of contamination, another important role of quality control 
is to ensure the correct identity of botanicals. The methods which have been employed 
for identification and authentication of botanicals [Zhao et al., 2006] involve various 
taxonomic, physical, chemical and DNA molecular biology methods. Taxonomic 
identification using macroscopic, microscopic, organoleptic analyses have to be 
performed to assure the species identity and purity at various processing stages 
[Mahady et al., 2001]. These analyses may be subjective and highly dependent on the 
experience and skills of the evaluator to recognise the various types of medicinal 
plants and their microscopic features. This is increasingly difficult when the various 
species are very similar or when the substituted herb closely resembles the genuine 
material [Shim et al., 2005]. Dangerous errors in identification may occur such as 
misidentification and substitution of Stephania tetrandra resulting in renal failures 
(Section 1.1.2.3). In addition, it may not be sensitive enough for detecting small 
amounts of substitution or when there is a mixture of several herbs in the preparations. 
At times, the whole plant may not be available or the samples may be processed into 
final dosage forms (e.g. powder, tablets), thus rendering it difficult to identify by 
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morphological analysis [Yuan and Hong, 2003]. Alternative methods will be 
necessary in such cases.  
Qualitative analysis of specific unique marker components using various 
chemical methods has been commonly used for species identification. It has the 
advantage of being able to analyse various types of dosage forms, mixture of herbs 
and different parts of the same species. However, identification based on markers 
requires knowledge of specific chemical characteristics of the medicinal herb. If the 
component is not unique in the species, it may be difficult to identify using a few 
chemical components and the results may not be conclusive. Furthermore, many of 
the intrinsic and extrinsic factors such as environment and development stages, 
conditions of cultivation, geographical sources, age and processing methods, may 
affect the chemical contents and marker components.  
 
1.1.4.4 DNA fingerprinting 
With the advancement of molecular biology, genetic or DNA fingerprinting of 
medicinal plants has been increasingly used for species identification. Unlike 
chemical identification, DNA analysis will not be affected by the variability in 
chemical components and it is non-tissue specific. It has been frequently used to 
identify the strain and origin of herbal medicines, to detect them at any phase of 
organism growth, as well as to differentiate them from adulterants/ substitutes or other 
species [Shim et al., 2005]. Unlike morphological analysis, it is less subjective and is 
suitable for closely resembling species. One limitation of DNA fingerprinting is that it 
will not differentiate different parts of the same plant and plants that have undergone 
different processing methods. It is usually done on fresh plant samples, as DNA is 
destroyed by harsh processing methods and is not intact in final dosage forms; 
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therefore making it unsuitable for the analysis of final herbal products and in-line 
process monitoring. Moreover, all the genotypic differences may not be translated 
into phenotypic differences in terms of chemical composition or contents and efficacy 
[Hong and Guo, 2006]. Therefore, chemical analysis is still needed to supplement the 
genetic information.  
 
1.1.4.5 Standardisation 
In addition to species authentication/ identification, quality control also 
involves standardising or controlling the contents of chemical components present in 
the botanicals to ensure consistent quality, safety and efficacy between batches. Some 
of the older analytical techniques include colorimetric and spectroscopic analyses 
which quantify the absorption of structurally related compounds at certain 
wavelengths. As several constituents may absorb at the same wavelengths, the 
methods are non-specific, and purification is needed before the analysis of a particular 
class of compounds, thereby their usage has been declining [Mahady et al., 2001].  
In recent years, with the advancement of analytical techniques, 
chromatographic techniques which have powerful separation abilities, have been the 
methods of choice for the analysis of the wide array of chemical constituents [Mahady 
et al., 2001]. The common analytical and separation methods include thin layer 
chromatography (TLC), high-performance thin layer chromatography (HPTLC), gas 
chromatography (GC), high performance liquid chromatography (HPLC), capillary 
electrophoresis (CE), near infrared (NIR) and the various hyphenated methods such as 
liquid chromatography-mass spectrometry (LC-MS), GC-MS, LC-nuclear magnetic 
resonance (NMR), hyphenated capillary electrophoresis etc [Liang et al., 2004]. 
Hyphenated techniques showed improved performances in terms of elimination of 
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instrumental interferences, correction of retention time shift, increase selectivity, 
precision and separation abilities. They provide additional spectral information, which 
is helpful for qualitative analysis and structural elucidation [Liang et al., 2004].  
Quality control using single active constituent is well established for synthetic 
pharmaceuticals. In general, a few pharmacologically active components are also 
widely employed for standardisation of the contents, and evaluation of the quality, 
authenticity, identity and quantitative chemical composition of medicinal herbs or 
preparations. For example, St John’s Wort products are standardised to 0.3% w/w 
hypericin and Panax ginseng extract G115 has been standardised to 4% w/w total 
ginsenosides. However, there are many challenges facing standardisation of herbal 
medicines. A single herb often contains numerous natural components, so a 
combination of several herbs in herbal products may give rise to hundreds of 
components. This wide array of constituents makes the analysis more complex as 
compared to conventional drugs with only a single active compound. Since not all 
active components have been isolated, characterised or quantified, so many of their 
identities and activities remain unknown and many chemical standards are unavailable 
for quality control.  
The choice of marker components that is representative of the whole botanical 
is difficult. For example, some researchers questioned [Fedec and Kolodziejczyk, 
2000] the standardisation of St John’s Wort based on hypericin, as other components 
also have antidepressant activities. In addition, the methods of extraction and sample 
preparation are also of importance in affecting the standardisation and quality control 
process, as the quantities of components varies with the methods of sample 
preparation. Although the quantities of a few markers are appropriate and consistent, 
it cannot be assumed that the quantities of other components are also consistent. As 
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the presence of multiple components may work together synergistically or 
complementarily to give therapeutic effects, so a few markers may not effectively 
represent the entire mixture. It does provide a criterion for quality control but may not 
be adequate to ensure therapeutic uniformity and the reliability of pharmacological 
and clinical research [Tyler, 1999]. Therefore, it is deemed necessary to develop 
quality control methods which regard the whole herbal preparation as a whole active 
‘compound’ [Liang et al., 2004]. 
 
1.1.4.6 Chemical fingerprinting 
In view of the above limitations of analysing a few components, in recent 
years, the use of chemical fingerprinting for the identification, standardisation and 
quality control of medicinal herbs has attracted a lot of interest. Chemical 
fingerprinting, which is a macro-analytical approach to evaluate the complex 
characteristics of medicinal herbs, usually utilises chromatographic methods 
(chromatographic fingerprinting) and the entire chromatogram’s characteristics to 
achieve overall quality assessment and classification [Xie and Wong, 2005]. The 
chromatographic fingerprint is therefore a pattern of the chemical components in the 
extracts. Besides chromatography, other methods of chemical fingerprinting such as 
the use of modern Fourier transform infra-red spectroscopy (FT-IR) have also been 
established [Sun, 2006]. Instead of using only a few selected markers, fingerprinting 
is increasingly recommended and accepted as a better solution for quality control. In 
fact, chromatographic fingerprinting is one of the recommendations proposed by US 
FDA for botanicals [US FDA, 2004] and The European Agency for the Evaluation of 
Medicinal Products for herbal preparations [The European agency for the evaluation 
of medicinal products, 2000], as the fingerprints are unique and represent powerful 
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tools for the comparison, classification, identification and evaluation of samples. In 
Germany, the concept of ‘phytoequivalence’ was first developed [Tyler, 1999] to 
ensure consistency of herbal products. According to this concept, a chemical profile 
should be constructed and compared with the profile of a clinically proven reference 
product, and this is basically achieved by chemical fingerprinting methods. 
Herbal medicines contain hundreds of unknown components of unknown 
activities and many of them are in low quantities. Moreover, there may be large 
variability within the same medicinal herb due to the various factors influencing 
quality (Section 1.1.4.1). Consequently, obtaining reliable chromatographic 
fingerprints that represent pharmacologically active and chemically characteristic 
components is not an easy or trivial task. After obtaining the fingerprints with the 
various analytical techniques, including the hyphenated techniques, the challenge is to 
efficiently evaluate the obtained fingerprints and to use the information to address the 
problems of quality control. Visual methods have been used for qualitative 
comparisons of chromatograms. With the help of chemometrics, a newer discipline 
developed both in chemistry and statistics, research on the evaluation of the 
chromatographic fingerprints have been ongoing [Liang et al., 2004]. More research 
on the chemical fingerprinting methods and evaluation of fingerprints are necessary. 
Since quality control is an essential prerequisite for ensuring their safety and 
efficacy, accurate assessment of quality is a critical step towards the widespread 
acceptance of herbal medicines. As seen from the above discussion, no single method 
is currently a perfect solution and multiple methods are usually needed for greater 
confidence of its quality [Liang et al., 2004]. Therefore, currently, one of the 
important challenges is to develop better methods and solutions for the quality 
assurance of herbal medicines. 
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1.2 Importance of antithrombotic and haemostatic therapies 
1.2.1 Antithrombotic therapies 
Cardiovascular diseases are leading causes of death and disability in the 
general world population, and more so amongst the elderly. Incidences have been 
rising due to unhealthy diets with high cholesterol food, affluent lifestyles and 
decreased physical activities. It is projected by WHO [WHO, 2003c] that 
cardiovascular diseases will be the leading killer in developed countries by 2010. 
Coronary heart diseases constitute one out of every five deaths in United States 
[American Heart Association, 2006]. In Singapore, for the past three years, ischaemic 
and other cardiovascular diseases contribute to the second while cerebrovascular 
diseases (including stroke) contribute to the fourth most common overall causes of 
death [Ministry of Health, 2005]. These diseases (contributing to 32% of total deaths) 
are also among the top ten conditions for hospitalisations [Ministry of Health, 2005]. 
Therefore, the continuous search for effective treatments for cardiovascular diseases 
is important, especially when the population is aging in many developed countries. 
Blood platelet activation is fundamental to a wide range of physiologic and 
pathologic processes. The platelets play a critical role not only in normal haemostasis 
but also in thrombosis at damaged blood vessels or in regions of disturbed blood flow 
and blood stasis. Thrombus formation occurs through the inappropriate activation and 
aggregation of platelets. Arterial thrombi are formed under high shear conditions and 
are primarily composed of platelet aggregates held together by fibrin strands. The 
platelets also play a major part in both the initiation and growth of the venous thrombi, 
which are formed under low shear conditions and compose predominantly of fibrin 
and red cells. These evidences have led to postulations that platelet aggregation is a 
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major pathogenic mechanism in thrombosis, which leads to occlusion of blood vessels 
and ischemic injuries [Freson et al., 2006].  
Aspirin, a non-steroidal anti-inflammatory drug (NSAID), is an example of an 
antiplatelet drug that is often used clinically to treat and prevent thrombotic events 
such as myocardial infarction, coronary heart disease, venous thromboembolism, deep 
vein thrombosis. It causes irreversible acetylation of hydroxyl group of the serine 
residue (Ser 530) in cyclooxygenase-1 within platelets, thereby preventing the 
biosynthesis of thromboxane A2 (TxA2), a potent vasoconstrictor and promoter of 
platelet aggregation [Vane and Botting, 2003]. As platelets are unable to regenerate 
cyclooxygenase, the effect remains for the lifespan of the platelet (8-10 days). 
However, the main drawback of long term usage of aspirin is the increase in the risk 
of gastrointestinal bleeding [Weisman and Graham, 2002]. Ticlopidine and 
clopidogrel are thienopyridine derivatives, belonging to another class of clinically 
used antiplatelet drugs, which covalently bind to platelet P2Y12 adenosine 
diphosphate (ADP) receptor and reduce platelet activation [Jacobson, 2004]. 
Ticlopidine, however, causes thrombocytopenia, neutropenia and aplastic anaemia. 
Clopidogrel has superseded ticlopidine as the drug of choice, but it causes diarrhoea 
and skin rashes. Dipyridamole, on the other hand, is a phosphodiesterase inhibitor 
which inactivates cyclic adenosine monophosphate (cAMP) and reduces activation of 
cytoplasmic second messengers. It also stimulates prostacyclin release and inhibits 
thromboxane A2 formation, thereby inhibiting platelet function, but its effects may be 
short lasting and limited [Hankey and Eikelboom, 2003]. 
After the formation of primary haemostatic plug, the activated platelets 
facilitate the assembly of coagulation factors on the activated platelet membrane, 
which leads to generation of thrombin and the subsequent formation of fibrin around 
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the platelet aggregates, thereby stabilising the initial platelet plug. Therefore, the 
activation of blood coagulation cascade plays an etiological role in several thrombotic 
disorders such as unstable angina, deep vein thrombosis, disseminated intravascular 
coagulation. Two commonly used anticoagulant drugs used to treat such clinical 
conditions include heparin and warfarin. Heparin binds to antithrombin III (AT-III), 
which results in its enhanced affinity to several activated forms of factors, namely 
Factors IIa (thrombin), Xa and IXa. This binding renders the factors inactive. 
However, it has to be given parenterally, either intravenously or subcutaneously 
[Mueller, 2004]. Warfarin, an oral anticoagulant, is a coumarin which acts as an 
inhibitor of vitamin K epoxide reductase in the hepatocytes, thereby inhibiting the 
synthesis of vitamin K-dependent clotting factors such as II, VII, IX and X [Mueller, 
2004]. However, warfarin has a narrow therapeutic index and haemorrhages are 
common complications when the plasma drugs levels are increased. Correct dosing 
and close monitoring of warfarin therapy are necessary. Another potential problem is 
it has many drug interactions with other drugs, herbs and even vitamin K-rich food, 
thus increasing the risk of adverse effects [Holbrook et al., 2005]. 
In view of the above, inhibitions of platelet function and coagulation pathways 
represent a very promising approach for the clinical prevention of thrombosis in 
pathological conditions. The current strategies that have been used to prevent or treat 
thrombotic disorders involve targeting the various steps in coagulation and platelet 
function. The thrombi are the source of thromboembolic complications of 
cardiovascular diseases such as arteriosclerosis, heart attacks, strokes, peripheral 
vascular diseases and angina, all of which represent the leading causes of morbidity 
and mortality. Therefore, with thrombosis playing the central role in the 
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pathophysiology of many cardiovascular diseases, the search for better antithrombotic 
medicines continues to be important. 
Besides synthetic drugs, researchers have been looking for novel active 
compounds and active extracts from a wide variety of botanicals and dietary sources, 
especially when the adverse effects of herbal medicines may seem comparatively less 
severe than synthetic drugs. In view of the importance of antithrombotic therapy in 
cardiovascular diseases, medicinal herbs and their phyto-components that prevent 
thrombosis by inhibition of either platelet functions or coagulation pathways are, 
therefore, of special therapeutic interest. Several Chinese traditional herbs such as 
Salvia miltiorrhizae, Ligusticum chuanxiong, Panax ginseng, Angelica sinensis, have 
been traditionally said to have antithrombotic activities and are consumed to treat or 
prevent cardiovascular diseases [Zhu, 1998]. Recently, a comprehensive list of 
medicinal plants was found to be potential sources of lead compounds for antiplatelet 
and anticoagulant activities. Many examples of natural compounds in these medicinal 
plants/herbs and foods were identified as active antiplatelet or anticoagulant agents 
[Chua and Koh, 2006] and the search for good and safer novel antithrombotics is still 
ongoing. 
 
1.2.2 Haemostatic therapies 
Bleeding is an undesirable event which can occur after trauma, surgery, 
pathologic conditions or pharmacologic treatment with antiplatelet, anticoagulant, or 
thrombolytic therapies. When bleeding is the consequence of a specific defect of 
haemostasis, the goal of treatment is to correct the defect. For example, haemophilia 
is treated by transfusion of Factor VIII. Vitamin K is used for vitamin K deficiency 
bleeding and in warfarin overdoses. In very severe cases of bleeding, blood 
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transfusions are warranted. However, specific treatment may be impossible when 
bleeding is a result of multiple defects, or sometimes, when no specific cause can be 
identified. Non-transfusional drugs are important in such situations [Mannucci, 1998]. 
The haemostatic drugs used clinically include antifibrinolytic amino acids 
(aminocaproic acid and tranexamic acid), aprotinin, desmopressin, ethamsylate and 
conjugated estrogens [Mannucci, 1998]. Most of these drugs are used systemically to 
counteract severe cases of bleeding [White et al., 2000; White et al., 2001]. There are 
few established agents for less severe bleeding conditions. Furthermore, no effective 
topical haemostatic agent has been firmly established. Potential uses of externally 
applied agents may include traumatic injuries, bruises and external bleeding at 
incision site [White et al., 2000; White et al., 2001].  
Other than synthetic drugs, several medicinal plants have been reported to 
have useful haemostatic effects. These haemostatic herbs such as Panax notoginseng, 
Sophora japonica, Trachycarpus fortunei and Imperata cylindrical [Zhu, 1998] may 
be used for internal and external bleeding/ haemorrhages. These include a broad range 
of haemorrhagic conditions such as vomiting blood (haematemesis), blood in urine 
(haematuria), blood in stools (haemafecia), uterine bleeding, excessive menstruation, 
and bleeding from trauma. Natural constituents from medicinal plants, for example 
dencichine, quercetin, have also been reported [Zhao and Wang, 1986; Ishida et al., 
1989] to have haemostatic activities. These medicinal herbs may be used in less 
severe cases of bleeding. However, there is a relatively lack of information in this area 





1.3 Medicinal plants as potential sources of novel therapeutic drugs 
Plants have been utilised as medicines for thousands of years. According to 
WHO [WHO, 2003a], about 25% of modern synthetic medicines are made from or 
derived from medicinal plants that have been used traditionally. Drug discovery from 
medicinal plants has led to the isolation of early drugs such as digitoxin, aspirin, 
penicillin, quinine and morphine, of which most are still in use today. However, for 
many decades, synthetic and semi-synthetic drugs have been the main focus in drug 
discovery due to higher predictability and availability of established techniques such 
as molecular modelling, combinatorial chemistry and other new synthetic chemistry 
techniques. Comparatively, less information is known about medicinal plants and the 
drug discovery process from medicinal plants is more lengthy, costly and complicated.  
In recent years, however, there has been rekindling of interest in the field of 
medicinal plants, as these plants provide a great diversity of new compounds. In fact, 
phytochemicals from medicinal plants are receiving greater attention in the scientific 
literature, in medicine and in the world economy. Medicinal plants continue to 
provide new and important leads against various pharmacological targets including 
cancer, HIV/AIDS, Alzheimer's, malaria, and pain [Balunas and Kinghorn, 2005]. 
Paclitaxel from Pacific Yew tree, and vincristine and vinblastine from Madagascar 
periwrinkle, have been used for the treatment of various types of cancers. Irinotecan, 
topotecan, docetaxel and camptothecin are also examples of anticancer agents 
obtained originally from natural sources. Artemisinin, a sesquiterpene lactone, is an 
antimalarial compound discovered from Artemisia annua, while huperzine A from 
Huperzia serrata is currently in clinical trials for the treatment of Alzheimer’s disease. 
Arteether, galantamine, nitisinone and tiotropium are also new medicinal plant-
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derived drugs that have been recently introduced into the U.S. market [Balunas and 
Kinghorn, 2005].  
The above successful examples showed the importance of medicinal plants for 
new drug discovery and have propagated more interests in this field. With such a 
large number of medicinal plants in the world and the large number of natural 
constituents present in each of these plants, this is definitely a very large resource for 
the search of new potential medicines. Therefore, more research should be done to 
discover the wide myriad of pharmacological activities from medicinal herbs and their 
phytochemicals. 
 
1.4 Panax species 
1.4.1 Species of Panax 
During the Han dynasty (206B.C. to 24A.D.), a plant known as ‘sheng’ was 
found and later known as ginseng, which literally means “man-root”, due to its man-
shaped figure. In 1883, the genus Panax was added to its name, which means “all 
healing” in Greek. The proponents of the “Doctrine of Signatures” believe that Panax 
ginseng is an all-healing man-root, and it is regarded as something of a panacea 
particularly in the East. Panax ginseng, together with the other Panax species, is later 
classified as one of the members of the plant family, Araliaceae [Sticher, 1998]. 
The root of Panax ginseng C. A. Meyer, commonly referred to as Chinese, 
Asian, or Korean ginseng, is one of the most established and earliest type of ginseng 
discovered. In fact, the annual market for this herb in United States is estimated to be 
about USD300 million [Mihalov et al., 2000]. P. ginseng can be processed into two 
forms, known as white and red ginseng. The former is the air or sun-dried root, 
whereas, the latter is steamed prior to drying or simply known as the steamed form of 
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fresh ginseng. The P. ginseng from Korea (Korean ginseng) usually refers to the 
steamed red root. Originally, P. ginseng is mainly grown in the wild in northeast 
China and Korea, especially in the mountainous areas. However, this wild-type 
ginseng is becoming less common and most of the commercial roots available in the 
market are the cultivated types of ginseng grown in large plantations [Tang and 
Eisenbrand, 1992; Court, 2000].  
Besides P. ginseng, several Panax species grow in the northern hemisphere, 
from eastern Himalaya through China and Japan to North America. They can be 
divided into two groups depending on the shape of their underground parts [Sticher, 
1998]. Group A contains carrot-like roots while Group B has long, horizontal 
rhizomes. Panax quinquefolium (American ginseng) and Panax notoginseng, which is 
indigenous to North America and northeast China respectively, belong to the same 
group (Group A) [Sticher, 1998] as P. ginseng and they are all well-known herbs used 
for different therapeutic purposes. Several researches have also been done on these 
two types of Panax species, in comparisons with P. ginseng. Examples of Group B 
include Panax japonicum (Japanese chikutsu ginseng), Panax pseudoginseng (Eastern 
Himalayas), and Panax zingiberensis (from southern China). There are still other 
Panax species and varieties [Court, 2000] such as Panax vietnamensis (Vietnamese 
ginseng), that have been discovered. In fact, more than ten Panax species reported in 
the world are valuable medicinal resources in traditional Chinese medicine and in folk 






1.4.2 Panax notoginseng (Burk.) F. H. Chen 
1.4.2.1 Introduction 
The main medicinal herb of interest in this study is the dried root of Panax 
notoginseng (Burk.) F. H. Chen (abbreviated as P. notoginseng), also known as Sanqi 
or Tianqi. It belongs to the same family and genus as P. ginseng. It is mainly 
cultivated in the province of Yunnan in China. Southwestern parts of Wenshan in 
Yunnan are believed to produce the best quality of P. notoginseng in China [Dong et 
al., 2003]. P. notoginseng is a perennial herbage that bears compound leaves with 
lanced-shaped leaflets and clusters of greenish-yellow flowers [State Administration 
of Traditional Chinese Medicine, 1996]. In autumn, the flowers mature and develop 
into berries that turn red or red-black when ripened. The root is normally harvested in 
autumn before flowering, after three years of growth. After harvesting, the roots are 
cleaned, divided into main root, branch root (“Jintiao” “ 筋条 ”) and rhizome 
(“Jiankou” “剪口 ”), and dried under the sun or with artificial heating at low 
temperatures [The State Pharmacopoeia Commission of People’s Republic of China, 
2000]. Sometimes, the roots (those commonly used in Singapore and Hong Kong) 
may be darkened with coal smoke and coated with insect wax to give a black shiny 
external appearance instead of its original greyish-brown appearance. P. notoginseng 
is divided into different traditional grades (called “tou” “头”in Chinese), which is 
ranked according to their dried size and weight. The “tou” means the number of 
individual roots in ~500 g, so the smaller the “tou”, the greater is the size of the roots. 
It is traditionally believed that the bigger the size (or smaller “tou”), the higher is the 




1.4.2.2 Processing of P. notoginseng 
Processing of Traditional Chinese herbs has a long history. Some of the 
processing methods used for Chinese herbs include cleaning the herb to remove 
unwanted materials, grinding, slicing, moistening, stir-frying with various agents, 
boiling and steaming. The reasons and significance of processing include reducing 
toxicity or side effects, potentiating the effects, changing the pharmacological 
properties, preserving active constituents, facilitating administration, increasing 
flavour or correcting the unpleasant taste, and increasing purity [Zhu, 1998]. For 
example, the cardiac toxicity of Aconitum species is due to aconitine, but it is 
hydrolysed to give non-toxic aconine after the herb is steamed. This process does not 
affect its anti-inflammatory and analgesic activities, which are due to other aconitine 
analogues e.g. pyro-type aconitine alkaloids [Zhu, 1998; Murayama et al., 1991]. 
Another example, raw Rehmanniae glutinosae is mainly used to purge heat and 
promote the generation of body fluids, but after processing, it has a warm property 
and becomes effective for enriching blood [Chan, 2005]. 
P. notoginseng is also available in two different forms—the raw and 
processed/ steamed form. Raw and steamed P. notoginseng are readily available as 
Chinese Proprietary Medicines (CPMs) (finished products such as tablets, capsules, 
powder, consisting of one or more ingredients) in the market. The raw roots can be 
processed by steaming or by stir-frying the roots in oil until the exterior is golden 
yellow [Yin and Guo, 1995]. There is very limited information regarding the exact 
procedures and conditions of steaming or frying, such as the equipments, temperature 
and duration used. Currently, there is no standard method of steaming raw P. 
notoginseng. The total amount of saponins was found to be greater in the steamed 
compared to the ‘fried’ and raw forms [Zhang, 1989]. Steaming is said to be a better 
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and preferred method of processing P. notoginseng as compared to frying which gave 
the lowest contents of saponins. P. notoginseng have also been stir-fried to different 
degrees by using different sizes of the roots [Tang, 1991]. The smaller roots were 
‘fried’ to a greater extent and have lower saponin contents (60-70%) compared to the 
raw ones. The active components may differ greatly if products are not processed by 
the same method. Therefore, standardisation of the processing and manufacturing 
processes is important to ensure that herbal medicines have consistent quality and 
efficacy. There should be more detailed studies to further understand the effects of 
processing on the quality of P. notoginseng, in terms of individual saponins contents 
and the effects of steaming on efficacy.  
 
1.4.2.3 Chemical constituents of P. notoginseng 
The chemical constituents of this root are very complex, consisting of various 
saponins, amino acids, polyacetylenes, volatile oils, polysaccharides and flavonoids 
[Zhu, 1998; State Administration of Traditional Chinese Medicine, 1996]. The 
dammarane-type saponins account for 12% of the total root content and they are the 
main bioactive components of the root with a wide variety of activities [Zhu, 1998; 
Ma et al., 1999]. P. notoginseng has a much higher percentage of total saponins 
compared to P. ginseng and P. quinquefolium. The saponins include various 
ginsenosides and notoginsenosides. Many of these ginsenosides in the root are also 
present in other Panax species such as P. ginseng and P. quinquefolium. Although the 
Panax species share some common saponins, the total chemical profiles of the various 
species are different and needs to be carefully differentiated to prevent 
misidentification, accidental or intentional substitution with lower grades or cheaper 
species.  
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More than 30 ginsenosides have been isolated in the past few decades and 
more are still being discovered. The saponins can be hydrolysed to give the aglycones 
and sugar molecules. They are then classified into three main classes based on their 
aglycones—protopanaxadiol (e.g. ginsenosides Rb1, Rb2, Rc, Rd), protopanaxatriol 
(e.g. ginsenosides Rg1, Re, Rf) and oleanolic acid (e.g. ginsenoside Ro) (Figure 1.1) 
[Court, 2000]. Besides ginsenosides, another group of saponins termed as 
notoginsenosides, such as notoginsenosides R1 to R4, R6 to R9 [State Administration 
of Traditional Chinese Medicine, 1996; Zhou et al., 1981; Taniyasu et al., 1982; 
Matsura et al., 1983; Zhao et al., 1996], notoginsenosides A to N [Yoshikawa et al., 
1997a; Yoshikawa et al., 1997b; Yoshikawa et al., 2001; Ma et al., 1999], 
notoginsenosides Fa, Fc and Fe [Yang et al., 1983], have also been isolated from P. 
notoginseng. Some of these were minor components present in P. notoginseng. 
Dencichine (β-N-oxalyl-L-α,β-diaminopropionic acid), an important and 
bioactive amino acid, present in P. notoginseng, is known to have haemostatic activity 
[State Administration of Traditional Chinese Medicine, 1996; Zhang et al., 1990; 
Zhao and Wang, 1986; Long et al., 1996]. At least 16 types of amino acids, with 
seven being essential amino acids such as aspartic acid, glutamic acid, arginine, lysine, 
leucine, were found and the total amino acids content is about 7.73% [State 
Administration of Traditional Chinese Medicine, 1996]. Trilinolein, a triacylglycerol 
with three linoleate residues, is another important component found to have protective 
effects against cardiovascular diseases by reducing thrombogenicity, arrhythmias, 
increasing erythrocyte deformability and counteract free radical damages [Chan et al., 
2002]. Polyacetylenes such as panaxynol (falcarinol), panaxydol, 1,8-heptadecadiene-
4,6-diyne-3,10-diol, panaxytriol (falcarintriol) have also been discovered in P. 







Protopanaxatriol (R1, R2 = H) 
Saponins R1 R2 
Ginsenoside Rg1 -Glc -Glc 
Ginsenoside Re -Glc2-1Rha -Glc 
Ginsenoside Rf -Glc2-1Glc -H 
Notoginsenoside R1 -Glc2-1Xyl -Glc 
Notoginsenoside R2 -Glc2-1Xyl -H 
Notoginsenoside R3 -Glc -Glc6-1Glc 






Protopanaxadiol (R1, R2 = H) 
Saponins R1 R2 
Ginsenoside Rb1 -Glc2-1Glc -Glc6-1Glc 
Ginsenoside Rb2 -Glc2-1Glc -Glc6-1Ara(p) 
Ginsenoside Rb3 -Glc2-1Glc -Glc6-1Xyl(p) 
Ginsenoside Rc -Glc2-1Glc -Glc6-1Ara(f) 
Ginsenoside Rd -Glc2-1Glc -Glc 
Notoginsenoside R4 -Glc2-1Glc -Glc6-1Glc6-1Xyl 
Notoginsenoside Fa -Glc2-1Glc2-1Xyl -Glc6-1Glc 
Notoginsenoside Fc -Glc2-1Glc2-1Xyl -Glc6-1Xyl 
Notoginsenoside Fe -Glc -Glc6-1Ara(f) 
 
Figure 1.1. Chemical structures of some saponins. Abbreviations: Glc, glucose; 
Ara(f), arabinose in furanose form; Ara(p), arabinose in pyranose form; Rha, 
rhamnose; Xyl, xylose. 
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inflammatory effects [Washida and Kitanaka, 2003]. Yoshikawa et al. [1997b] 
isolated an acetylenic fatty acid glycoside known as notoginsenic acid beta-
sophoroside, from the roots. Polysaccharides such as sanchinan-A, arabinogalactan, 
extracted from P. notoginseng are considered to be active immunostimulatory 
constituents [State Administration of Traditional Chinese Medicine, 1996; Gao et al., 
1996]. Detailed characterisation of the polysaccharides from P. notoginseng root cell 
walls showed that they include cellulose, pectic polysaccharides such as 
homogalacturonan and rhamnogalacturonan, and non-cellulosic polysaccharides [Zhu 
et al., 2005]. A small chitinase-like antifungal protein with a molecular weight of 15 
kDa was also isolated from the root [Lam and Ng, 2001a]. Moreover, the root 
contains a series of sesquiterpenes essential oils/ volatile oils and some of the major 
volatile components have been identified as α-guaiene, β-guaiene, and octadecane 
[Zhu, 1998]. Some other components include flavonoids such as quercetin, 
kaempferol, and common plant sterols such as β-sitosterol, stigmasterol, daucosterol 
[Yin and Guo, 1995].  
With regards to comparisons of chemical constituents between raw and 
steamed P. notoginseng, only one report has been found. Yang et al. [1985] have 
isolated some saponins from both raw and processed P. notoginseng using open 
column chromatography and identified some of the saponins. It was found that the 
yields of ginsenosides Rb1, Rd, Re, Rg1, Rh1 and notoginsenosides R1 and R4 were 
lower in the steamed form as compared to the raw form. Ginsenosides Rg2 and Rg3  
were obtained from processed herb but not from the raw form. The saponins may be 
thermolabile. Therefore, more studies are needed to understand the differences 
between raw and steamed P. notoginseng using advance analytical techniques.  
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Since P. notoginseng contains some common constituents as P. ginseng, the 
stability and possible changes in the ginsenosides content of P. ginseng after heat 
processing may provide some insights on the possible changes in P. notoginseng. 
White and red ginseng (produced by steaming raw ginseng) have been compared 
[Kim et al., 2000; Kwon et al., 2001]. Kim et al. [2000] found some differences in 
chemical constituents and pharmacological activity between them. Ginsenosides F4, 
Rg3 and Rg5, which were not present in raw P. ginseng, were produced after 
steaming, with ginsenosides Rg3 and Rg5 being the most abundant ginsenosides in 
steamed ginseng. White ginseng was found to contain panaxynol and panaxydol while 
red ginseng contains, in addition to the two components, heptadec-1-ene-4,6-diyne-
3,9-diol and panaxytriol [Kitagawa et al., 1987]. The degradation of ginsenosides in P. 
quinquefolium during microwave and conventional heating (heating using water bath) 
was investigated [Ren and Chen, 1999]. Malonyl ginsenosides (m-Rb1, m-Rc, and m-
Rd) were much less stable and readily demalonylated on heating, with 3 to 60 times 
higher rate constant value than that of the neutral ginsenosides (e.g. Rb1, Rc, Rd, Re). 
Interestingly, at the same temperature, the effect of microwave heating on the 
degradation of ginsenosides was the same as that of conventional heating, so there 
were no significant differences between the heating methods. Although there is some 
information on the chemical changes in P. ginseng, there is still a need for studies in P. 
notoginseng as the chemical profiles between species are different and the changes 
may not be completely inferred from P. ginseng. 
 
1.4.2.4 Pharmacological studies of P. notoginseng 
The two forms of P. notoginseng have different traditional uses. The raw form 
is officially recognised in Chinese medicine for its haemostatic and cardiovascular 
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properties, to arrest bleeding, disperse blood clots, improve blood circulation, disperse 
bruises, cause subsidence of swelling and alleviate pain [Zhu, 1998; The State 
Pharmacopoeia Commission of People’s Republic of China, 2000 and 2005]. 
Interestingly, promoting circulation and haemostasis seems to be of opposite effects 
scientifically, but this may reflect the theory of Traditional Chinese Medicine 
whereby there are opposing factors to maintain overall physiological balance. On the 
other hand, the steamed P. notoginseng has been claimed to be more of a tonic used to 
“nourish” blood, to increase production of various blood cells in anaemic conditions 
[State Administration of Traditional Chinese Medicine, 1996] and it is traditionally 
said to be used in ‘weaker’ patients who cannot tolerate the more ‘potent’ raw form. 
Due to the different pharmacological actions and clinical indications of raw and 
steamed P. notoginseng, using the wrong form of herb may lead to undesirable results 
for the patients or consumers. Differentiating between the two forms is therefore 
important. 
Currently, most of the investigations are focused on raw P. notoginseng, as 
this is more commonly used for therapeutic purposes. Its well-known haemostatic 
effect has been studied scientifically [White et al. 2000; White et al. 2001; Fan et al., 
2005]. Besides the above effects, it also showed several beneficial cardiovascular 
effects. Animal studies have shown that P. notoginseng extracts decreased blood 
pressure and peripheral vascular resistance. It increases coronary blood flow, treats 
experimental myocardial ischemia, alleviates angina pectoris, increases cardiac 
contractility, may have anti-arrhythmic effects and helps in craniocerebral trauma 
[Zhu, 1998; Tang and Eisenbrand, 1992]. Other reported pharmacological activities of 
raw P. notoginseng extracts and its total saponins (P. notoginseng saponins, PNS) 
include reduction of blood viscosity, inhibition of platelet aggregations [Ma and Xiao, 
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1998; Liao and Li, 1997; Wang et al., 2004; Su et al., 1996], anti-inflammatory and 
analgesic effects [Zhu, 1998; Tang and Eisenbrand, 1992; Rhule et al., 2006], 
retardation of the progress of early diabetic nephropathy [Lang et al., 1998], 
immunological adjuvant activities [Sun et al., 2006], prevention of liver fibrosis and 
hepatic microvascular dysfunction [Park et al., 2005]. Furthermore, anti-carcinogenic 
and anti-proliferative activities have been reported in the roots of P. notoginseng 
[Konoshima et al., 1999; Lam and Ng, 2001b]. Notoginsenoside R1, one of the 
distinct saponins present in P. notoginseng, has been found to increase the fibrinolytic 
potential in cultured endothelial and smooth muscle cells [Zhang et al., 1997a; Zhang 
et al., 1995], to counteract endotoxin-induced activation of endothelial cells [Zhang et 
al., 1997b] and to inhibit TNF-alpha-induced PAI-1 production in human aortic 
smooth muscle cells [Zhang and Wang, 2006].  
Few scientific studies have been done on steamed P. notoginseng, so very few 
researchers compared the pharmacological actions of the two different forms. One 
such comparative study [Zhang et al., 1989] found that the total saponins from raw P. 
notoginseng caused a greater increase in protein synthesis compared to processed P. 
notoginseng. Chen et al. [1984] showed that steamed P. notoginseng increased the 
cholesterol and triglycerides in rats while raw P. notoginseng can reduce the 
cholesterol slightly. The traditional uses of both forms are on the haematological and 
cardiovascular system. However, there are currently no scientific evidences on their 
pharmacological differences on the haematological system. Therefore, more studies 
are needed to provide evidences and understanding of the specific differences 
between raw and steamed P. notoginseng. 
As some of the P. notoginseng saponins are present in P. ginseng, some 
information can be gained from the extensive literature which studied the 
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pharmacology of some common saponins individually. It was found that the 
bioactivities of ginsenosides varied depending on different types of aglycones, various 
sugar moieties and stereoisomerism [Attele et al., 1999]. One study revealed that 
ginsenosides with protopanaxadiol type aglycone have neurite outgrowth activity on 
human neuroblastoma cells, while other types of ginsenosides have no effect [Zhu et 
al., 2004a]. Within the same herb, the pharmacological actions of the components 
may also work in opposition. For example, ginsenoside Rg1 is central nervous system 
(CNS)-stimulative while ginsenoside Rb1 is CNS-sedative [Shibata, 2001]. Another 
ambiguity in vascular pathophysiology was revealed by the evidences that 
predominance of ginsenoside Rg1 led to angiogenesis for wound healing, while a 
predominance of ginsenoside Rb1 inhibited angiogenesis and prevented 
chemoinvasion [Sengupta et al., 2004]. A wide range of pharmacological actions 
including CNS, cardiovascular, cholesterol-lowering, immunomodulatory effects, 
have been reported in individual ginsenosides [Shibata et al., 2001]. Therefore, this 
large diverse class of saponins are often regarded as the main bioactive components in 
the Panax species. Antitumour activities were reported for some saponins [Attele et 
al., 1999; Shibata, 2001], especially those components and fractions obtained from 
heat-processed ginseng or red ginseng [Keum et al., 2000; Yun et al., 2001a; Park et 
al., 2002a]. Therefore, the ginsenosides demonstrated ability to target a myriad of 
tissues. Since the components produce effects that are different from each other and a 
single component can initiate multiple actions, these may account for the complexity 
of the overall pharmacology of Panax species and more work is needed to understand 




1.4.2.5 Quality control of P. notoginseng and its related species 
As discussed in Section 1.1.4, quality control involves identification and 
authentication of the plant, as well as determination of its chemical contents to ensure 
consistent qualities. Therefore, this section gives an overview of the existing DNA 
fingerprinting, chemical fingerprinting methods and chemical assays that have been 
specifically used for the quality control of P. notoginseng roots and its products [Lau 
and Koh, 2006]. 
 
DNA fingerprinting and molecular biological methods 
Some of the Panax species are very similar macro-morphologically and 
microscopically, making them difficult to differentiate and prone to misidentification 
and substitution. One approach will be the use of genetic methods for more objective 
identification of the individual species. A diverse array of DNA-based marker 
technologies has been established to explore various DNA polymorphisms [Shaw et 
al., 2002].  
Arbitrarily-primed polymerase chain reaction (AP-PCR) and Randomly 
amplified polymorphic DNA (RAPD) techniques have been applied [Shaw and But, 
1995] to differentiate three Panax species from one another and their common 
adulterants. P. ginseng is more closely related to P. quinquefolium than to P. 
notoginseng. Both methods were equally successful but the amount of DNA required 
for RAPD was 10-fold less than AP-PCR and the primers for RAPD were 
commercially available. Six Panax species and two common adulterants [Ngan et al., 
1999] were successfully differentiated using restriction fragment length 
polymorphism (RFLP). Using different enzymatic digestion, more than one 
distinctive RFLP profiles can be generated, thus providing more markers for 
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identification. 5S-rRNA spacer domains were also isolated [Cui et al., 2003] from P. 
notoginseng and other Panax species. The spacer domains showed 75% DNA identity 
among all Panax species, but not the adulterants. Multiplex amplification refractory 
mutation system [Zhu et al., 2004b] allowed authentication of five Panax species with 
simultaneous detection of four sites of nucleotide differences on two completely 
different genes. Identifying a herb within a complex matrix of numerous herbs in the 
final products is challenging. However, a ginseng marker primer (SIM2) that 
specifically amplified a fragment from the DNA of Panax species, was identified 
[Shim et al., 2005]. The gradient PCR method using the SIM2 primer was used to 
uniquely identify Panax species in herbal preparations containing diverse herbal 
components. The study suggests the possibility of developing a Panax species 
identification kit for medicinal plants and their preparations. The technique may be 
applied to other herbs and a new simultaneous identification method of herbal 
medicines may be possible in the future. 
 
Chemical assays and fingerprinting 
Besides differentiating between different species, it is important to determine 
the quality within each species. This difference in quality in terms of chemical 
contents, however, may not be detected using DNA fingerprinting methods. These 
chemical components may be directly related to the safety and therapeutic efficacies 
of the herbal medicines. Therefore, chemical analysis and chemical fingerprinting 
would be needed to supplement the information provided by DNA fingerprinting 
(Section 1.1.4.4).  
Compared to the analysis of P. ginseng and P. quinquefolium, reports 
describing the methodology for the quality control of raw P. notoginseng were less 
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abundant. Older studies employed TLC with densitometry [Zhou and Zhang, 1981] 
for the analysis of saponins. HPLC methods are now the most commonly used 
methods for their quality control. The qualitative profiling of the raw P. notoginseng 
roots compared to other Panax species has been reported [Zhou et al., 2001; Zhai et 
al., 2001]. The ratios of ginsenoside Rg1 to Re is different for P. ginseng, P. 
quinquefolium and P. notoginseng. Furthermore, HPLC fingerprints of P. notoginseng 
were analysed using cluster analysis, allowing classification of the roots into four 
different qualities [Wang and Bi, 2003].  
Due to the complexity of the chemical components and the similarity of 
numerous saponins, the simultaneous analysis of all saponins is difficult. Wang et al. 
[2000a] and Jiang et al. [2000] quantified up to three saponins present in the raw 
herbs using HPLC. Another HPLC-UV method [Li et al., 2005] simultaneously 
quantified six major saponins in another 23 P. notoginseng samples. Chuang et al. 
[1995] has managed to analyse twelve ginsenosides in P. notoginseng and compared 
them to other Panax species. The saponin contents in P. notoginseng and P. 
quinquefolium were generally higher than P. ginseng. Using the chemical data and 
external appearance, the quality and origin of the herb can be postulated. Similarly, 
Yamaguchi et al. [1988] analysed twelve acidic and neutral saponins, namely, 
ginsenosides Ro, mRb1, mRb2, mRc, mRd, Rb1, Rb2, Rc, Rd, Re, Rf, Rg1, and 
found differences in their contents in five Panax species. P. notoginseng did not 
contain saponins of the oleanolic acid prototype unlike P. ginseng and P. japonicus.  
Ginsenosides in raw P. notoginseng were also quantified using HPLC-
evaporative light scattering detector (ELSD) [Li and Fitzloff, 2001; Wan et al., 2006]. 
ELSD, a mass detector, was found to be a suitable detector for saponins and it can 
quantify the saponins proportionally. Twenty-three P. notoginseng samples collected 
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from different locations were analysed by HPLC-ELSD [Sha and Zhang, 2005] and it 
was found that there was no absolute linkage between the content of saponins and the 
traditional grade of the root. A comprehensive study [Zhu et al., 2004a] involving 47 
samples from 12 Panax taxa was conducted. Eleven ginsenosides were quantified by 
HPLC to characterise the chemical constituent pattern of each Panax species and their 
relationship with the genetic varieties. Each Panax taxon showed its own 
characteristic chromatographic profile, which also appeared as a specific shape in an 
11-direction radar graph constructed on the basis of the quantitative results. The 12 
Panax species were grouped into two main groups based on their components. 
Different grades (called “tou” “头”, Section 1.4.2.1) of P. notoginseng were analysed. 
Results showed that there was a small increase in saponin content with the increase in 
size or grades, but the differences were not significant. The absence of oleanolic acid 
saponins also distinguished this taxon from the other Panax species [Zhu et al., 
2004a].  
In another study, using HPLC and spectrophotometry, four saponins, 
dencichine, flavonoids and polysaccharides in raw P. notoginseng roots from different 
regions of growth in China, as well as from different seasons of harvest and market 
grades, were analysed separately [Dong et al., 2003]. This is one of the few detailed 
studies on the regional and seasonal variations of its chemical constituents. It was 
found that the roots from southwestern parts of Wenshan were of the best quality and 
the best season for harvest was September to October. The unseeded plants (flower-
picked plants) also produced a better quality. Being an active haemostatic constituent 
in P. notoginseng, dencichine can also serve as a quality control marker. Unlike 
saponins that differ greatly in roots obtained from different sources, the contents of 
dencichine in P. notoginseng roots from different regions and seasons did not vary 
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significantly [Dong et al., 2003]. These results provided useful information for the 
quality control and development of GAP standards for P. notoginseng.  
Capillary electrophoresis (CE), specifically, micellar electrokinetic 
chromatography (MEKC), has been developed for determining saponins in P. 
notoginseng. Its sensitivity permitted the analysis of minor saponins such as 
ginsenosides Rh1 and Rg2 [Wang et al., 2006]. Besides saponins, proteins from P. 
notoginseng have been used to distinguish it from other varieties and these were also 
analysed using CE [Hou et al., 2000]. 
LC-MS, being a sensitive and specific analytical technique, is increasingly 
used for a wide variety of applications including authentication and analysis of 
complex samples. P. ginseng and P. quinquefolium can be differentiated based on 
their ginsenosides using LC-MS techniques. LC-MS-MS [Kite et al., 2003] with 
negative ion electrospray conditions was used to profile the malonylated and 
acetylated ginsenosides in P. notoginseng, P. ginseng and P. quinquefolium. Analyses 
revealed different profiles of malonyl-ginsenosides in the three Panax species and this 
method assisted in the quality control of Panax species. LC-MS was also employed to 
identify P. notoginseng roots and its presence in complex Chinese patented medicines 
containing other herbs such as Salvia miltiorrhiza (Danshen) [Xiao et al., 2004; 
Zhang and Cheng, 2006]. Recently, ‘Xuesetong’ injection, a CPM consisting of total 
saponins from P. notoginseng, has been analysed using HPLC-ESI-MS/MS methods 
and the large variability of contents among ten samples was shown [Lai et al., 2006].  
Besides the widely used chromatographic methods, near infrared spectroscopy 
[Chen and Sorensen, 2000] has been demonstrated to have the potential for rapid 
quality control of crude herbal plant materials such as P. notoginseng. The results 
obtained were satisfactory for the classification of crude herbs into low, medium and 
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high qualities and the technique is non-destructive. The main drawback of this method 
is the calibration step, which requires analyses of several natural samples covering the 
spectral variation of the samples.   
Although most work has been carried out on the non-volatile components of 
the Panax species, fingerprinting of semi-volatile components also provided good 
differentiation of the various species [Shellie et al., 2003]. Comprehensive two-
dimensional gas chromatography (GC x GC) chromatograms revealed the presence of 
numerous common components and some species-specific components. Furthermore, 
the use of GC x GC-quadrupole mass spectrometry permited the identification of 
some major components [Di et al., 2004]. 
Novel immunochemical methods have been proposed for the analysis of 
Panax species. An interesting combination of Enzyme-linked immunosorbent assay 
(ELISA), western blotting and immunoaffinity concentration using an anti-
ginsenoside Rb1 monoclonal antibody was used for the qualitative and quantitative 
analysis of ginsenosides in Panax species and traditional Chinese herbal medicines 
[Fukuda et al., 2000]. Recently, the authors have also developed new monoclonal 
antibodies against the protein components of P. ginseng and a combination of ELISA, 
RAPD, and TLC with blotting and immunostaining methods, enabled authentication 
of four different Panax species including P. notoginseng [Tanaka et al., 2006]. 
Although these immunochemical methods are specific for individual chemical 
components and showed good correlation with HPLC methods, but they may be too 
elaborate for simple routine analysis of samples.  
A variety of genetic and chemical methods have been used for the quality 
control of Panax species, involving both the identification/ authentication of the 
correct species as well as the quantification and standardisation of its chemical 
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constituents. From the above chemical studies, the quantitative results showed a 
general lack of consistent quality among different Panax species. Due to the many 
factors influencing quality, total quality management is definitely complex and is an 
uphill task. Therefore, a combination of different complementary technologies or 
methods is usually needed. 
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CHAPTER 2 
HYPOTHESES AND OBJECTIVES 
The quality of herbal medicines is a critical and challenging issue that needs to 
be addressed to ensure their safety and efficacy. The importance of quality has been 
extensively discussed in Section 1.1.4. More research is needed to develop better 
methods to ensure the quality of herbal medicines, to understand their chemical 
compositions and to explore the scientific basis for their traditional uses.  
The root of P. notoginseng is an important Chinese medicinal herb with a long 
history of usage. Its processing, chemical constituents, pharmacological actions and 
current quality control are reviewed in Section 1.4.2. The raw and steamed forms have 
different traditional uses. It is important to understand the chemical and biological 
changes upon steam processing and to develop methods for quality control so as to 
safeguard the interests of patients consuming herbs and herbal products. Due to the 
above reasons and the general lack of scientific studies comparing raw and steamed P. 
notoginseng, P. notoginseng is thus selected as the main herb of study in this thesis. 
Chemical assays and chromatographic fingerprinting are useful quality control 
measures. Most of the previous analytical studies focused on other Panax species, 
especially P. ginseng, while for those studies on P. notoginseng, only the raw form of 
P. notoginseng has been studied (Section 1.4.2.5). DNA fingerprinting for the 
identification and authentication of Panax species has been reported. However, DNA 
fingerprinting is not able to detect the effects of processing on the samples as steam 
treatment destroys the DNA. There are very few reports on the effects of processing 
in this species. This general lack of quality control and analytical methods for raw and 
steamed P. notoginseng makes it difficult for further research on this root, as safety 
and efficacy studies will require validated analytical methods to ensure that the 
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studies are reproducible and the qualities are consistent. To date, the differences in 
chemical composition of raw and steamed P. notoginseng are still not clearly 
understood. Although there are some chemical studies on the differences between 
white and red (steamed) P. ginseng, the results may not be directly extrapolated to P. 
notoginseng, as different species have different chemical compositions. The 
potentially unique chemical components may serve as important marker compounds 
for identifying steamed P. notoginseng. Most research has focused on the bioactive 
saponins (e.g. ginsenosides and notoginsenosides) present in these Panax species. 
Besides saponins, dencichine (Section 1.4.2.3), a haemostatic agent, is another 
important component present in P. notoginseng. Although one of the traditional 
indications for raw P. notoginseng is haemostasis, but this effect has not been 
indicated for the steamed form, and it is not known what the contributing factors are 
or whether dencichine plays a role in this particular difference in their indications, 
therefore studying this component may provide a better understanding of their 
differences. 
As discussed in Chapter 1, botanicals are potential sources for novel 
therapeutic drugs and there is still a wide myriad of pharmacological activities to be 
discovered. Moreover, antithrombotic and haemostatic therapies are important classes 
of drugs where ongoing search for good alternatives and potential drugs is still needed. 
P. notoginseng has been traditionally used for haemostasis and cardiovascular 
diseases (Section 1.4.2.4). It may be promising as an alternative antithrombotic. To 
date, there are not many studies on the anticoagulant activities of P. notoginseng roots. 
Although the pharmacological effects of raw P. notoginseng roots have been 
relatively well studied, studies are lacking for the steamed form, especially with 
regards to its haematological effects and on the difference (if any) in activity between 
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raw and steamed form. With modernisation of herbal medicines, it is important to 
provide clear scientific evidences for efficacy to support their traditional uses. 
Furthermore, it is of interest to see if differences in chemical components may result 
in any differences in biological activities. To date, few studies investigated both the 
antiplatelet and anticoagulant effects of individual chemical components (Section 
1.4.2.4). Besides, most of the haematological studies were done on the common 
saponins present in P. ginseng (e.g. ginsenosides Ro, Rg1, Rg2, Rg3, Rb1 and 
panaxatriol). There are still many components that have not been tested for 




In view of the previous literature, it is hypothesised that processing of raw P. 
notoginseng roots by steaming changes the concentration and composition of 
chemical constituents in P. notoginseng and that the chemical profiles of the raw and 
steamed forms can be differentiated from each other and from its closely related 
species, using various qualitative and quantitative methods.  
Furthermore, it is hypothesised that with the changes in chemical constituents 
upon steaming, there may be changes in the biological activities (namely, platelet 








In order to test the above hypotheses, the overall objectives of this study are to 
develop methods for the quality control of P. notoginseng, and to study the effects of 
processing on the chemical and biological differences between raw and steamed P. 
notoginseng. To achieve this, the current study is designed to meet the following 
specific objectives:  
1. To develop novel and validated HPLC methods for the quality control of P. 
notoginseng and its related Panax species, to study the effects of processing on the 
various saponin concentrations in P. notoginseng and to quantitatively compare 
the chromatographic fingerprints of raw and steamed P. notoginseng. 
2. To isolate and identify the main unknown marker components present in steamed 
P. notoginseng, and to develop a novel and validated LC-MS/MS method for the 
analysis of dencichine in raw and steamed P. notoginseng samples and its related 
species. 
3. To investigate the effects of the different forms of P. notoginseng and its related 
species on the haematological system, specifically, on blood coagulation pathways 
and platelet aggregations in both in vitro and ex vivo models, and their in vivo 
haemostatic effects. 
4. To investigate the activities of chemical components of P. notoginseng on blood 
coagulation and platelet aggregations in vitro, so as to understand the components 




HIGH PERFORMANCE LIQUID CHROMATOGRAPHIC 
ANALYSES OF PANAX NOTOGINSENG AND RELATED 
SPECIES 
 In this chapter, novel HPLC analytical methods for the quality control of P. 
notoginseng and its related Panax species, are developed and validated. This chapter 
consists of 2 parts. Firstly, a novel HPLC method for the chemical fingerprinting and 
analyses of saponins is developed. The validated method is applied to P. notoginseng 
from various sources, other Panax species and P. notoginseng products. It is also 
applied to raw and steamed P. notoginseng to study the effects of processing on the 
chemical components (Section 3.1). Secondly, a quantitative pattern matching method 
is optimised and successfully used for the comparisons of whole chromatograms of 
raw and steamed P. notoginseng samples (Section 3.2).  
 
3.1 Chemical fingerprinting and analyses of saponins 
3.1.1 Introduction 
As discussed in Chapter 1, it is important to differentiate raw and steamed P. 
notoginseng due to their different traditional indications. Misidentification of the 
samples may lead to undesirable effects or inefficacy. Saponins (e.g. ginsenosides and 
notoginsenosides) are the main class of bioactive compounds in Panax notoginseng 
and several of them have rather similar structures or are isomers of each other. Due to 
the complexity of the chemical components and the similarity of numerous saponins, 
the analysis of P. notoginseng and its related species is a challenge. With the 
advancement of newer technologies, there are currently many methods such as TLC, 
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HPLC, GC, CE, IR and immunochemical methods, which can be employed for the 
analysis of ginsenosides that were mainly in P. ginseng [Fuzzati, 2004]. Sensitivity, 
separation, resolution and precision are some important criteria to consider. There are 
several guidelines for the validation of analytical methods of synthetic drugs 
[International conference on harmonisation, 1996; EURACHEM, 1998], but there are 
not many validated analytical methods for the analysis of herbal samples such as P. 
notoginseng.  
Although there are some reports of methodology for the quality control of raw 
P. notoginseng (Section 1.4.2.5), however, to date, no extensive analytical study on 
steamed P. notoginseng was found. In fact, to date, only one study [Yang et al., 1985] 
estimated the concentrations of some saponins from raw and processed P. 
notoginseng using the yields obtained from simple open column chromatography. 
There are no further detailed analytical or comparative studies on the qualitative and 
quantitative analysis of both raw and steamed P. notoginseng using analytical 
techniques such as HPLC, GC-MS or LC-MSn. The existing HPLC methods for raw P. 
notoginseng were not satisfactory for the analysis of steamed P. notoginseng, due to 
the presence of numerous saponins of lower polarity than those in the raw herb. These 
saponins may not elute out or separate using existing methods.  
The objective of this section is to develop novel and validated HPLC method 
for the quality control of P. notoginseng and its related Panax species and to study the 
effects of processing on the various saponin concentrations in P. notoginseng. HPLC 
with UV detection, being one of the most commonly used methods in routine quality 
control, will be employed in this study to qualitatively and quantitatively analyse P. 
notoginseng. Qualitative comparisons of chromatograms are carried out visually and 
by hierarchical clustering analysis (HCA). In addition to qualitative comparisons, 
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simultaneous quantification and comparison of the concentration of six main saponins 
in raw P. notoginseng, P. ginseng and P. quinquefolium samples obtained from 
several different sources will be carried out. The saponin concentrations of individual 
P. notoginseng roots collected from a good agricultural practice (GAP) farm will be 
determined to study their variation. Lastly, the effects of steaming on the chemical 
profiles, and the saponin concentrations in raw and steamed P. notoginseng will also 




The solvents used were of HPLC grade. The water used was treated with a 
Milli-Q water purification system (Millipore, Molsheim, France). Ginsenosides Rb1, 
Rb2, Rc, Rd, Re, Rf and Rg1 standards were purchased from Indofine Chemical 
Company (Somerville, NJ, USA). Notoginsenoside R1 was obtained from National 
Institute for the Control of Pharmaceutical and Biological Products (Beijing, China). 
Ginsenoside Rb3 was obtained from Delta Information Centre for Natural Organic 
Compounds (China). 
The raw P. notoginseng roots were obtained from six different Chinese 
medical shops/ sources in Singapore (Samples 1 to 3) and China (Samples 4 to 6). 
Dried raw P. notoginseng roots, which were three-year-old and graded as 30 ‘tou’ 
(about 30 roots in 500 g), were randomly collected and pooled from a good 
agricultural practice (GAP) farm in Wenshan (Wenshan Miaoxiang Notoginseng 
Industry Corporation, Yunnan, China) (Sample 7). The reference standard raw P. 
notoginseng (Sample 8) was obtained from the National Institute for the Control of 
Pharmaceutical and Biological Products (Beijing, China). Three different quality 
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grades of P. notoginseng sample 1, 40 ‘tou’ (Sample 1-40), 80 ‘tou’ (Sample 1-80), 
120 ‘tou’ (Sample 1-120), were obtained from a medical shop in Singapore. Twelve 
individual P. notoginseng roots (labelled as roots WS-1 to WS-12), which were three-
year-old and graded as 30 ‘tou’, were separately collected from the single farm in 
Wenshan (Wenshan Miaoxiang Notoginseng Industry Corporation, Yunnan, China). 
Furthermore, two samples of two-year-old roots (Y2-1 and Y2-2) in the same farm 
were randomly collected from the same shaded plot and dried in the oven at low 
temperatures of 40-45°C. A P. notoginseng injection (50 mg/ml), containing P. 
notoginseng saponins (PNS), was obtained from Yick-Vic Chemicals and 
Pharmaceuticals Ltd (Hong Kong).  
Eleven pairs of raw and steamed P. notoginseng products (CPMs) consisting 
of only one herb, were bought from various local Chinese medical shops. Products 
from the same manufacturer but in different dosage forms were considered as separate 
products. The products are listed in Table 3.1. 
Samples of P. ginseng and P. quinquefolium roots were obtained from several 
different medical shops in Singapore. A Korean red ginseng was obtained from 
Pungki Ginseng Cooperative Association (Kyoungsangbuk-do, Korea). The reference 
standard red ginseng (P. ginseng) was purchased from the National Institute for the 
Control of Pharmaceutical and Biological Products (Beijing, China). The photos of 











Sample name Brand 
1 1R Pure Raw Pseudoginseng Powder Meihua 
 1S Pure Steamed Pseudoginseng Powder Meihua 
2 2R Raw Tienchi Ginseng Tablet Meihua 
 2S Steamed Tienchi Ginseng Tablet Meihua 
3 3R Yunnan Tienchi Powder (Raw) Nature’s Green 
 3S Yunnan Tienchi Powder (Steamed) Nature’s Green 
4 4R Yunnan Tienchi Tablets (Raw) Nature’s Green 
 4S Yunnan Tienchi Tablets (Steamed) Nature’s Green 
5 5R Tienchi Powder (Raw) Yunfeng 
 5S Tienchi Powder (Steamed) Yunfeng 
6 6R Tienchi Tablets (Raw) Yunfeng 
 6S Tienchi Tablets (Steamed) Yunfeng 
7 7R Tienchi Powder (Raw) Camellia 
 7S Tienchi Powder (Steamed) Camellia 
8 8R Tienchi Tablets (Raw) Camellia 
 8S Tienchi Tablets (Steamed) Camellia 
9 9R Tienchi Tablet (Raw) Yulin 
 9S Tienchi Tablet (Steamed) Yulin 
10 10R Yunnan Tian Qi Powder (Raw) Kiat Ling 
 10S Yunnan Tian Qi Powder (Steamed) Kiat Ling 
11 11R Chinese Yunnan Tien Chi Tablet (Raw) Luen Shing 






Figure 3.1. Photographs showing (A) different types of Panax species and (B) 















Slices Whole root 
 52
3.1.2.2 Sample preparation 
The roots were ground into powder using a laboratory blender (Waring, 
Connecticut, USA). 10 ml of 70% v/v aqueous methanol was added to 1 g of the 
powdered sample. The suspension was ultrasonically (230 V, Branson model 5510, 
Danbury, CT, USA) extracted for 20 min and filtered. This extraction was repeated 
two additional times. The combined filtrate was evaporated to dryness in vacuo at 
40°C, using a rotary evaporator. The residue was then dissolved in 5 ml of 70% v/v 
methanol and filtered through a 0.45 µm nylon filter membrane prior to HPLC 
analysis. The solutions were then diluted for quantification. 
For comparison of solvents, CPM sample pair 1 (1R and 1S) and raw P. 
notoginseng roots sample 2 were extracted with different compositions of aqueous 
methanol using the ultrasonication method described above. For comparison of 
extraction methods, CPM sample pair 1 (1R and 1S) and raw P. notoginseng roots 
sample 2 were extracted using the soxhlet method. 1 g of powdered samples were 
placed in the cellulose extraction thimbles and extracted with 70 ml of 70% v/v 
methanol for 6 h. The solvent was removed in vacuo at 40°C and the residue 
dissolved in 5 ml of 70% v/v methanol. Prior to HPLC analysis, the solutions were 
filtered through a 0.45 µm filter membrane. 
 
3.1.2.3 Steaming of samples  
Samples of the powdered raw P. notoginseng roots (Sample 2) were steamed 
at 105°C and 120°C using an autoclave (Hirayama, Japan) for various durations (1, 2, 
3, 6 and 9 h). The powder was then dried in a vacuum oven at about 80 °C until 
constant weight and extracted using ultrasonication as described above.  
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For comparisons with steamed P. notoginseng, a powdered P. ginseng root 
was also steamed at 120°C using autoclave for various durations (3, 6 and 9 h), dried 
and extracted using similar methods.  
 
3.1.2.4 Standards preparation 
Ginsenosides Rf (0.5 mg/ml), Rb2 (0.5 mg/ml) and Rb3 (0.5 mg/ml) standards 
were prepared in 70% methanol. Three composite stock solutions were prepared in 
70% v/v methanol for the calibration curves of notoginsenoside R1, ginsenosides Rg1, 
Re, Rb1, Rc and Rd. Composite solution 1 consisted of notoginsenoside R1 (0.9 
mg/ml) and ginsenoside Re (0.6 mg/ml). Composite solution 2 consisted of 
ginsenosides Rg1 (0.5 mg/ml) and Rb1 (0.5 mg/ml). Composite solution 3 consisted 
of ginsenosides Rc (0.6 mg/ml) and ginsenoside Rd (0.5 mg/ml). The 3 composite 
stock solutions were diluted with 70% methanol to give 5 to 6 different concentrations 
for the calibration curves. Each concentration was analysed in triplicate.  
 
3.1.2.5 HPLC method for qualitative and quantitative analysis 
An Agilent 1100 liquid chromatograph (Palo Alto, CA, USA) equipped with 
quaternary gradient pump, autosampler and diode array detector (DAD) was used. A 
HPLC method was developed using a reversed phase column (Waters Symmetry C18, 
250 x 4.6 mm I.D., 5 µm). The binary gradient elution system consisted of water (A) 
and acetonitrile (B) and separation was achieved using the following gradient: 0-30 
min, 20% B; 30-60 min, 20-45% B; 60-78 min, 45-75% B; 78-80 min, 75-100% B. 
The column temperature was kept constant at 35°C. The flow rate was 1 ml/min and 
the injection volume was 5 µl. The UV detection wavelength was set at 203 nm and 
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DAD was scanned from 190 to 400 nm. HPLC chromatograms and data were 
acquired and processed using Agilent ChemStation software. 
The concentrations of 6 saponins (notoginsenoside R1, ginsenosides Rg1, Re, 
Rb1, Rc and Rd) present in all the samples were determined and compared.  
 
3.1.2.6 Method validation 
The calibration curves were analysed using linear regression model (least 
squares method). The correlation coefficients were determined. The calibration curves, 
residuals and standardised residuals were visually inspected to assess linearity. 
The instrument/ injection precision (repeatability) was obtained by analysing 
the peak area variations of 13 injections of each saponin standard. The intra- and 
interday repeatability of the method was evaluated using multiple preparations of a 
sample. 5 replicate samples (raw P. notoginseng sample 2) were extracted and 
analysed in a single day and on 3 different days, i.e, a total of 15 replicated 
extractions of the sample were obtained. Calibration curves were generated each day 
before the analysis of samples. The intra- and interday variations (in relative standard 
deviations, RSD) of the concentrations of six saponins within the samples were 
calculated. The results were analysed by one-way analysis of variance (ANOVA) to 
determine any significant difference between the days.   
The recoveries of the saponins were determined by the standard addition 
method. The sample (raw P. notoginseng sample 2) was spiked with notoginsenoside 
R1 (0.7 mg), ginsenosides Rg1 (1.2 mg), Re (0.9 mg), Rb1 (1.2 mg), Rc (0.5 mg), and 
Rd (0.6 mg) and extracted as described above. For comparison, an unspiked sample 





LC-MS was carried out for unambiguous and confirmatory identification of 
the peaks. A Finnigan LCQ ion trap mass spectrometer (San Jose, CA, USA) coupled 
to a ThermoQuest TSP P4000 quaternary pump liquid chromatography system with 
autosampler (TSP AS3000) was used. Separation was carried out using Phenomenex 
Luna C18(2) microbore column (150 x 2 mm id, 5 µm). The binary gradient elution 
system consisted of 10 mM ammonium acetate in water (A) and acetonitrile (B). The 
following gradient was used: 0-15 min, 20% B; 15-40 min, 20-40% B; 40-70 min, 40-
75% B; 70-72 min, 75-100% B. The flow rate was 0.2 ml/min and the injection 
volume was 5 µl. The MS conditions were optimised. An electrospray ionisation (ESI) 
interface with positive-ion mode was employed. The ESI conditions were as follows: 
source voltage 4.5 kV, capillary temperature 230°C, sheath gas flow 80 units, 
auxillary gas flow 20 units, capillary voltage 10 V. Chromatograms and data were 
acquired and processed using Finnigan Xcalibur software (San Jose, CA, USA). 
 
3.1.2.8 Data analysis and hierarchical clustering analysis 
Statistical data analyses were performed using unpaired Student's t-test (for 
comparisons between two groups) and one-way analysis of variance (ANOVA) (for 
comparisons between three or more groups). Data were considered to be statistically 
significant when p values were <0.05. Hierarchical clustering analysis (HCA) was 
performed using SPSS (SPSS for windows 14.0, SPSS Inc., USA). Average linkage 
between groups was applied and Pearson correlation was selected as the measurement 




3.1.3 Results and Discussion 
3.1.3.1 Method development 
Extraction is the first important step to obtain the highest yield of chemical 
components from the plant materials. The choice of solvents and methods are some of 
the parameters which will affect extraction yields. Methanol and aqueous methanol 
[Court et al., 1996; Samukawa et al., 1995; Li et al., 1996] were commonly used for 
the extraction of ginsenosides in studies on P. ginseng or P. quinquefolium. A range 
of composition, ranging from 30 to 100% v/v methanol, was initially tested. The 
amount of saponins extracted from samples 1R, 1S and raw P. notoginseng sample 2 
using methanol and 70% v/v aqueous methanol was fully compared. Generally, it was 
found that the concentrations of saponins extracted with 70% v/v methanol were 4.1-
30.6% (n=3) higher than the saponin concentration extracted with methanol (Table 
3.2). The difference was statistically significant for some saponins. Therefore, 70% 
v/v methanol was the preferred solvent for the extraction and quantification of 
saponins. 
 Traditional extraction methods usually use heat and agitation to increase 
solubility of the phytochemicals and the rate of mass transfer. Soxhlet extraction has 
often been regarded as the standard conventional method for herbal extraction. 
However, it requires long extraction time of 6-12 h and the heat may degrade 
sensitive components. Besides soxhlet, the use of high intensity ultrasound to extract 
various phytochemicals from various parts of plants has been reported [Wu et al., 
2001]. Its mechanism is mainly by the mechanical effects of acoustic cavitation, 
which enhances both solvent penetration into the plant materials and the intracellular 
product release by disrupting the cell walls [Wu et al., 2001]. It reduces the extraction 
time and prevents thermal degradation of components. Preliminary study optimised  
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Table 3.2. Comparison of saponins concentration (% w/w) obtained using methanol 
and 70% methanol as the extraction solvents (n=3) 
 
 
Concentration of saponins (% w/w, mean ± SD)  
Saponins 
Extraction 




R1 70% Methanol 0.786 ± 0.038 0.364 ± 0.012 0.547 ± 0.012 
 Methanol 0.737 ± 0.011 0.335 ± 0.012 0.573 ± 0.009 
Rg1 70% Methanol 2.411 ± 0.102  1.413 ± 0.040 1.987 ± 0.166 
 Methanol 2.213 ± 0.106 1.261 ± 0.052 2.104 ± 0.042 
Re 70% Methanol 0.452 ± 0.025 0.271 ± 0.013 0.387 ± 0.007 
 Methanol 0.392 ± 0.024 0.229 ± 0.004 0.348 ± 0.008 
Rb1 70% Methanol 2.300 ± 0.074  1.412 ± 0.094 2.629 ± 0.198 
 Methanol 2.154 ± 0.066 1.159 ± 0.036 2.013 ± 0.043 
Rc 70% Methanol 0.170 ± 0.010 0.176 ± 0.004 0.118 ± 0.010 
 Methanol 0.143 ± 0.011 0.178 ± 0.010 0.098 ± 0.004 
Rd 70% Methanol 0.617 ± 0.043 0.347 ± 0.008 0.557 ± 0.008 









the amount of samples to use for extraction, as the solvents may be saturated when the 
quantities of sample were too high [Anderson and Burney, 1998]. Three ultrasonic 
extractions (20 min each) were found to be sufficient to completely extract the 
saponins of interest. The concentrations of saponins extracted using ultrasonication 
and soxhlet method were compared and the results are presented in Table 3.3. For 
notoginsenoside R1, ginsenosides Rg1, Re, Rb1 and Rd, it was found that ultrasonic 
extraction gave either comparable or slightly higher quantities (n=3). The use of heat 
in soxhlet extraction may have slightly reduced the concentration of saponins [Court 
et al., 1996]. Furthermore, high temperatures may affect the raw samples and 
complicate the comparison of raw and steamed P. notoginseng. Ultrasonic extraction, 
which has the advantage of being fast and efficient at ambient temperatures as 
compared to soxhlet extraction, was therefore employed in this study.  
The chromatographic conditions were developed using the standards, as well 
as a pair of raw and steamed P. notoginseng. Several potassium phosphate buffer-
acetonitrile and water-acetonitrile gradient systems were evaluated as mobile phases. 
Both systems gave similar profiles for P. notoginseng. Water-acetonitrile system was 
chosen, as it was a simple system that gave sufficient separation of the saponins from 
the other neighbouring peaks for their subsequent quantification. This gradient 
program was also able to elute and give good separation of the numerous less polar 
components found to be present in steamed P. notoginseng. Co-elution of ginsenoside 
Rg1 and Re is a common problem reported in other studies [Lee et al., 2002; Soldati 
et al., 1980], especially when one component is in much higher concentration than the 
other. However, in this study, a relatively good baseline resolution of the two 
ginsenosides was achieved for quantification. A gradient program with an initial 
isocratic flow of 80% water for at least 30 min enabled their separation. 
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Table 3.3. Comparison of saponins concentration (% w/w) obtained using ultrasonic 
and soxhlet extraction (n=3) 
 
 
Concentration of saponins (% w/w, mean ± SD)  
Saponins 




R1 ultrasonication 0.786 ± 0.038 0.364 ± 0.012 0.547 ± 0.012 
 soxhlet 0.708 ± 0.031 0.274 ± 0.014 0.507 ± 0.010 
Rg1 ultrasonication 2.411 ± 0.102 1.413 ± 0.040 1.987 ± 0.166 
 soxhlet 2.245 ± 0.086 1.049 ± 0.081 1.939 ± 0.024 
Re ultrasonication 0.452 ± 0.025 0.271 ± 0.013 0.387 ± 0.007 
 soxhlet 0.407 ± 0.019 0.210 ± 0.011 0.366 ± 0.006 
Rb1 ultrasonication 2.300 ± 0.074 1.412 ± 0.094 2.629 ± 0.198 
 soxhlet 2.269 ± 0.120 0.919 ± 0.088 2.552 ± 0.040 
Rc ultrasonication  0.170 ± 0.010 0.176 ± 0.004 0.118 ± 0.010 
 soxhlet 0.169 ± 0.006 0.252 ± 0.006 0.123 ± 0.009 
Rd ultrasonication 0.617 ± 0.043 0.347 ± 0.008 0.557 ± 0.008 









3.1.3.2 Identification of saponins 
Preliminary studies showed that the protopanaxatriol group (R1, Rg1, Re and 
Rf) of saponins were generally eluted before protopanaxadiol group (Rb1, Rc, Rb2, 
Rb3 and Rd). Ginsenosides Rb1, Rc, Rd, Re, Rg1 and notoginsenoside R1 were 
detected in all P. notoginseng samples. Ginsenosides Rb2, Rf and Rb3 were absent or 
present below the detection limits. The peaks were identified by comparing their 
retention times and UV spectra with those of the standards and spiking of the 
standards into the extract. UV spectra of the various saponins closely resembled each 
other. MS detection, which provides greater specificity than UV detection, was also 
employed for identification purposes. Despite the differences in the LC conditions for 
HPLC and LC-MS studies, the elution order of the six saponins under the conditions 
of LC-MS was found to be similar to that obtained in the HPLC elution. Identities of 
the six saponins were unambiguously confirmed by comparing their mass spectra with 
those of the standards. Under this positive ESI mode, notoginsenoside R1 has [M+H]+, 
[M+NH4]+, [M+Na]+ molecular ions at m/z 932, 950 and 955 and several 
characteristic product ions at m/z 405, 423, 441, 454, 459, 621, 680, 734, 751 and 769. 
The characteristic molecular and product ions of the other five saponins (ginsenosides 
Rg1, Re, Rb1, Rc and Rd) were similar to those reported in other positive-mode LC-
MS studies [Chan et al., 2000; Wang et al., 1999] on P. ginseng and their structures 
have been discussed. Prior to this work, LC-MS study on P. notoginseng crude 
extracts, however, has not been reported previously. 
  
3.1.3.3 Method validation 
The analytical method has been validated. The linearity of the calibration 
curves was verified by the correlation coefficients as well as by the visual inspection 
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of the line, residuals and standardised residuals. The linear calibration curves, 
concentration range, limit of detection (LOD, signal/noise=3) and limit of 
quantification (LOQ, signal/noise=10) of ginsenosides Rb1, Rc, Rd, Re, Rg1 and 
notoginsenoside R1 are given in Table 3.4. The injection precision (repeatability) for 
the six saponins was found to be within the range of 1.8-2.9% (n=13). The intraday 
(n=3) and interday precisions (RSD) (n=15) of the six saponins in the samples were 
0.7-4.0% (n=5) and 1.2-2.8% (n= 15) respectively. ANOVA analysis showed no 
statistical difference in results for all saponins between the 3 days, implying that the 
whole method was precise and consistent between different days. The recoveries of 
all six saponins were within the range of 97-102% (n=3, RSD<6.4%), showing that 
the extraction methods gave sufficiently good recoveries. 
 












R1 y = 1426x - 3.817 0.9988 0.180-0.600 0.013 0.042 
Rg1 y = 2034.5x + 2.589 0.9997 0.100-0.500 0.011 0.036 
Re y = 1407.6x - 12.471 0.9989 0.120-0.400 0.008 0.027 
Rb1 y = 1429.7x + 12.209 0.9993 0.100-0.500 0.010 0.033 
Rc y = 1247.2x + 5.198 0.9997 0.030-0.300 0.009 0.029 
Rd y = 1618.7x + 7.707 0.9996 0.050-0.500 0.012 0.039 
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3.1.3.4 Qualitative and quantitative comparisons of different Panax samples 
The chromatographic profiles of extracts of Panax species were compared to 
see the applicability of the optimised method in differentiating them as well as to 
correctly identify P. notoginseng for quality control purposes. Each species obtained 
from three or more different sources was analysed. It was found that the profiles 
between sources were similar qualitatively. The chromatograms of P. notoginseng, P. 
ginseng and P. quinquefolium showed some consistent differences and their typical 
chromatograms are shown in Figure 3.1. For P. notoginseng, ginsenoside Rg1 was 
present in higher quantities than ginsenoside Re (Rg1/Re ratio of 4.68). The opposite 
was obtained for P. quinquefolium, where the average ratio of Rg1/Re was 0.09. 
However, for P. ginseng, the difference in peak areas of ginsenoside Rg1 and Re was 
less (Rg1/Re was 0.53). Another important difference was the presence of 
notoginsenoside R1 in P. notoginseng. This component, however, was not detected in 
P. ginseng or P. quinquefolium. These differences may be used as markers to 
differentiate the three species. The results were consistent with studies [Chuang et al., 
1995, Zhai et al., 2001] comparing the Panax species using different analytical 
methods. Another commonly reported difference between P. ginseng and P. 
quinquefolium was the presence of ginsenoside Rf in the former and 24(R)-
pseudoginsenoside F11 in the latter [Chan et al., 2000]. However, both of these 
components were not detected in P. notoginseng. Quantitative analysis of the 
common saponins, ginsenosides Rg1, Re, Rb1, Rc and Rd, was performed for all the 
Panax samples. It was found that the average total content in P. notoginseng was 2.1 
times higher than P. ginseng, and 1.5 times higher than P. quinquefolium. Except for 
ginsenoside Rc and Re, ginsenosides Rg1, Rb1 and Rd were higher in P. notoginseng 



















































Figure 3.2. Typical HPLC chromatograms of extracts of (A) P. ginseng, (B) P. 




















notoginseng and the two species were significant (p<0.05) for ginsenoside Rg1 and 
Rd. Each of these individual saponins can have differences in pharmacological 
activities, for example ginsenoside Rg1 and Rb1 (discussed in Section 1.4.2.4). 
Therefore, these differences in their relative proportions may have resulted in 






























Figure 3.3. Comparison of the average concentration of saponins (% w/w) in the 








Hierarchical clustering analysis (HCA) is a technique that examines the inter-
point distances between all the samples and represents that information in the form of 
two-dimensional row spaces. To generate the dendrogram, HCA methods form 
clusters of samples based on their nearness in row space [Zhao et al., 2005]. A 
common approach is to initially treat every sample as a cluster and join closest 
clusters together. Variations of HCA use different approaches to measure distances 
between clusters [Zhao et al., 2005]. In this study, average linkage between groups 
was applied and Pearson correlation was used as the measurement. HCA method has 
the advantage of visually clustering large number of samples using many variables, 
instead of comparing just a few peaks. In this study, twenty five common 
characteristic peaks were selected and their peak areas in the fifteen samples formed a 
matrix of 15 x 25. The dendrogram (Figure 3.3) showed that the samples were divided 
into three main clusters and each cluster corresponded to each Panax species. From 
the distances, the clustering also showed that P. ginseng and P. quinquefolium were 
more closely related to each other than P. notoginseng.  
Therefore, this proposed method with HCA has been shown to be able to 
rapidly fingerprint the three common Panax species and differentiate them. With this 
understanding of the differences between the species, this is also one step towards 
quality control of P. notoginseng, as correct authentication of the roots is important 
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Figure 3.4. Dendrogram of the three Panax species using hierarchical clustering 
analysis with average linkage between groups. Samples 1-3 are P. quinquefolium, 























3.1.3.5 Qualitative and quantitative comparisons of different raw P. notoginseng 
samples 
Raw P. notoginseng samples obtained from different sources 
When the different sources of raw P. notoginseng samples 1 to 8 (random, 
pooled samples from different sources) were compared, consistent HPLC profiles 
were obtained qualitatively. The major components present in all the raw P. 
notoginseng samples were ginsenosides Rg1 and Rb1. However, some variations in 
their concentrations were observed. The total concentrations of the six saponins were 
5.1 to 9.1% w/w and the total concentrations of the four main saponins ranged from 
4.6 to 8.5% w/w respectively (Table 3.5). Each of the various ratios such as R1/Rg1, 
Rb1/Rg1 and Rd/Rg1, were fairly consistent, without large variations or outliers. 
Dong et al. [2003] has studied a large number of samples obtained from different 
parts of China and found that the total concentrations of four saponins (R1, Rg1, Rb1 
and Rd) ranged from 7.67 to 11.29% w/w. As the roots were obtained from different 
sources, some variations may be inevitable due to various factors such as strains, 
geographical sources, cultivation, harvest, storage and processing of the roots 
[Mahady et al., 2001]. In addition, the profiles and contents of P. notoginseng roots 
(Samples 5 and 7), which were uncoated, were found to be similar to the rest of the 
coated roots, showing that the coating process did not affect the saponin 
concentrations. When roots of three different quality or ‘tou’ obtained from the same 
source were compared, it was found that the total of the six saponins decreased with 
lower quality (or larger number of ‘tou’). This was consistent with a study which also 
showed a slight decrease in four major saponins with the increasing order of the ‘tou’ 
[Dong et al., 2003]. Two-year-old (Y2-1 and Y2-2) and three-year-old roots (Sample 
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Table 3.5. Concentration of saponins (% w/w) in raw P. notoginseng roots obtained from different sources (n=3) 
 
Samples Concentration of saponins (% w/w)  Ratio of saponins 
 
 R1 Rg1 Re Rb1 Rc Rd Total (all) 
Total of 4 
(R1+Rg1+Rb1+Rd)
 
R1/Rg1 Rb1/Rg1 Rd/Rg1 
1 (1-80) 0.945 2.759 0.644 2.676 0.206 0.772 8.003 7.152  0.343 0.970 0.280 
2 0.542 1.985 0.384 2.612 0.114 0.554 6.192 5.693  0.273 1.316 0.279 
3 0.809 2.482 0.449 2.603 0.128 0.613 7.085 6.507  0.326 1.049 0.247 
4 0.861 2.896 0.552 2.429 0.139 0.674 7.550 6.860  0.297 0.839 0.233 
5 0.545 1.583 0.560 3.020 0.136 0.631 6.476 5.779  0.344 1.908 0.399 
6 0.542 1.925 0.375 1.711 0.088 0.450 5.092 4.628  0.282 0.889 0.234 
7 0.570 2.930 0.792 2.606 0.165 0.620 7.684 6.726  0.195 0.889 0.212 
8 0.736 2.523 0.456 2.276 0.135 0.561 6.687 6.097  0.290 0.900 0.220 
1-40 0.733 3.298 0.474 3.299 0.177 1.127 9.109 8.457  0.222 1.000 0.342 
1-120 0.700 2.544 0.343 2.739 0.112 0.620 7.059 6.603  0.275 1.077 0.244 





7) obtained from Wenshan were found to have similar profiles and contents. P. 
notoginseng injection containing PNS was analysed and found to have the same 
profiles as the other raw P. notoginseng roots except for the large peaks eluting within 
the first 5 min, thus showing that it has been semi-purified to contain high amount of 
saponins and confirming that most of the peaks seen in the chromatogram belong to 
the saponins class of components. Therefore, these results showed that the raw 
samples from different sources have similar profiles but their saponins concentrations 
may vary considerably depending on several factors. 
 
Raw P. notoginseng individual roots obtained from the same source 
Using the established and validated HPLC method, twelve individual P. 
notoginseng roots, which were randomly collected from a GAP farm in Wenshan, 
were studied in triplicates. Their average values are shown in Table 3.6 and the RSD 
of the six saponins in different extracts ranged from 1.2 to 9.6% (average of 7.1%). 
Except for three roots, the chromatographic fingerprints of most of the roots were 
consistent with the other sources, as well as that of the reference standard sample 
(Sample 8) (Figure 3.4). The total concentrations of the four major saponins (R1, Rg1, 
Rb1 and Rd) in different individual roots ranged from 4.56 to 8.91% w/w, with 
samples WS-3 and WS-4 having the highest total concentration of saponins while 
samples WS-1 and WS-2 have the lowest total concentration. The total concentrations 
were generally lower than the previously reported concentrations (7.67 to 11.29% 
w/w) in the roots obtained from different subregions of Wenshan [Dong et al., 2003], 
although the roots in this study were also obtained from similar region. For the 
individual saponins, notoginsenoside R1 in all the analysed samples (0.59 to 3.66% 
w/w) were found to be 1.8 to 15.4 times higher than the previous study [Dong et al.,
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Table 3.6. Concentration of saponins (% w/w) (n=3) in the different individual roots obtained from the same source, compared to reference raw 
P. notoginseng root (sample 8). The values in bold were analysed to be outliers using boxplot (SPSS) 
 
Samples Concentration of saponins (% w/w)  Ratio of saponins 
 
 R1 Rg1 Re Rb1 Rc Rd Total (all) 
Total of 4 
(R1+Rg1+Rb1+Rd)
 
R1/Rg1 Rb1/Rg1 Rd/Rg1 
sample 8 0.736 2.523 0.456 2.276 0.135 0.561 6.687 6.097  0.29 0.90 0.22 
WS-1 0.787 2.265 0.310 1.263 0.069 0.245 4.940 4.560  0.35 0.56 0.11 
WS-2 1.110 1.340 0.259 1.903 0.084 0.280 4.976 4.633  0.83 1.42 0.21 
WS-3 1.950 3.820 0.853 2.569 0.161 0.573 9.928 8.913  0.51 0.67 0.15 
WS-4 0.623 1.483 0.152 5.351 0.109 1.185 8.903 8.642  0.42 3.61 0.80 
WS-5 3.658 1.069 0.084 1.554 0.013 0.295 6.674 6.576  3.42 1.45 0.28 
WS-6 1.202 2.129 0.668 2.945 0.167 0.393 7.504 6.669  0.56 1.38 0.18 
WS-7 0.688 2.232 0.351 2.197 0.088 0.494 6.049 5.610  0.31 0.98 0.22 
WS-8 1.527 2.242 0.310 3.419 0.344 0.496 8.338 7.684  0.68 1.52 0.22 
WS-9 0.593 3.033 0.335 2.221 0.086 0.510 6.778 6.357  0.20 0.73 0.17 
WS-10 1.338 2.623 0.644 1.759 0.091 0.368 6.823 6.088  0.51 0.67 0.14 
WS-11 2.327 1.695 0.395 2.045 0.080 0.456 6.998 6.523  1.37 1.21 0.27 
























Figure 3.5. HPLC chromatograms of extracts of (A) the reference raw P. notoginseng 
sample (Sample 8), (B) sample WS-4 and (C) sample WS-5 from a GAP farm. 
Majority of the roots showed the typical fingerprints as in (A). 













































2003]. This was not unexpected as the samples may be obtained from different 
cultivation sites or farms and the concentrations do vary between sources (as shown 
by the above results in Section 3.1.3.5). 
However, out of the twelve roots, there were three roots that have distinct 
profiles. The R1/Rg1 ratios in samples WS-5 and WS-11, and Rb1/Rg1 and Rd/Rg1 
ratios in sample WS-4 were statistical outliers (analysed using Boxplots from SPSS) 
compared to the respective ratios in other samples (Table 3.6). Abundance of Rb1 and 
Rd in relative to Rg1 were increased for sample WS-4 (Figure 3.4B and Table 3.6). 
The Rb1/ Rg1 and Rd/Rg1 ratios were 3.61 and 0.80 in sample WS-4 compared to 
0.90 and 0.22 in the reference standard sample (Sample 8) respectively. There was a 
substantial increase of R1 relative to Rg1 (Figure 3.4C and Table 3.6) for sample WS-
5, from a ratio of 0.29 in the reference sample to a ratio of 3.42. Similarly for sample 
WS-11, the ratio of R1 to Rg1 was 1.4. Compared to the previous study [Dong et al., 
2003], R1/Rg1 ratios were much higher for all the samples. Since each of these 
individual saponins can have differences in pharmacological activities, therefore these 
differences in their relative proportions may possibly affect its overall and specific 
activities. For example, ginsenoside Rg1 promotes angiogenesis, while ginsenoside 
Rb1 inhibits angiogenesis. Since these two components have opposing effects, the 
ratio Rb1/Rg1 has been found to be important [Sengupta et al., 2004]. The differences 
in chemical composition could be a result of differences in the genetic makeup of P. 
notoginseng plants. As the GAP farm is located in a mountainous region and covers a 
large area, growth conditions such as soil pH or soil moisture content, the amount of 
solar radiation may differ for different sections of the farm. Therefore, these subtle 
variations in growth conditions may have affected the chemical composition of the 
roots.  
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Hierarchical clustering analysis was used to compare the chromatograms of 
twelve individual roots. Twenty common characteristic peaks were selected and their 
peak areas in the twelve samples formed a matrix of 12 x 20. Triplicate analysis was 
carried out. From the dendrogram generated (Figure 3.5), the samples were divided 
into three main clusters: samples WS-1, 3, 7, 9 and 10 as cluster one; samples WS-2, 
6, 8 and 12 as cluster two; samples WS-4, 5 and 11 as cluster three. Cluster one and 
two were more closely related than cluster three. Similar to above discussion on their 
chemical concentrations and ratios, samples WS-4, 5 and 11 (cluster three) were not 
closely related in the cluster. The three samples appeared to be different from each 
other and they were the most distinct from the rest of the samples.  
Most of the root samples have profiles that were similar to the pooled samples 
from various sources. However, these results highlighted that some of the profiles of 
the roots were dissimilar and there is a surprisingly large variation in the relative 
abundances of the saponins in the different roots obtained from the same GAP farm or 
source. Therefore, the assumption that samples from the same source harvested at the 
same time is not necessarily true in all cases. This also highlighted the general lack of 
quality control and uniformity in a GAP farm. Due to such quality problems, this is 
one reason why reproducibility of preclinical studies and clinical trials of herbal 
medicines is difficult. Proper sampling is definitely important for herbal samples. 
Therefore, it is proposed that by analysing a number of pooled samples from different 
sources, the typical average profiles of P. notoginseng samples can be determined and 
using the same batches of pooled typical samples for further studies may help to 
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Figure 3.6. Dendrogram of P. notoginseng individual roots WS-1 to 12, using 















3.1.3.6 Qualitative and quantitative comparisons of raw and steamed P. 
notoginseng samples 
To determine the effects of steam processing on P. notoginseng, two 
representative sources of powdered raw roots were steamed. The HPLC 
chromatograms of raw and steamed P. notoginseng samples were found to be 
distinctively different, that is, the HPLC profiles were changed after processing 
(Figure 3.6). All the steamed samples from both sources showed numerous additional 
peaks (more than 10 peaks) eluting in the region between 63-76 min. These peaks 
were not distinct or were absent in the chromatograms of raw P. notoginseng. The 
numerous unique peaks, especially the four major peaks in this region (W, X, Y, Z), 
may serve as potential markers to differentiate the two forms.  
To study the effects of different extents of steaming, a powdered raw P. 
notoginseng root was steamed at different conditions and analysed. It was found that 
the differences between the raw and steamed samples were more distinct when the 
duration of steaming was increased from 1 to 9 h (Figure 3.6). The unknown peaks 
were increased when the duration of steaming was increased, and more distinctive 
peaks (such as S to Z) may be seen after 9 h of steaming. Quantitative analysis 
showed that notoginsenoside R1, ginsenosides Rg1, Re, Rb1, Rd were reduced upon 
steaming at 120°C from 1 to 9 h (Figure 3.7). Significant differences were obtained 
for all the saponins when the roots were steamed for more than 2 h, at 120°C. There 
were no significant differences between samples that were steamed for 6 and 9 h for 
ginsenosides Re, Rb1 and Rc, showing that these saponins were no longer reduced 
beyond 6 h of steaming and the levels were becoming constant (as seen in Figure 3.7). 
At lower temperatures of 105°C, the decrease in saponins was lesser for the same 


































Figure 3.7. (A) Typical chromatogram of raw P. notoginseng (sample 2); (B) 
Chromatogram of steamed P. notoginseng (steamed for 2 h at 120°C), showing the 
main characteristic W, X, Y and Z peaks; (C) Chromatogram of steamed P. 
notoginseng (steamed for 9 h at 120°C), showing further increases in the 
characteristic S, T, U, V, W, X, Y and Z peak areas and reductions in notoginsenoside 
R1, ginsenosides Rg1, Re, Rb1 and Rd peak areas. 
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Figure 3.8. Concentrations of saponins (% w/w) in P. notoginseng before and after 
steaming for 1, 2, 3, 6 and 9 hours (n=3) (* p<0.05 for all the saponins, compared to 
the values at time 0 h, using one-way ANOVA). 
 
 
and heating methods such as the use of oven for the same duration of 9 h, were similar. 
Autoclave method was more efficient and faster than other methods of heating the 
powdered roots. Furthermore, autoclaving has the advantage of providing a more 
accurate way of controlling the steaming temperature and duration than traditional 
steaming methods. It may be suitable for development into a GMP process for the 
steaming of traditional herbs. A greater decrease in the concentrations of the above 
saponins would therefore imply that the samples were steamed to a greater degree. 
The effect of steaming extent on P. notoginseng has not been previously studied in 
other reports. These results showed the implications and importance of standardising 






The results in this study were consistent with a report [Yang et al., 1985], 
which isolated lower amounts of ginsenosides Rg1, Re, Rb1, Rd and notoginsenside 
R1 from steamed P. notoginseng using column chromatography. These changes in 
concentrations might have occurred due to chemical degradation and conversion of 
some thermolabile ginsenosides to other components at high temperatures during the 
steaming process, as were reported for P. ginseng and P. quinquefolium [Kim et al., 
2000; Ren and Chen, 1999]. As discussed in Section 1.4.2.3, it has been postulated 
that the changes in saponins were due to the initial breakdown of the sugar moiety at 
the C-20 position, followed by further rearrangement of groups, to give rise to new 
saponins [Kim et al., 2000; Kwon et al., 2001; Yang et al., 1985]. However, except 
for one report [Yang et al., 1985], most of these changes and analysis were only 
reported in P. ginseng. 
P. ginseng roots were steamed, analysed and compared to steamed P. 
notoginseng. The chromatographic profiles are shown in Figure 3.8. As the raw forms 
of both species were different, their steamed forms may also have distinct profiles 
despite the presence of some similar saponins. It was noted that the relative proportion 
of the unknown marker peaks were different for the two species steamed with the 
same conditions. For example, marker peaks W and X were higher in concentration 
than peaks Y and Z for P. notoginseng, but this trend was opposite for P. ginseng. 
Korean red ginseng and the reference standard red ginseng are examples of steamed 
forms of P. ginseng and have similar profiles to each other (Figure 3.8). From the 
profiles, steamed P. ginseng samples obtained by the autoclaving method had been 
steamed to a greater extent as compared to the reference red ginseng or Korean red 
ginseng. Quantitative analysis of ginsenosides Rg1, Re, Rb1, Rc and Rd in P. ginseng 
that were steamed 3 to 9 h (Figure 3.9) also showed similar decreasing trends as the 
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steamed P. notoginseng roots. Most of the saponin concentrations in Korean and 
reference red ginseng were also lower than that obtained in P. ginseng. Therefore, 































Figure 3.9. Typical chromatogram of extracts of (A) Korean red ginseng; and (B) 
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Figure 3.10. Saponins concentration (% w/w) in P. ginseng before and after steaming 
for 3 and 9 hours (n=3). 
 
 
With the above knowledge on steamed P. notoginseng roots, the method was 
then applied to eleven pairs of raw and steamed P. notoginseng products to see if the 
method was applicable to detect differences in manufactured products or CPMs. By 
visual comparisons, out of the eleven pairs, the chromatograms of eight pairs were 
consistent with the profile of raw and steamed herbs, as shown in Figure 3.6. 
Therefore, confirming that steaming of the roots by autoclave methods gave similar 
chromatographic profiles as those steamed manufactured products. One raw (sample 
11R) and two steamed P. notoginseng CPMs (samples 9S and10S), however, were 
found to have chromatograms that resemble their counterpart products instead (Figure 
3.10). For pairs 9 and 10, the products labelled as ‘steamed’ were found to have 
chromatograms resembling a raw sample. Whereas, for pair 11, the product labelled 
as ‘raw’ have distinctive peaks in the region 63–76 min, resembling a steamed 
product. This may imply possible mislabelling. In the preparation of raw samples, the 


























Figure 3.11. (A) HPLC chromatogram of an extract of raw P. notoginseng CPM 
(sample 10R) and (B) HPLC chromatogram of an extract of steamed P. notoginseng 
CPM (sample 10S) where the product labelled “steamed” was found to resemble a 
“raw” product. Note the absence of S, T, U, V, W, X, Y and Z peaks in the region 



















Product labelled as steamed P. notoginseng 
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or drying, and this may have caused some chemical components to be changed. Thus, 
these raw products have chromatographic profiles that resemble those of steamed 
products. On the other hand, if the steamed products are not steamed/ processed 
sufficiently, they may yield profiles similar to those of the raw products. Due to their 
different pharmacological indications, this may pose a danger or have different effects 
on patients using these products.  
Quantitative analysis of the concentration (% w/w) and percentage 
concentration change of the saponins in all samples are presented in Table 3.7. The 
concentrations of ginsenosides Rg1, Re, Rb1, Rd and notoginsenoside R1 in most of 
the raw samples were found to be higher than those in the corresponding steamed 
samples (Table 3.7). Significant differences were also obtained for some pairs. The 
steamed CPMs may have been steamed to different degrees, resulting in great 
variabilities in the percentage change of saponins for the different pairs of CPMs.  
The lack of quality control and standardisations of herbal products and 
samples are important issues to address. Currently, among the different manufacturers, 
to our knowledge, there is no standardisation of the processing conditions used to 
steam the samples. Such information is also not available or may be kept confidential 
by the manufacturers. As quality control and standardisation of the processing 
methods are currently not present, the wide variations of results for different pairs of 
CPMs can be expected. 
Therefore, this validated method has been successfully developed and found 
capable of analysing various sources and products of P. notoginseng and its related 
species. Steam processing was found to change P. notoginseng significantly in terms 
of its chemical fingerprints, the compositions and concentrations of some saponins. 
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Table 3.7. Concentration of saponins (% w/w) (n=3) in the raw and steamed samples and the percentage change in concentration (in parenthesis) 
of the steamed samples (calculated with respect to the corresponding raw samples) (*p<0.05, using Student’s t-test) 
 
 
Pair Samples Concentration (% w/w)  (% change) 
  R1 Rg1 Re Rb1 Rc Rd 
1 1R 0.835  2.579  0.477  2.399  0.167  0.669  
 1S 0.362 (-56.67)* 1.442 (-44.06)* 0.268 (-43.76)* 1.405 (-41.42)* 0.176 (5.49) 0.345 (-48.50)* 
2 2R 0.614  2.156  0.347  2.060  0.116  0.503  
 2S 0.405 (-34.10)* 1.553 (-27.96)* 0.278 (-20.00)* 1.525 (-25.98)* 0.152 (31.16)* 0.353 (-29.92)* 
3 3R 0.658  2.134  0.372  2.084  0.134  0.532  
 3S 0.623 (-5.35) 2.449 (14.77)* 0.442 (18.85)* 2.374 (13.91)* 0.154 (14.93)* 0.579 (8.83)* 
4 4R 0.671  2.121  0.390  2.043  0.132  0.545  
 4S 0.599 (-10.65)* 2.030 (-4.29) 0.373 (-4.22) 1.918 (-6.08) 0.129 (-2.35) 0.480 (-11.93)* 
5 5R 0.701  2.272  0.394  2.179  0.140  0.566  




6 6R 0.597  1.969  0.334  1.830  0.109  0.468  
 6S 0.367 (-38.60)* 1.432 (-27.28)* 0.294 (-12.03)* 1.373 (-24.97)* 0.164 (50.88)* 0.360 (-23.09)* 
7 7R 0.596  1.874  0.321  1.739  0.107  0.483  
 7S 0.416 (-30.29)* 1.523 (-18.73)* 0.267 (-16.63)* 1.334 (-23.31)* 0.131 (22.69)* 0.377 (-21.84)* 
8 8R 0.572  1.863  0.342  1.798  0.123  0.518  
 8S 0.378 (-33.95)* 1.324 (-28.94)* 0.237 (-30.63)* 1.256 (-30.16)* 0.146 (18.75)* 0.336 (-35.15)* 
9 9R 0.624  2.149  0.352  2.137  0.132  0.490  
 9Sa 0.620 (-0.72) 2.116 (-1.52) 0.354 (0.68) 2.092 (-2.12) 0.122 (-6.98) 0.482 (-1.57) 
10 10R 0.700  2.668  0.436  2.518  0.133  0.586  
 10Sa 0.647 (-7.54) 2.571 (-3.64) 0.493 (13.12)* 2.370 (-5.86) 0.153 (15.29)* 0.558 (-4.75) 
11 11Rb 0.369  1.265  0.256  1.241  0.106  0.300  
 11S 0.343 (-7.25)* 1.163 (-8.06)* 0.244 (-4.83) 1.146 (-7.71) 0.121 (14.62)* 0.285 (-5.01) 
 
a: Samples labelled as “steamed” but their chromatograms resembled that of a raw product 




3.2 Pattern matching of extracts of P. notoginseng 
3.2.1 Introduction 
Unlike synthetic drugs of high purity, medicinal herbs and their products have 
a very complex mixture of chemical components whose identities are only partially 
known. Often, a few chemical markers in the chromatograms are selected and 
employed in evaluating the quality and authenticity of herbs. This method does not 
evaluate the entire chromatographic profile and large amounts of data in the 
chromatograms are discarded. Furthermore, similar integration results may not be 
achievable if baseline resolution is not achieved in complex mixtures. Selection of 
suitable markers to correctly identify the herb is also difficult and subjective. 
Therefore, this approach is not completely sufficient for quality control of herbs. The 
use of chromatographic chemical fingerprinting for the identification and quality 
control of medicinal herbs has attracted a lot of interest [Schaneberg et al., 2003; 
Gong et al., 2004; Cheng et al., 2003; Gong et al., 2003]. However, due to the 
complex fingerprints of herbal samples and chromatographic variations, accurate 
analysis and interpretation of the chromatograms in chemical fingerprinting pose a 
great challenge to analysts.  
One method to compare complex fingerprints is by visual comparison. This 
traditional method of visual chromatographic comparison is simple, but it is very 
subjective and non-quantitative. For complex chromatograms with incomplete 
separation of peaks, visual comparisons can be difficult and may miss subtle 
differences. Moreover, chromatography always varies from run-to-run due to pump, 
temperature, sample injection variations as well as changes in mobile phase and 
column chemistries. The resulting run-to-run chromatographic variations such as 
retention time drift and baseline drift, make the visual comparison method more 
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ambiguous. In some cases, these variations may make the methods analysing simple 
difference or variance of the chromatographic response non-applicable. Therefore, 
there is a need for a simple, valuable tool to objectively compare the entire 
chromatograms, detect real sample differences between them and measure the degree 
of differences quantitatively.  
With the rapidly increasing computational power and rapid development of the 
field of chemometrics in the last two decades, it is now possible to use complex 
mathematical algorithms to analyse the whole chromatogram quantitatively, and 
automatically. Such large data sets, which are previously considered impractical, can 
now be handled. This approach has been applied to many types of samples including 
medicinal herbs [Gong et al., 2004; Cheng et al., 2003; Gong et al., 2003], 
pharmaceuticals [Welsh et al., 1996], and food [Cordella et al., 2003; Quesada 
Granados et al., 2002]. Typically, most chromatographic analysis techniques involve 
developing a method of identifying some peaks to be compared, developing a method 
of comparing the various aspects of the peaks (e.g. peak area, height), and then 
actually performing the comparisons. However, the inevitable variations of 
chromatographic peak parameters such as retention time have always been a major 
impediment against accurate data processing in most chemometric analysis techniques. 
Multivariate chemometric analysis with entire chromatographic profiles as input data, 
is very sensitive to even minute variations. Therefore, many new approaches for 
retention time adjustments/peak alignment [Gong et al., 2004; Johnson et al., 2003; 
Malmquist and Danielsson, 1994; Torgrip et al., 2003] and extracting information 
from the fingerprints [Cheng et al., 2003] have been studied to address this 
challenging problem for chemometric analysis. Malmquist and Danielsson's 
alignment algorithm [1994] involved four rounds of iterative shifting to optimise 
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sample-to-target correlation. Gong et al. [2004] used chemometrics to select marker 
compounds, correct the retention time shifts and reconstruct the chromatographic 
fingerprints with correction. Torgrip et al. [2003] also developed a new search 
algorithm, which was shown to be favourable in terms of computational speed. After 
alignment of chromatograms and extracting the relevant information from the 
fingerprints, samples can then be classified based on several multivariate data analysis 
methods such as principal component analysis (PCA), soft independent modelling of 
class analogy (SIMCA), K-nearest neighbours (KNN), linear discriminant analysis 
(LDA). Artificial neural networks (ANN) are also rapidly emerging in the field of 
analytical chemistry as a powerful tool for pattern searching, mapping, and 
fingerprinting. There are some studies [Welsh et al., 1996; Cordella et al., 2003] using 
ANN and on the comparison of ANN architectures with standard classifiers.  
Besides the above chemometric analysis methods, novel chromatographic 
pattern matching software [Gorenstein, 1999; Waters Corporation, 2002] which 
combines the alignment and analysis of chromatograms will be specifically useful as a 
simple and convenient method for comparing chromatographic fingerprints. This 
method treats the entire chromatogram as a pattern and compares chromatograms in 
pairs. One is specified as reference (typically a known standard) against which the 
software compares the other sample chromatogram. In this application, the raw P. 
notoginseng samples were specified as reference. It uses a chromatographic alignment 
algorithm to align corresponding retention intervals from two chromatograms.  
The alignment algorithm is based on a two-step procedure. First, the algorithm 
fixes the responses in the sample chromatogram and mathematically adjusts the 
reference responses by least-squares optimisation to produce the best fit between the 
two chromatograms. The algorithm is based on the assumption that the normal 
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chromatographic variations can be described by five parameters 
(concentration/response ratio, baseline offset, baseline drift, retention time offset, 
retention time scale). It measures and applies these alignment parameters to the 
reference chromatogram. The response ratio refers to the factor by which the 
reference chromatogram is multiplied along the y-axis to best align with the sample 
chromatogram. The retention time offset refers to the amount of time by which the 
peak apices of reference chromatogram is adjusted. Retention time scale refers to the 
amount by which the retention time scale (x-axis) of the reference chromatogram is 
stretched or compressed to best align with the sample. Baseline offset refers to the 
amount by which the reference chromatogram is adjusted in the y-axis while baseline 
drift refers to the slope applied to the reference chromatogram baseline. In measuring 
all these values, only the raw data is used and no peak integration is performed. The 
pattern matching algorithm simulates, or models a possible range of responses for the 
reference chromatogram and finds the values for the five parameters by finding those 
values that minimise the sum of squared differences between the two chromatograms.  
Secondly, after alignment, the algorithm calculates the degree of differences 
(in terms of standard deviations) between the sample chromatogram and the 
parameter-adjusted reference chromatogram. The standard deviation is the square root 
of the average of a squared difference. The formula is: 














where fi are the response values in the fixed, sample chromatogram and ai are the 
adjusted response values from the reference chromatogram. The index i ranges over 
the N time samples in the comparison interval. The value for N is reduced by 5 to take 
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into account the effect of the five-parameter alignment on the magnitude of 
differences.  
During a scan of the entire chromatogram, the algorithm centers an alignment 
interval of fixed width (typically 2-peak widths) on each point over the entire 
chromatogram, regardless of the presence of peaks. It performs the alignment for each 
interval and computes the five alignment parameters as well as the standard deviations 
for each interval within the scan region (from start to stop time). From the whole scan, 
the pattern match standard deviation (PMSD) value is computed. It is the root-mean-
square value of all the individual standard deviations measured within the entire scan 
region. The term “standard deviation” is used in this study and it means a value of the 
pairwise differences calculated by the above corresponding formula. A Matlab 
implementation of this alignment algorithm is available [Gorenstein, 1999]. 
In this method, the variations due to normal chromatographic variations will 
not affect the comparisons, thereby revealing only changes due to the samples. This 
alignment algorithm has the advantage of adjusting for five underlying 
chromatographic variations simultaneously. Furthermore, no selection of peaks, 
internal standards, or traditional peak integration is needed, compared to known 
techniques. The algorithm detects peaks using the second derivative of the 
chromatogram. The apex of the inverted second derivative identifies the apex of a 
peak. Besides showing how similar or different the samples are, it can also rapidly 
identify which specific retention time interval of the chromatograms has significant 
pattern differences or new peaks. This may help to identify and isolate the 
differentiating peaks of interest. Other than chromatograms from LC separation, it can 
also be applied to GC, CE separation or other imported data. 
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In Section 3.1, it was shown that there were visually distinct differences 
between the chromatograms of raw and steamed samples and the concentrations of 
some saponins were changed. The whole chromatograms were qualitatively compared 
and clustered using HCA. Therefore, this part of the study aims to use a high-
performance liquid chromatographic (HPLC) pattern matching method as a new 
approach to objectively and quantitatively differentiate between the whole 
chromatograms of raw and steamed P. notoginseng samples [Lau et al., 2004]. Prior 
to this work, this pattern matching analysis tool has not been studied or applied to 
complex samples such as medicinal herbs. This method will be applied on 11 pairs of 
raw and steamed P. notoginseng CPMs to ascertain their degree of similarity or 




The water was treated with a Milli-Q water purification system (Millipore, 
Molsheim, France). HPLC-grade solvents were used for the analysis. The raw P. 
notoginseng roots (sample 2) and the eleven pairs of raw and steamed P. notoginseng 
CPMs were obtained from local Chinese medical shops (Table 3.1). Notoginsenoside 
R1, ginsenosides Rb1, Rc, Rd, Re and Rg1 standards were purchased as described in 
section 3.1.2.1. 
 
3.2.2.2 Sample preparation  
Sample preparation and steaming procedure were carried out using the same 
method as Section 3.1.2.2 and 3.1.2.3. The P. notoginseng samples, which were 
steamed at 120°C for 2, 6 and 9 h, were used. Four pairs of raw and steamed P. 
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notoginseng products, whose identities and labels were not known to the analyst, were 
extracted in the same way for the ‘blind’ test. 
 
3.2.2.3 HPLC with chromatographic pattern matching analysis 
HPLC analysis was performed on a Waters Alliance liquid chromatograph 
(Milford, MA, USA) equipped with Alliance separation module 2695 and photodiode 
array detector 2996. The reversed-phase column used was Waters Symmetry C18 
(250 mm× 4.6 mm i.d., 5 µm). The binary gradient elution system consisted of (A) 
water and (B) acetonitrile. Separation was achieved using the same gradient and 
conditions described in section 3.1.2.5. Sample analysis was processed by Waters 
Empower software 2002 with chromatographic pattern matching tool.  
The chromatographic pattern match processing method parameters used for 
the comparisons of samples were optimised as follows. Replicate injections of 
identical samples were carried out and used to develop method parameters, namely, 
scan start and stop times, peak width, alignment interval, retention time search limit, 
detection threshold, response value, and percent peak height. The scan start and stop 
times were 10 and 78 min. The detection threshold was set at 350. The response value 
and percent peak height were 0.0005 and 4.3%, respectively. After the parameters 
were optimised, the same pattern match processing method was then applied to all the 
samples compared.  
Statistical data analysis in this study was performed using one-way ANOVA 
for comparisons of more than two groups. Differences were considered to be 




3.2.3 Results and Discussion 
3.2.3.1 Optimisation of pattern match processing method 
The pattern match processing method was developed with repeated (n≥6) 
replicate injections of the raw samples, as well as replicate injections of steamed (2 h) 
samples, to detect true differences between samples. The scan region of 10–78 min 
was chosen to include the region of interest and to exclude regions of void volume, 
injection artefacts at the beginning and the re-equilibration region at the end of the 
chromatogram. In the preliminary pattern matching method, the scan time was 
selected while the software automatically calculated the rest of the parameters 
(alignment interval, retention time search limit, peak width, detection threshold, 
response value, and percent peak height) for the pattern matching process. In the 
optimisation routine, the autocalculated values can be further optimised to suit the 
particular set of samples and applications of the study.  
The retention time search limit affects the alignment results. It was further 
optimised to ensure the retention time offset encompasses the largest possible 
retention time offsets between the chromatograms. Retention time search limit of 15 s 
specified the retention time range over which the reference chromatogram was offset 
in search for the best alignment. The detection threshold affects the interpretation of 
the results. It was set to determine which peak apices were detected and plotted on the 
chromatogram. Detection threshold was set at 350 for optimal number of detected 
peaks in this case and to prevent over-clustering of peak apex markers in the plots.  
To objectively determine if a difference is genuine (not due to baseline noise), 
the individual standard deviations should be compared against a threshold. The 
threshold values do not affect the alignment or the standard deviation values. It only 
helps in the interpretation of the results. This standard deviation threshold is obtained 
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from comparing similar chromatograms (replicate injections). This threshold is 
calculated automatically by the software from response value and percent peak height. 
These two parameters were further optimised to correspond to the highest standard 
deviation values that an interval could have when the compared samples were the 
same. It ensured that the standard deviations of the replicate injections (identical 
samples) were detected below the threshold line. Therefore, it is a kind of limit-of-
detection test, which should be sensitive to detect true differences between different 
samples and not similar samples. The formula for the standard deviation threshold is: 
Standard deviation threshold = response + [percent peak height/100 × (maximum 
peak height in the interval)] 
The response is the minimum value for the standard deviation threshold. The percent 
peak height adds a value to the response that is proportional to the peak height within 
the compared interval.  
As described in Section 3.2.1, this tool will take into account 5 parameters of 
chromatographic variations to align the chromatograms, and it does not require the 
characterisation of peaks or other chromatographic features that are required by other 
known techniques. After chromatographic alignment and comparison, a quantitative 
value showing the relative difference between the samples will be generated and it 







3.2.3.2 Chromatographic pattern matching results of raw and steamed P. 
notoginseng  
Before comparing the raw and steamed samples, pairs (n≥6 pairs) of identical 
raw samples (replicate injections) were compared. Replicate injections of identical 
steamed samples (n≥6 pairs) were also performed and they gave similar results as 
replicate injections of raw samples. The typical pattern matching results of a pair of 
replicate injections of raw samples are shown in Figure 3.11A. The top plot shows the 
overlay of a pair of chromatograms in the scan region between 10 and 78 min. The 
middle plot shows their individual standard deviations of all points within the scan 
region. The standard deviation is a measure of the magnitude of point-to-point 
differences between the two chromatograms after alignment, as shown by the formula 
above. For similar samples (such as these replicate injections), the standard deviations 
were small and below the threshold line and they represented the background noise 
present. For replicate injections of raw P. notoginseng and replicate injections of 
steamed (2 h) P. notoginseng, the pattern match standard deviation values were found 
to be below 0.0006 and their average values were not statistically significant from 
each other (Table 3.8). Response ratios (sample/reference) of the peaks in both 
chromatograms were close to 1 for identical samples, as shown in the bottom plot of 
Figure 3.11A. The response ratios measure the approximate ratio of concentrations 













Figure 3.12. Typical results from chromatographic pattern matching for (A) replicate 
injections of raw P. notoginseng and (B) raw and steamed (2 h) P. notoginseng. Each 
of the top plots shows an overlay of the chromatograms, with black markers on peak 
apices. Each of the middle plots shows their corresponding standard deviations for all 
points in the scan region. Each of the bottom plots shows response ratios 




Table 3.8. Pattern match standard deviations (PMSD) of raw and steamed root 




Samples Brand name PMSD 
(AU) 
 Raw P. notoginseng (replicate injections)  0.0004 
 Steamed P. notoginseng (replicate injections)  0.0004 
 Steamed (2h) vs raw P. notoginseng sample  0.0024 
 Steamed (6h) vs raw P. notoginseng sample  0.0096 
 Steamed (9h) vs raw P. notoginseng sample  0.0120 
1 Pure Raw Pseudoginseng Powder 
Pure Steamed Pseudoginseng Powder 
Meihua 0.0041 
2 Raw Tienchi Ginseng Tablet 
Steamed Tienchi Ginseng Tablet 
Meihua 0.0021 
3 Yunnan Tienchi Powder (Raw) 
Yunnan Tienchi Powder (Steamed) 
Nature’s Green 0.0012 
4 Yunnan Tienchi Tablets (Raw) 
Yunnan Tienchi Tablets (Steamed) 
Nature’s Green 0.0009 
5 Tienchi Powder (Raw) 
Tienchi Powder (Steamed) 
Yunfeng 0.0050 
6 Tienchi Tablets (Raw) 
Tienchi Tablets (Steamed) 
Yunfeng 0.0028 
7 Tienchi Powder (Raw) 
Tienchi Powder (Steamed) 
Camellia 0.0026 
8 Tienchi Tablets (Raw) 
Tienchi Tablets (Steamed) 
Camellia 0.0025 
9 Tienchi Tablet (Raw) 
Tienchi Tablet (Steamed) 
Yulin 0.0005 
10 Yunnan Tian Qi Powder (Raw) 
Yunnan Tian Qi Powder (Steamed) 
Kiat Ling 0.0004 
11 Chinese Yunnan Tien Chi Tablet (Raw) 
Chinese Yunnan Tien Chi Tablet (Steamed) 




Using pattern matching analysis, the raw and steamed samples were 
successfully differentiated. The top plot of Figure 3.11B shows the typical overlaid 
chromatograms of raw and steamed (2 h) P. notoginseng. The standard deviations 
increased above threshold line at various points in the scan region, especially in the 
region 63–76 min, as shown in the middle plot of Figure 3.11B. This indicated that 
the samples were not similar in this region. Response ratio also increased to a value of 
45 at one point (65th minute). The pattern match standard deviation value was also 
significantly higher than that obtained from replicate injections of samples. As the 
duration of steaming increased, the differences between the chromatograms also 
increased. This was reflected in the pattern match plot. The average pattern match 
standard deviation values increased with duration of steaming (Figure 3.12). The 
values (Table 3.8) increased from 0.0024 to 0.0120 for 2 and 9 h of steaming, 
respectively. These were about 3 to 17 times the PMSD values for replicate injections 
of identical samples and the PMSD values were statistically higher (p < 0.05) than 
that obtained for replicate injections. The values obtained for steamed samples (2, 6 
and 9 h) were also statistically significant from each other. Therefore, these values 
gave useful indications of the similarity of the sample pairs and served as a similarity 













































Figure 3.13. Pattern match standard deviation values of replicate injections and P. 
notoginseng samples that were steamed for 2, 6 and 9 h. Values were means ± SD, 
n≥6. For the steamed samples, the pattern match standard deviation values were 
obtained from the pattern matching comparisons with the corresponding raw sample 
(before steaming). The asterisk (*) denotes statistically significant differences 
















3.2.3.3 Chromatographic pattern matching of raw and steamed P. notoginseng 
products 
After establishing the method and differentiating the known raw and steamed 
samples, the chromatographic pattern matching method was then applied to the 
comparisons of 11 pairs of raw and steamed P. notoginseng proprietary herbal 
products. Their pattern match standard deviation values are summarised in Table 3.8. 
Eight pairs (pairs 1–8) of raw and steamed CPMs showed distinctive differences from 
the pattern match plots. The pattern match standard deviation values of these eight 
pairs ranged from 0.0009 to 0.0050. Values above 0.0008 were found to be 
statistically different (p < 0.05) from the replicate injections of identical samples. 
Similar to the above study (Section 3.1), three raw and steamed pairs (pairs 9–11) 
were found to have similar chromatographic patterns from their pattern match plots. 
The pattern match standard deviation values for the three pairs were close to that 
obtained for replicate injections. The standard deviations were below threshold line 
and their response ratios were close to 1, which were similar to the typical results of 
the replicate injections. This implies that these pairs of sample were similar, although 
they were labelled as ‘raw’ and ‘steamed’. Although the above study (Section 3.1) 
reported the clear differentiation of chromatographic fingerprints of extracts of raw 
and steamed P. notoginseng, the current method provided further quantitative 
comparisons of pairs of such products. Visual chromatographic comparisons of the 
extracts of three pairs out of eleven pairs of such products showed that the 
differentiation between the pairs was not clear and was inconsistent with the label 
claims. Indeed, upon quantitative comparisons of the chromatograms, we have 
demonstrated that the method is able to detect such discrepancies.  
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From the values of the pattern match standard deviation, additional useful 
information regarding the degree in which the raw herb was steamed or changed by 
the process may be obtained. This information may not be objectively obtained by 
visual comparisons or clustering methods. Among the CPMs, pair 10 has the lowest 
PMSD value, while pair 5 has the highest value. The greater the differences, the 
greater the degree in which the herbs were steamed or the components were changed 
by the processing method, with respect to the corresponding raw sample. This is 
useful in standardisation of the steamed herb whereby a particular target range may be 
set. A ‘blind’ test was carried out whereby the identities of four pairs of raw and 
steamed products were not known to the analyst. Using pattern matching analysis, 
accurate identification of the raw and steamed products was obtained, confirming the 
usefulness of this method.  
Therefore, this method provided quantitative differentiation of raw and 
steamed P. notoginseng samples and was capable of showing the degree in which 
steaming has changed the samples. It may be applied to identify herbs, check the 
quality or source by comparing an unknown with a known or standard herb. Using the 
pattern match standard deviation values, it can determine which samples are most 










In this chapter, a new, simple and reliable HPLC-DAD analytical method has 
been successfully developed and found to be suitable for the routine differentiation 
between raw and steamed forms of P. notoginseng. The method has been validated for 
linearity, precision, specificity, LOD and LOQ, and can be used for the simultaneous 
quantification of six saponins present in both forms. Together with HCA, it was 
applicable for the authentication of raw P. notoginseng from its closely related Panax 
species. Raw P. notoginseng samples from different and same sources were also 
investigated. This is the first report of qualitative and quantitative comparisons of the 
saponins concentrations in both raw and steamed P. notoginseng using HPLC-DAD. 
The concentrations were decreased upon steaming and several new unknown peaks 
were increased. The developed method has been successfully applied to 11 pairs of 
raw and steamed P. notoginseng CPMs. Three products were found to show 
discrepancies between their labelled claims (raw or steamed) and the results of 
analysis.  
In addition, a new HPLC method coupled with chromatographic pattern 
matching analysis further enhanced the method by allowing rapid, simple, automated, 
and quantitative comparisons of complex chromatograms. The method was successful 
in providing quantitative differentiation of raw and steamed P. notoginseng root 
samples and its products, and in rapidly detecting inconsistencies in the products. The 
degree of similarity and degree in which the raw sample has been changed by the 
steaming process can be deduced. Therefore, these methods have important 
applications and they are proposed as potentially useful tools for ensuring quality and 
safety of herbal medicines.  
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CHAPTER 4 
ISOLATION AND IDENTIFICATION OF CHEMICAL 
COMPONENTS FROM STEAMED  
PANAX NOTOGINSENG 
4.1 Introduction 
The chemical components from Panax species have been studied and the 
largest class of bioactive components is found to be saponins. More than 30 
ginsenosides have been isolated and structurally elucidated, but there is still ongoing 
research on the components of P. ginseng, including new and minor components. The 
components obtained from different species and different parts of the same plant may 
be different. The types of saponins that are present in raw P. notoginseng roots have 
been reported [State Administration of Traditional Chinese Medicine, 1996; Zhou et 
al., 1981; Taniyasu et al., 1982; Matsura et al., 1983; Zhao et al., 1996; Yoshikawa et 
al., 1997a; Yoshikawa et al., 1997b; Yoshikawa et al., 2001; Ma et al., 1999; Yang et 
al., 1983]. However, to date, the chemical components in steamed P. notogoinseng 
have not been as well-studied as the raw form. Prior to this work, only one study 
[Yang et al., 1985] was found (Section 1.4.2.3). However, there may be more 
components in the steamed form than the previously reported saponins. Subsequent 
studies are needed to further understand the differences between them. As discussed 
in Chapter 3, the chromatograms of raw and steamed P. notoginseng were different 
and the steamed form contained many additional peaks with unknown identities. 
These components are important in differentiating the two forms and may result in 
different activities. Although there were some chemical studies on red or steamed 
ginseng [Kim et al., 2000; Kwon et al., 2001; Ren and Chen, 1999; Kitagawa et al., 
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1987; Kasai et al, 1983; Ryu et al, 1997; Baek et al., 1996; Park et al., 1998], the 
results may not be directly extrapolated to  P. notoginseng.  
Therefore, the objective of this study is to isolate and identify the main 
biomarkers in steamed P. notoginseng, which can serve to differentiate the raw and 
steamed forms, to better explain their differences and to understand the main 




The raw P. notoginseng roots (sample 2), notoginsenoside R1, ginsenosides 
Rb1, Rc, Rd, Re and Rg1 standards were purchased (Section 3.1.2.1). 20R- and 20S-
ginsenoside Rg3 were generous gifts from Professor J.H. Park (College of Pharmacy, 
Seoul National University, Korea). 20RS-ginsenoside Rg2 mixture and 20S-
ginsenoside Rh2 were obtained from Delta Information Centre for Natural Organic 
Compounds, China.  
The solvents used for extraction and separation were of analytical grades, 
while the solvents used for HPLC were of HPLC-grade. The water was treated with 
Milli-Q water purification system (Millipore, Molsheim, France). Silica gel 60 (63-
200 µm, 70-230 mesh) for column chromatography, and TLC aluminium sheets pre-
coated with silica gel 60 (layer thickness 0.2 mm, 20 x 20 cm) were purchased from 
Merck KGaA (Darmstadt, Germany). Tetramethylsilane (TMS) and pyridine-d5 





4.2.2 Extraction and separation of fractions 
Raw P. notoginseng powder (~600 g) was steamed for 9 h using the method 
described in Section 3.1.2.3. Steamed P. notoginseng powder (230 g) was extracted 
with methanol (2 L) by ultrasonication for 2 h and filtered under vacuum. This step 
was repeated for a total of five times. The combined filtrates were evaporated to 
dryness in vacuo, giving a crude methanolic extract (34 g, 15%). The crude residue 
was dissolved in 140 ml water, washed with 200 ml n-hexane (three times), and 
extracted with 300 ml water-saturated n-butanol (five times), using liquid-liquid 
extraction methods. The water, hexane and butanol extracts were evaporated to 
dryness in vacuo. A small portion of each extract was reconstituted with methanol and 
analysed by HPLC using the same conditions as described in Section 3.1.2.5. 
The butanol extract was subjected to multiple normal-phase open-column 
chromatography (silica gel 60, 63-200 µm particle sizes, 500 length x 30 mm 
diameter). 4 g of the concentrated butanol extract (dissolved in initial composition of 
mobile phase) was applied to the column and gradient elution using different 
compositions of dichloromethane and methanol (9:1, 7:1, 5:1, 7:3, 1:1, 0:1) was 
employed. The collected fractions were analysed by TLC using dichloromethane and 
methanol (9:1) as the mobile phase. The spots on the TLC plates were detected by 
spraying with 40% v/v sulphuric acid in ethanol and heating the plate at 100°C for 10 
min. Similar fractions were combined, evaporated, reconstituted and analysed by 
HPLC using the same HPLC conditions as described in Section 3.1.2.5, except for the 
shorter gradient: 0-10 min, 20-45% acetonitrile (B); 10-25 min, 45-75% B; 25-28 min, 
75-100% B; 28-35 min, 100% B. From the HPLC chromatograms, further 
combination of similar fractions containing the peaks of interest was carried out. 
Three main fractions, each containing a pair of the peaks of interest as the major 
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components, were concentrated to a small volume and subjected to further 
purification, as described below (Section 4.2.3). The whole column chromatography 
process was repeatedly performed to obtain sufficient quantities for subsequent 
studies.  
 
4.2.3 Purification and isolation of pure components 
Semi-preparative HPLC methods, using an Agilent 1100 liquid chromatograph 
(Palo Alto, CA, USA) equipped with quaternary gradient pump, autosampler and 
DAD, were carried out to purify and isolate the pure components. Separation was 
achieved using semi-preparative reversed-phase column (Agilent Zorbax SB-C18, 
250 x 9.4 mm I.D., 5 µm particle size) and isocratic elution using water and 
acetonitrile. The column temperature was kept constant at 35°C. The UV detection 
wavelengths were set at 203, 230, 254, 280 nm and DAD was scanned from 190 to 
400 nm. Three different isocratic elution profiles (A, B, C) were developed and used, 
that is, (A) 33% v/v acetonitrile, flow rate was 2.5 ml/min, run time was 25 min, each 
injection volume was 100 µl; (B) 43% v/v acetonitrile, flow rate was 2.8 ml/min, run 
time was 25 min, each injection volume was 75 µl; (C) 51% v/v acetonitrile, flow rate 
was 3 ml/min, run time was 32 min, each injection volume was 150 µl. The fractions 
were collected by monitoring retention times and peak areas. The tailing portions of 
each peak were not collected to prevent contamination with close neighbouring peaks. 
The HPLC runs were repeated until the total volume of the fractions were injected. 






Melting points were determined with a melting point apparatus (220-240V, 
Gallenkamp, Loughborough, UK). Mass spectra were obtained using a Finnigan LCQ 
ion trap mass spectrometer (San Jose, CA, USA). The positive mode ESI parameters 
were set as: sheath gas flow rate 80 units, auxilliary gas flow rate 20 units, spray 
voltage 4.5kV, capillary temperature 230°C, capillary voltage 10 V, tube lens offset 0 
V. Samples dissolved in methanol (~100 µg/ml) were injected directly (5 µl) into the 
mass spectrometer with 50% v/v ammonium acetate (10 mM) and 50% v/v 
acetonitrile. The MS data was acquired by Finnigan Xcalibur software. 10-15 mg of 
the samples was dissolved in pyridine-d5 and their proton and carbon-13 NMR spectra 
were acquired at 300MHz on a Bruker AVANCE 300 spectrometer. The chemical 
shifts (δ) were expressed in parts per million (ppm) relative to TMS as the internal 
standard. 
 
4.3 Results and Discussion 
The crude extract was obtained by ultrasonic extraction using methanol and 
the yield was approximately 15% w/w of the quantity of powdered root used. Initial 
separation of the crude extract into water, butanol and hexane extracts gave dried 
yields of 3.7%, 12.3% and 0.3% w/w of the quantity of powdered root (or 24.5%, 
82.6% and 2.4% w/w of the dried crude extract) respectively. These corresponded to 
the polar, moderately polar and non-polar fractions respectively, as seen from the 
chromatograms of the components present in each of the extracts (Figure 4.1). The 
hexane extract may consist of non-polar compounds such as lipids, fatty acids, and 
polyacetylenes. After extraction with n-butanol, the remaining water extract may 









































Figure 4.1. HPLC chromatograms of (A) butanol, (B) water, and (C) hexane extracts 
of steamed P. notoginseng (9 h). 
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not retained by the reversed-phase column. The HPLC profile of the butanol extract 
was rather similar to the crude extract except for the large peaks eluting at the solvent 
front. Therefore, saponins, including the six saponins analysed in Chapter 3, were 
extracted and found in the butanolic extract. The peaks of interest, which served as 
differentiating marker compounds to identify the samples, were those present in the 
steamed form but not detected in the raw form. As these peaks were predominantly in 
the butanolic extract, therefore subsequent separation and isolation were focused on 
this particular fraction.  
Column chromatography using silica gel was used to fractionate the butanol 
extract into different fractions, each containing several components. Repeated 
chromatography was needed to isolate six pure components (U to Z) from complex 
herbal extracts. Three impure fractions (fraction with U, V: 4.2%  w/w of the butanol 
extract used, fraction with W, X: 3.6% w/w, and fraction with Y, Z: 4.6% w/w), each 
containing a pair of compounds together with many other minor components, were of 
interest because they were the differentiating marker compounds for steamed P. 
notoginseng. As the polarities of the pairs of compounds were similar, they eluted 
together and low resolution normal-phased chromatography was found unsuitable to 
separate them. Each of the three pairs can only be separated by subsequent semi-
preparative HPLC methods, which were optimised to separate the compounds 
sufficiently to obtain pure compounds. Therefore, the six pure compounds (U to Z) 
were finally isolated from the butanol extract. Their identities were determined using 































































Saponins R1 R2 R3 
Protopanaxatriol    
R1 -H -O-Glc2-1Xyl -Glc 
Rg1 -H -O-Glc -Glc 
Re -H -O-Glc2-1Rha -Glc 
Rg2 -H -O-Glc2-1Rha -H 
20S-Rh1 -H -O-Glc -H 
20R-Rh1 -H -O-Glc -H 
    
Protopanaxadiol    
Rb1 -Glc2-1Glc -H -Glc6-1Glc 
Rc -Glc2-1Glc -H -Glc6-1Ara(f) 
Rd -Glc2-1Glc -H -Glc 
20S-Rg3 -Glc2-1Glc -H -H 
20R-Rg3 -Glc2-1Glc -H -H 














Saponins R1 R2 
Rg5 -Glc2-1Glc -H 
Rh4 -H -O-Glc 










Saponins R1 R2 
Rk1 -Glc2-1Glc -H 




Figure 4.2. Chemical structures of some saponins present in raw and steamed P. 
notoginseng. Those in bold are characteristic for the steamed samples. Abbreviations: 
Glc, glucose; Ara(f), arabinose in furanose form; Ara(p), arabinose in pyranose form; 





Compound U: It was obtained as a white amorphous powder with a melting 
point of 246-248°C (literature: 245-246.5°C) [Ahmad and Basha, 2000]. The yield 
was 1.6% w/w of butanol extract and purity was >95% as determined by HPLC. UV 
spectrum was a typical saponin spectrum. Positive ionisation mode ESI-MS revealed 
a [M+H]+ at m/z 639 and [M+Na]+ at m/z 661, thereby suggesting a compound with a 
molecular mass of 638. Product ions at m/z 405, 423, and 441 also suggested a 
protopanaxatriol type of ginsenoside [Miao et al., 2002; Chan et al., 2000; Wang et 
al., 1999]. Furthermore, a loss of one and two water molecules from the molecular 
[M+H]+ ion gave rise to product ions at m/z 621 and 603 respectively [Wang et al., 
1999]. The 13C-NMR data were acquired and tabulated in Table 4.1. From 
comparison with the chemical shifts in the literature for protopanaxatriol, 
protopanaxadiol and various structurally similar ginsenosides, the signals were 
assigned. One anomeric carbon signal at 106.01 ppm and signals between 60-80 ppm 
suggested that the compound has one sugar moiety. Two olefinic carbon signals at 
130.81 and 126.31 ppm suggested one double bond, typical of a protopanaxatriol 
which has a double bond at C-24(25). Its 13C-NMR spectra was found to be similar to 
ginsenoside Rg1, except that the latter has signals corresponding to two sugar 
moieties and the signals around C-17, 20, 21 differed [Teng et al., 2002], suggesting 
that the sugar moiety at C-20 may be removed in compound U. Furthermore, the mass 
difference between compound U and ginsenoside Rg1 was 162, which corresponded 
to a loss of a glucose unit. The NMR data correlated well with published data [Teng et 
al., 2002], and together with all the above data which supported its identity, 
compound U was determined to be 3β,6α,12β,20S-tetrahydroxydammar-24-ene-6-O-
β-D-glycopyranoside or also named as 20S-ginsenoside Rh1.   
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Table 4.1. 13C-NMR chemical shifts (δ, ppm) (300MHz, in pyridine-d5) of 
compounds U, V, W, X, Y and Z, corresponding to 20S-ginsenoside Rh1, 20R-
ginsenoside Rh1, ginsenosides Rk3, Rh4, Rk1 and Rg5 respectively 
 
Chemical shifts (ppm) 
20S-Rh1 20R-Rh1 Rk3 Rh4 Rk1 Rg5 Carbon 
positions U V W X Y Z 
Aglycone 
1 39.40 39.40 39.53 39.50 39.28 39.31 
2 27.88 27.90 27.95 27.92 26.72 28.13 
3 78.61 78.61 78.59 78.59 89.09 88.98 
4 40.36 40.38 40.41 40.39 39.73 40.28 
5 61.43 61.44 61.48 61.44 56.41 56.44 
6 80.08 80.10 80.09 80.08 18.44 18.47 
7 45.22 45.19 45.35 45.33 35.34 35.37 
8 41.09 41.13 41.29 41.35 40.19 39.74 
9 50.19 50.21 50.67 50.69 48.23 50.80 
10 39.66 39.68 39.74 39.75 37.01 37.06 
11 32.04 32.17 32.77 32.30 32.64 32.23 
12 71.05 70.95 72.46 72.59 72.48 72.63 
13 48.22 48.88 52.10 50.60 52.42 50.46 
14 51.65 51.73 51.17 50.86 51.24 51.06 
15 31.23 31.34 32.53 32.56 32.64 32.67 
16 26.82 26.62 30.74 28.84 30.82 26.78 
17 54.73 50.57 48.30 50.42 50.86 50.93 
18 17.38 17.41 17.37 17.39 16.46 16.46 
19 17.70 17.72 17.77 17.74 15.79 16.62 
20 73.04 73.09 155.45 140.11 155.50 140.20 
21 27.00 22.74 108.14 13.14 108.15 13.19 
22 35.83 43.19 33.73 123.56 33.86 123.22 
23 23.00 22.59 27.05 27.46 27.07 27.48 
24 126.31 126.03 125.38 123.88 125.36 123.55 
25 130.81 130.82 131.22 131.26 131.26 131.29 
26 25.83 25.84 25.78 25.70 25.78 25.70 
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27 17.64 17.72 17.37 17.74 17.77 17.73 
28 31.72 31.73 31.73 31.73 28.09 28.87 
29 16.39 16.40 16.38 16.38 16.59 15.85 
30 16.78 17.08 16.76 16.81 16.99 17.05 
Sugar moieties 
6-Glc 
1' 106.01 106.00 106.03 106.02   
2' 75.47 75.49 75.48 75.47   
3' 79.62 79.65 79.68 79.66   
4' 71.84 71.85 71.84 71.83   
5' 78.13 78.17 78.17 78.16   
6' 63.05 63.08 63.09 63.08   
3-Glc 
1'     105.10 105.13 
2'     83.04 83.42 
3'     78.12 78.27 
4'     71.58 71.66 
5'     77.98 78.00 
6'     62.75 62.77 
1''     105.79 106.02 
2''     77.00 77.12 
3''     78.34 78.38 
4''     71.70 71.72 
5''     77.98 78.12 










Compound V: It was obtained as a white amorphous powder with a melting 
point of 155-158°C (literature: 154-158°C). The yield was 0.5% w/w of butanol 
extract and purity was >95% as determined by HPLC. The positive ionisation mode 
ESI mass spectrum was similar to that of compound U, with [M+H]+ at m/z 639 and 
[M+Na]+ at m/z 661, thereby suggesting that the two compounds, U and V, were 
isomers with a similar molecular mass of 638. The NMR signals of compounds U and 
V were almost identical, except for the slight differences in carbon signals at three 
carbon positions. As seen from Table 4.1, the differences in NMR chemical shifts 
between compounds U and V were mainly at C-17 (+4.16 ppm), C-21 (+4.26 ppm) 
and C-22 (-7.36 ppm). They were likely to be structurally similar. From comparison 
with all published literature and the above deductions, the results obtained in this 
study was found to correlate well with previously reported data [Teng et al., 2002] of 
3β,6α,12β,20R-tetrahydroxydammar-24-ene-6-O-β-D-glycopyranoside or also known 
as 20R-ginsenoside Rh1. Therefore, compounds U and V are epimers of each other 
and the change in configuration at C-20 has mainly affected the chemical shifts of the 
neighbouring carbons (C-17, C-21, C-22). Similar changes at these positions were 
observed for another pair of 20S and 20R-ginsenoside Rg3 [Teng et al., 2000].  
Compound W: It was obtained as a white amorphous powder with a melting 
point of 146-148°C (literature: 145-147°C). The yield was 1.0% w/w of butanol 
extract and purity was >96% as determined by HPLC. Positive ionisation mode ESI-
MS revealed a [M+H]+ at m/z 621 and [M+NH4]+ at m/z 638, thereby suggesting a 
compound with a molecular mass of 620. From the 13C-NMR data (Table 4.1), one 
anomeric carbon signal at 106.03 ppm and signals between 60-80 ppm suggested that 
the compound has one sugar moiety. However, there were four olefinic carbon signals 
at 155.45, 131.22, 125.38, 108.14 ppm which suggested two double bonds. The 
 115
signals were quite similar to that of ginsenoside Rh3 (molecular weight = 604), except 
for one additional hydroxyl group (16 mass units), and it is likely to be 
protopanaxatriol type ginsenoside. The 1H and 13C-NMR data correlated well with a 
literature report (Park et al., 2002), and compound W was determined to be 
3β,6α,12β-trihydroxydammar-20(21),24-diene-6-O-β-D-glycopyranoside or 
otherwise named as ginsenoside Rk3. 
Compound X: It was obtained as a white amorphous powder with a melting 
point of 156-158°C (literature: 155-157°C). The yield was 1.0% w/w of butanol 
extract and purity was >96% as determined by HPLC. The mass spectrum showed a 
[M+H]+ at m/z 621 and [M+NH4]+ at m/z 638, thereby suggesting a compound with a 
molecular mass of 620 and may be an isomer of compound W. The 13C-NMR data 
signals (Table 4.1) were similar to that of compound W, except for some of the 
olefinic carbon signals, suggesting that the double bonds were at different positions. 
Furthermore, these olefinic signals were similar to that of ginsenoside Rh3, 
suggesting similar double bond positions. The 1H and 13C-NMR data correlated well 
with the data in a previous report [Park et al., 2002b], and together with the above 
supporting data, compound X was therefore identified to be 3β,6α,12β-
trihydroxydammar-20(22),24-diene-6-O-β-D-glycopyranoside or also known as 
ginsenoside Rh4. 
Compound Y: It was obtained as a white amorphous powder with a melting 
point of 177-180°C (literature 178-181°C). The yield was 0.4% w/w of butanol 
extract and purity was >95% as determined by HPLC. The molecular mass was 
determined to be 766 from the positive mode ESI-MS which showed a [M+H]+ ion at 
m/z 767, [M+NH4]+ at m/z 784 and [M+Na]+ at m/z 789. From the 13C-NMR data 
(Table 4.1), two anomeric carbon signals at 105.10 and 105.79 ppm and at least ten 
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signals between 60-90 ppm suggested that the compound has two sugar moieties. 
Four olefinic carbon signals at 155.50, 131.26, 125.36, 108.15 ppm also suggested the 
presence of two double bonds. The molecular mass was 18 units less than ginsenoside 
Rg3 (molecular mass = 784) and was likely to be its dehydrated compound. The NMR 
signals were rather similar to ginsenoside Rg3 except for the number of olefinic 
carbon signals, suggesting that it has one more double bond. The methyl carbon signal 
from C-21 was not observed in compound Y, but a methylene carbon signal at 108.15 
ppm was detected instead. The 1H and 13C-NMR data correlated well with previous 
report [Park et al., 2002], and compound Y was deduced to be 3β,12β-
dihydroxydammar-20(21),24-diene-3-O-β-D-glycopyranosyl (1→2)-β-D-
glucopyranoside or also named as ginsenoside Rk1. 
Compound Z: It was obtained as a white amorphous powder with a melting 
point of 188-191°C (literature: 188-192°C). The yield was 0.5% w/w of butanol 
extract and purity was >97% as determined by HPLC. It is an isomer of compound Y 
with a similar molecular mass of 766 due to a [M+H]+ at m/z 767, [M+NH4]+ at m/z 
784 and [M+Na]+ at m/z 789. The 13C-NMR data signals (Table 4.1) were similar to 
that of compound Y, except for some of the olefinic carbon signals, suggesting that 
the double bonds were at different positions. These olefinic signals were the same as 
that of ginsenoside Rh3, implying that the double bond positions were at similar 
positions. However, compound Z has another glucose moiety compared to 
ginsenoside Rh3. The 1H and 13C-NMR data correlated well with previous report 
[Kim et al., 1996] and together with the above supporting data, compound Z was 
found to be 3β,12β-dihydroxydammar-20(22),24-diene-3-O-β-D-glycopyranosyl 
(1→2)-β-D-glucopyranoside or also known as ginsenoside Rg5.  
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Besides the above six compounds, peaks S and T in the HPLC chromatograms 
(Figure 3.6C in Chapter 3) were also increased in P. notoginseng samples that were 
steamed for 9 h. They were identified as 20S-ginsenoside Rg3 (S) and 20R-
ginsenoside Rg3 (T) respectively (Figure 4.3). Their identities were confirmed by 
comparing their retention times, UV spectra, MS spectra with those of the standards, 
as well as spiking of the standards into the steamed extracts. 20S and 20R-
ginsenosides Rg3 have similar mass spectra. Similar to 20S- and 20R-ginsenoside 
Rh1, it can be seen that 20S-ginsenoside Rg3 was eluted earlier and it was present in 
higher quantities than its corresponding 20R-epimer. Ginsenosides Rk3 and Rk1 
(∆20(21)) were also eluted earlier than its ∆20(22) isomers (ginsenosides Rh4 and 
Rg5). Moreover, 20RS-ginsenosides Rg2 and 20S-ginsenoside Rh2 were detected in 
low quantities in steamed P. notoginseng crude extracts. These components were also 
detected in red P. ginseng [Li, 1986; Kim et al., 2000; Kitagawa et al, 1987].  
All of these compounds (S to Z) were not detected in raw samples, so the 
steaming process has caused chemical degradation and conversion of some saponins 
to new components. From the structures, it can be seen that 20S- and 20R-ginsenoside 
Rg3 are most likely produced by the loss of glycosyl moiety at C-20 position of 
protopanaxadiol type saponins (e.g. ginsenosides Rb1, Rc, Rd). 20RS-ginsenoside 
Rg2 may arise from protopanaxatriol type saponins (e.g. ginsenoside Re) in the same 
manner. Upon steaming, isomerisation of the hydroxyl configuration at C-20 gives 
rise to the S and R isomers. Similarly, it is proposed that 20S- and 20R-ginsenosides 
Rh1 may arise from protopanaxatriol type saponins (e.g. ginsenoside Rg1) by the loss 
of glycosyl moiety at C-20. Alternatively, they may also be formed by the loss of C-
20 glucose and one rhamnose sugar moiety at C-3 of ginsenoside Re. Ginsenosides 





20(21) of ginsenoside Rg3 respectively. Similar dehydration of ginsenoside Rh1 at C-
20 can also give rise to ginsenosides Rh4 and Rk3. Therefore, these explain the 
changes in components and the reasons for the decrease in concentrations (as shown 




































Figure 4.3. HPLC chromatograms of (A) raw and (B) steamed P. notoginseng (2 h). 
(1)R1, (2)Rg1, (3)Re, (4)Rb1, (5)Rc, (6)20S-Rh1, (7)20R-Rh1, (8)Rd, (9)Rk3, 
(10)Rh4, (11)20S-Rg3, (12)20R-Rg3, (13)Rk1, (14)Rg5. Peaks 6, 7, 9, 10, 11, 12, 13 
and 14 corresponded to peaks U, V, W, X, S, T, Y and Z in Figure 3.6C respectively. 
 
 
Raw P. notoginseng 



























Eight major potential markers (20S-ginsenoside Rh1, 20R-ginsenoside Rh1, 
20S-ginsenoside Rg3, 20R-ginsenoside Rg3, ginsenosides Rk3, Rh4, Rk1 and Rg5) 
that play key roles in differentiating the chromatograms of raw and steamed P. 
notoginseng were successfully identified in this study. This is the first report of the 
detection and isolation of ginsenosides Rk1 and Rk3 from P. notoginseng roots, as 
well as the first separation of these fourteen main saponins in a single HPLC 
chromatogram of steamed P. notoginseng. These biomarkers are potentially useful for 
the quality control of raw and steamed P. notoginseng roots and their products.
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CHAPTER 5  
LIQUID CHROMATOGRAPHY-TANDEM MASS 
SPECTROMETRIC ANALYSIS OF DENCICHINE IN 
PANAX NOTOGINSENG AND RELATED SPECIES 
5.1 Introduction 
Dietary non-protein amino acids have been implicated as potential factors 
interfering with fundamental biochemical processes and causing clinical disorders 
[Rubenstein, 2000]. The naturally occurring β-N-oxalyl-L-α,β-diaminopropionic acid 
(β-ODAP) (Figure 5.1A), a neuro-excitatory non-protein amino acid, was first 
isolated from the seeds of Lathyrus sativus (grass pea seeds) [Rao et al., 1964]. It is 
also known as dencichine. It was identified as the main cause of a primary upper 
motor neuron degenerative disease known as neurolathyrism, a condition with 
symptoms such as hyper-irritability, severe weakness and irreversible paralysis of the 
leg muscles, and convulsions. This disease is prevalent in endemic form, often 
occurring after drought-induced famines in the Indian subcontinent or in Ethiopia, 
when grass pea seed becomes the exclusive or main dietary staple for several months. 
Besides being present in the seeds of 21 Lathyrus species, β-ODAP was found in 
other genera of leguminous plants including Acacia and Crotalaria species [Quereshi 
et al., 1977].  
The mechanisms whereby β-ODAP causes neurotoxicity have been researched 
by some investigators. It showed strong agonistic activity on recombinant AMPA (α-
amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) receptors, and has facilitating 





































Figure 5.1. Chemical structures of (A) dencichine, i.e., β-N-oxalyl-L-α,β-
diaminopropionic acid (β-ODAP), (B) α-N-oxalyl-L-α,β-diaminopropionic acid (α-
ODAP), and (C) α,β-diaminopropionic acid (DAP). 
 
Mol. Wt: 176 
Mol. Wt: 104 
Mol. Wt: 176 
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transport [Kuo et al., 2003]. Mitochondrial dysfunction mediated by β-ODAP was 
also suggested as an underlying cause of neurolathyrism [Ravindranath, 2002].  
Interestingly, dencichine is also found to be present in Panax species, the only 
non-leguminous plants in which β-ODAP is known to be present [Kuo et al., 2003]. 
Furthermore, it is a bioactive therapeutic amino acid component in P. notoginseng. 
Studies have reported dencichine as the component responsible for the herb’s main 
haemostatic and platelet increasing properties in vivo [Zhao and Wang, 1986]. The 
exact mechanisms whereby dencichine causes haemostatic effects are still not known. 
The haemostatic effect was present at a low dose of dencichine [Zhao and Wang, 
1986], while neurotoxicity occurred at higher doses. Medicinal herbs or tonics, when 
used appropriately, are usually not consumed in quantities as high as staple food like 
the Lathyrus species. Therefore the possibility of developing neurolathyrism from 
over-consumption of such herbs is very much lower. The amount of dencichine in raw 
P. notoginseng roots [Zhang et al., 1990; Dong et al., 2003; Long et al., 1996], P. 
ginseng [Kuo et al., 2003; Long et al., 1996; Zheng and Li, 1990] and P. 
quinquefolium [Zheng and Li, 1990] have been reported. However, to our knowledge, 
the concentration of dencichine present in steamed P. notoginseng has not been 
previously reported prior to this work. Since the raw root but not the steamed root is 
used to promote haemostatic effects, it is postulated that the steamed root may have a 
lower concentration of dencichine. However, to test this postulation, an accurate, 
sensitive and specific analytical method must be developed.  
Due to the concerns regarding neurotoxicity, previous methods developed for 
the analysis of β-ODAP have focused mainly on the Lathyrus species. In the earlier 
studies the most common approach was a colorimetric method which utilised the 
reaction of ο-phthalaldehyde (OPT) with α,β-diaminopropionic acid, a hydrolysis 
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product of β-ODAP [Rao, 1978; Briggs et al., 1983]. Dencichine in raw P. 
notoginseng root was also determined by HPTLC with fluorometric detection [Zhang 
et al., 1990]. As dencichine has weak UV absorption and high polarity, various 
derivatisation methods have been adopted for reversed-phase HPLC analysis. Pre-
column derivatisation methods involved phenyl isothiocyanate [Kuo et al., 2003; 
Khan et al., 1994; Khan et al., 1993], 9-fluorenyl methylchloroformate [Geda et al., 
1993], 1-fluoro-2,4-dinitrobenzene [Wang et al., 2000b] and 6-aminoquinolyl-N-
hydroxysuccinimidyl carbamate [Chen et al., 2000]. A GC/MS method [Pan et al., 
1997] using N-ethoxycarbonyl ethyl ester derivatives was also reported. However, all 
the above methods required derivatisation steps and were laborious, inconvenient and 
time-consuming. Other potential problems include poor derivative stability, side 
reactions, reagent interferences and reagent toxicities. An alternative and relatively 
simple but less sensitive capillary electrophoresis method [Arentoft and Greirson, 
1995; Zhao et al., 1999a] without derivatisation was subsequently developed. 
Alternative detection methods such as electrochemical and direct low-wavelength UV 
detection [Dong et al., 2003] have also been proposed. Novel LC-Biosensor systems 
[Moges and Johansson, 1994; Belay et al., 1997a; Yigzaw et al., 2001] allowed 
selective analysis of β-ODAP, but they involved complicated procedures such as the 
preparation of bienzyme-modified electrode. 
LC/MS is an important analytical method due to its high speed, specificity, 
selectivity and sensitivity. It provides additional structural information and is 
especially useful for complex samples where chromatographic resolution is limited. 
LC/MS analyses of small protein amino acid molecules without derivatisation [Petritis 
et al., 2000; Qu et al., 2002; Nagy et al., 2003; Desai and Armstrong, 2004] were 
advantageous, but difficulties existed in both the chromatographic retention and 
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detection of these polar hydrophilic compounds that lack chromophoric groups. Most 
of the current HPLC methods for analysis of protein amino acids utilised volatile ion-
pairing reagents [Petritis et al., 2000; Qu et al., 2002] to retain the underivatised 
amino acids on the reversed-phase column.  
Due to the high polarity and low molecular weight of dencichine, it is a 
challenge to analyse it using HPLC or LC/MS. To date, to our knowledge, no LC/MS 
method has been reported for the analysis of dencichine prior to this current work 
[Koh et al., 2005]. Therefore, the present chapter aims to develop a LC/MS/MS 
method for the quantification of underivatised dencichine in complex plant matrices 
of Panax species. The developed method will be used to determine if dencichine is 
present at different levels in raw and steamed P. notoginseng samples. The dencichine 
concentrations of these samples will also be compared with those present in two other 
Panax species, i.e., P. ginseng and P. quinquefolium.  
 
5.2 Experimental  
5.2.1 Materials 
Dencichine standard was obtained from Lathyrus Technologies (Hyderabad, 
India). Diaminopropionic acid (99% purity) was obtained from Bachem AG 
(Bubendorf, Switzerland). The water was deionised and purified by Milli-Q Gradient 
A-10 water purification system (Millipore, Molsheim, France). HPLC-grade 
acetonitrile and methanol were obtained from J. T. Baker (Phillipsburg, NJ, USA). 
Analytical-grade ammonium formate (97% purity), HPLC-grade ammonium acetate 
(≥ 99% purity) and mass spectrometry-grade formic acid (98%) reagents were 
purchased from Sigma-Aldrich (St. Louis, MO, USA). The raw P. notoginseng roots 
(Samples 1-7) and the reference raw P. notoginseng roots (Sample 8) were obtained 
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from different sources, as mentioned in Section 3.1.2.1. Eleven pairs of raw and 
steamed P. notoginseng CPMs were shown in Table 3.1. Samples of P. ginseng, P. 
quinquefolium and Korean red ginseng were also used (Section 3.1.2.1). 
 
5.2.2 Sample and standard preparation 
The roots were ground into powder using a laboratory blender. A total of 100 
mg of each powdered sample were accurately weighed and extracted with 1 ml of 
water by ultrasonication for 2 h. The extracts were centrifuged at 20,000 g for 20 min. 
The supernatants were then diluted with water/ acetonitrile (40:60) and filtered 
through a 0.45 µm nylon filter membrane prior to analysis.  
Samples of a powdered raw P. notoginseng root were steamed at 120°C for 2, 
6 and 9 h respectively (Section 3.1.2.3). The steamed powders were then extracted 
using ultrasonication as described above. A 1 mg/ml dencichine standard stock 
solution in water was prepared. For the calibration curves, the stock solution was 
diluted with water/ acetonitrile (40:60) to give five different concentrations ranging 
from 2 to100 ng/µl.  
 
5.2.3 HILIC/ESI-MS/MS 
A Micromass Quattro micro API triple-quadrupole mass spectrometer, 
equipped with a Z-spray electrospray source, was interfaced with a Waters Alliance 
2695 separation module (Milford, MA, USA). Chromatography was performed on a 
Waters Atlantis HILIC silica (50 x 2.1 mm I.D., 3 µm) column. The mobile phases 
used were: (A) 200 mM ammonium formate (pH 3.0) and (B) acetonitrile; isocratic 
elution using 40% v/v A and 60% v/v B was employed for dencichine. The total run 
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time was 5 min. Column temperature was kept constant at 30°C. The flow rate was 
0.3 ml/min and the injection volume was 2 µl. Due to the relatively low flow rate, the 
LC effluent entered the mass spectrometer interface directly, without splitting.  
The mass spectrometer was operated in positive electrospray ionisation (ESI) 
mode. The mass scale of the instrument was calibrated using a solution of sodium and 
caesium iodides. Tuning was performed by direct infusion of a solution of dencichine 
in 40% v/v mobile phase A plus 60% v/v acetonitrile at a flow rate of 5 µl/min, using 
the built-in syringe pump. Nitrogen gas was used as the desolvation gas at a flow rate 
of 500 L/h. The following optimised MS tune parameters were used: ESI capillary, 
3.0 kV; cone, 18 V; extractor, 3.0 V; RF lens, 0 V; source temperature, 120°C; 
desolvation temperature, 300°C; resolution (LM1, HM1, LM2, HM2), 15.0; ion 
energy 1, 0.2; ion energy 2, 1.0; entrance, -1; exit, 3; multiplier, 650 V. MS/MS 
experiments were performed using argon as the collision gas. The collision energy 
was optimised to give the highest product ion intensities; the optimal collision energy 
was 12 eV. Dencichine was analysed and quantified in the multiple reaction 
monitoring (MRM) mode using the transition m/z 177 → 116. The dwell time was 0.5 
s, and the interscan delay was 0.05 s. Data were acquired and processed using 
MassLynxTM version 4.0 software (Waters, Milford, MA, USA).  
 
5.2.4 Method validation 
To assess linearity, the calibration curves were analysed by linear least-
squares regression analysis. The LOD and LOQ were obtained by diluting the 
dencichine standard until the signal-to-noise (S/N) ratio reached 3:1 and 10:1, 
respectively. The injection/instrument precision (calculated as relative standard 
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deviation, RSD), for a low concentration of dencichine at the LOQ limit, was 
determined by six consecutive injections. For intra-day assay precision, five 
concentrations of dencichine standard were each assayed five times within a day. For 
inter-day assay precision, triplicate analyses of five concentrations of dencichine were 
performed on three different days. Recoveries (accuracies) of dencichine from the 
plant matrix were determined by spiking dencichine at 3 different levels (0.2, 0.15, 
0.09 mg/ml) into raw P. notoginseng samples before extraction and then 
experimentally measuring the added amounts. A calibration curve was acquired each 
day, before the analysis of each set of samples, to ensure accuracy. Blanks (40% v/v 
water plus 60% v/v acetonitrile) and a quality control standard (5 ng/µl of dencichine) 
were run intermittently between the samples to verify the instrument response. 
 
5.3 Results and Discussion 
5.3.1 Optimisation of MS/MS conditions 
Positive mode ESI spectra of dencichine contained the [M+H]+ ion at m/z 177. 
The product ion scans of m/z 177 indicated fragmentations dominated by product ions 
at m/z 160, 159, 131, 116, 105, 88, 87, 70, 59 (Figure 5.2). MS/MS is preferable to 
MS for detection because of the higher sensitivity (S/N ratio) and selectivity, 
especially when dencichine is present in complex matrices. Selection of a proper 
transition for MS/MS detection of an analyte is based on two main factors. Firstly, the 
transition should be specific to the compound, and secondly, the product ion should 
be sufficiently abundant for sensitive detection. The transition from m/z 177 → 116 
was chosen based on these criteria. Flow injection analysis of dencichine produced 
stable total ion currents for the chosen MRM transition. Blank injection analysis also 
excluded the possibility that any background compound would produce a response in 
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the chosen MRM transition. Therefore, this transition m/z 177 → 116 was used for the 















Figure 5.2. MS/MS product ion spectrum of the [M+H]+ ion of dencichine obtained 




A postulated fragmentation pathway of protonated dencichine is as follows. 
The product ions m/z 160 and 159 correspond to losses of NH3 and of water, 
respectively. Loss of CO from m/z 159 results in the formation of an immonium ion 
(m/z 131). The key product ion at m/z 116 probably arises from protonation at the 
primary amine group followed by loss of NH3 and then rearrangement of the resulting 
carbonium ion to lead to loss of CO2.  The ion at m/z 105 probably corresponds to 
protonated α,β-diaminopropionic acid, resulting from initial protonation on the amide 
nitrogen followed by an H-atom transfer and losses of CO2 and CO. Further losses of 
ammonia, water or CO2 from m/z 105 give rise to the product ions at m/z 88, 87 and 
59, respectively.  
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The various MS/MS parameters were optimised for sensitivity by experiments 
using syringe infusion. Both the cone voltage and collision energy have important 
influences on the product ion intensity (Figure 5.3). By modifying the cone voltage 
and collision energy, the product intensity fluctuated and achieved optimised level at 
18 V and 12 eV, for cone voltage and collision energy, respectively. These optimised 
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Figure 5.3. Product ion intensity (m/z 116) of dencichine versus changes in collision 
energy and cone voltage. 
 
 
5.3.2 Optimisation of LC conditions 
Several C18 reversed-phase columns were tested during method development 
and results showed that dencichine was not retained by any of the reversed-phase 
packing. It was eluted in less than 0.45 min in the void volume of these columns, 
despite a highly aqueous condition of 95-100% v/v water or buffer. Under such highly 
aqueous conditions the MS sensitivity may be compromised. Besides derivatisation, 
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other options for retaining polar analytes include the use of ion exchange and ion 
pairing chromatography. Ion exchange chromatography often involves solvents with 
high concentrations of non-volatile inorganic salts, which is incompatible with 
coupling to MS. Ion pairing chromatography was explored in the preliminary study. 
0.1% trifluoroacetic acid (TFA), a commonly used volatile mobile phase modifier 
used for peptides and proteins, was found unable to retain dencichine. Furthermore, a 
disadvantage of ion pairing agents such as TFA is the possible ion suppression in ESI-
MS. Another common alternative to retain polar compounds is the manipulation of 
pH to make the compounds neutral. Despite the use of various types of buffers with 
different pH range, dencichine was not retained. This is due to the fact that dencichine 
can undergo three acid dissociation steps, similar to glutamic acid and aspartic acid. 
The pKa values 1.95, 2.95 and 9.25, corresponding to the two carboxylic and α-amino 
functions respectively, are very different. Therefore, in the pH range of most usable 
buffer systems, the compound will be in the charged zwitterionic form (all three 
groups ionised).  
Hydrophilic Interaction Chromatography (HILIC) was subsequently found to 
retain dencichine and was selected for the present work on dencichine. HILIC is a 
type of separation technique which was first described by Alpert in 1990 [Alpert, 
1990], consisting of a hydrophilic stationary phase that is eluted with a more 
hydrophobic mobile phase so that retention times increase with the hydrophilicity of 
the solutes. It is a variant of normal phase chromatography in which the presence of 
water in the mobile phase is crucial for the establishment of a stagnant enriched 
aqueous layer on the surface of the stationary phase into which analytes may 
selectively partition. Retention involves a mixed mode mechanism involving both 
partitioning and cation exchange mechanisms. With its high organic content mobile 
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phases, HILIC also promotes enhanced MS response. Applications of this separation 
technique to highly polar compounds have been reported previously [Alpert, 1990; 
Strege, 1998; Schlichtherle-Cerny et al., 2003; Tolstikov and Fiehn, 2002].  
Further optimisation of several conditions such as injection volume, flow rate, 
pH, and mobile phase composition, was then performed to reduce the peak width, as 
the peak was initially broad. Typically, the use of buffers can affect the electrostatic 
interactions between the solute and stationary phase, and changing the buffer 
concentration had the most significant effect on the peak shape. It was found that by 
increasing the buffer concentration (10, 20, 40, 50, 60, 70, 80 mM), the peak was 
sharpened. 80 mM of ammonium formate on-column gave optimal results, and still 
permitted sufficient MS sensitivity. Ammonium acetate and ammonium formate 
buffers were compared at the same concentration; the nature of the buffer anions had 
minimal effects on the dencichine peak. A change in pH (pH 2.75 to 4.75) did not 
have much effect on the peak shape, i.e., the method was robust with respect to slight 
variations in pH. Increasing the acetonitrile composition, however, increased the 
retention time; with 60% v/v acetonitrile and 40% v/v aqueous buffer, the retention 
time for dencichine was about 1 min, which was beyond the void volume of the 
column used to prevent any ion suppression by early eluting polar compounds. 
The complex samples were analysed by HILIC/MS/MS in the MRM mode 
and only one peak was found, showing high selectivity of the method. Furthermore, 
this rapid elution of 1 min is advantageous for the high-throughput analysis of 
numerous samples. The LC/MRM chromatograms for dencichine standard and for the 





























Figure 5.4. LC/MRM chromatograms of (A) 10 ng/µL dencichine standard, (B) 
extract of raw P. notoginseng sample, and (C) extract of steamed (2 h) P. notoginseng 
sample. The MRM transition was m/z 177 → 116. 
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5.3.3 Optimisation of sample preparation 
Previous studies have used several different methods and solvents to extract 
dencichine from Lathyrus sativus and Panax species. To experimentally determine the 
optimum solvents for extraction of dencichine from the P. notoginseng samples, each 
of two different raw P. notoginseng samples was extracted using 100% methanol, 
70% v/v, 50% v/v, and 30% v/v aqueous methanol, and 100% water. Peak areas of 
dencichine in the samples increased with increasing proportions of water, for example, 
it increased several folds from 1250 (100% methanol) to 14236 (100% water) for one 
of the samples. The results showed that 100% water consistently gave higher 
extraction yield of dencichine than the different mixtures of aqueous methanol. This 
was within expectations, as dencichine showed much better solubility in water than in 
methanol. Although the type of solvents used in previous studies varies and includes 
30-75% aqueous methanol/ethanol [Rao, 1978; Briggs et al., 1983; Wang et al., 
2000b; Chen et al., 2000; Zhao et al., 1999a], water [Dong et al., 2003; Long et al., 
1996; Geda et al., 1993] and aqueous buffer (pH 7-7.5) [Moges and Johansson, 1994; 
Belay et al., 1997b; Yigzaw et al., 2001], but water has been selected based on the 
results of this study.  
Among the wide variety of extraction methods, such as homogenisation, 
ultrasonication, agitation with a magnetic stirrer, mechanical shaking, rotation in an 
oven, and overnight maceration, ultrasonication was found to be useful in reducing 
the time required for extraction and increasing the extraction efficiency. This method 
was employed in this study. Ultrasonication duration of 1 h and 2 h were also 
compared in the preliminary study. It was found that 2 h extraction gave a slightly 
higher amount of dencichine. However, repeating the ultrasonication process three 
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times and concentrating to the same volume made a negligible difference to the 
amount of dencichine extracted. 
This sample preparation method was simple and rapid compared to methods 
requiring derivatisation. This is definitely advantageous for preparation of a large 
number of samples. Further purification of the complex samples is not necessary as 
MRM is highly selective. Sufficient sensitivity was obtained for the analysis of the 
samples, despite the complex plant matrices. 
 
5.3.4 Method validation 
The LOD (S/N = 3) and LOQ (S/N = 10) for dencichine were found to be 0.3 
ppm (or 0.6 ng on column) and 1.5 ppm (or 3 ng on column) respectively. The 
calibration curves constructed for the assay of dencichine showed good linearity over 
the concentration range 2 to 100 ng/µl with correlation coefficient r2 = 0.9996 (y = 
129.26x – 201.93). The inter-day retention time precision (RSD) was 2.1%. The 
injection precision (RSD) for a low concentration of dencichine standard (at the LOQ 
limit, 1.5 ppm) was 6.7% (n = 6). The intra-day and inter-day assay precisions (RSD) 
of dencichine for the concentration range of 2 to 100 ng/µl were 1.7-4.6% (n = 5) and 
3.3-7.9% (n = 3) respectively. The values reported above were obtained using pure 
dencichine standard, as it is not possible to have a blank P. notoginseng matrix 
without the presence of dencichine. This is an intrinsic limitation in the analysis of 
natural components present in natural products and the method used here for 
validation is a pragmatic approach to the validation of such samples. To investigate 
the accuracy, recovery studies were performed by spiking P. notoginseng samples 
with different amounts of dencichine. The recoveries of dencichine at the three spiked 
 135
concentration levels ranged from 94.9 to 98.9% (n=3 for each concentration). The 
precision for the spiked samples was found to be 4.6-9.1%.  
 
5.3.5 Quantification of dencichine 
The concentrations (% w/w) of dencichine in all the samples are presented in 
Table 5.1. The eight raw P. notoginseng samples were found to have dencichine 
concentrations ranging from 0.134 to 0.293% w/w. Thus, a typical piece of root will 
contain 14 to 47 mg of dencichine, depending on the size of the roots. According to 
the Chinese Pharmacopoeia [The State Pharmacopoeia Commission of PR China, 
2000], the recommended daily dose of raw P. notoginseng is about 3 to 9 g, so this 
will correspond to about 4 to 26 mg of dencichine. These variations in concentration 
were not unexpected as the roots were obtained from different sources. The quality 
and chemical contents of medicinal herbs may vary greatly due to many factors, e.g. 
species variation, geographical source, and methods used in cultivation, harvest, 
storage and processing. In this study, the sample obtained from Wenshan (China) 
(sample 7) was found to contain the highest dencichine amount. The findings obtained 
in this study are also consistent with previous reports. Raw P. notoginseng samples 
were reported to contain 0.316-0.382% w/w dencichine, using high-performance TLC 
technique [Zhang et al., 1990]. Long et al. [1996] studied dencichine from Panax 
species using anion exchange column chromatography, and reported a concentration 
of 0.16% w/w in the main roots. Dong et al. [2003] showed the regional and seasonal 
variations in dencichine concentration in raw P. notoginseng sample, from 0.325 to 




Table 5.1. Concentrations (% w/w, n=3) of dencichine in raw P. notoginseng, 
steamed P. notoginseng (2, 6 and 9 h), P. ginseng and P. quinquefolium samples  
 
 
Sample Concentration of 
dencichine (% w/w) 
Raw P. notoginseng sample 1 0.2361 
Raw P. notoginseng sample 2 0.1814 
Raw P. notoginseng sample 3 0.1927 
Raw P. notoginseng sample 4 0.1739 
Raw P. notoginseng sample 5 0.1827 
Raw P. notoginseng sample 6 0.1337 
Raw P. notoginseng sample 7 0.2935 
Raw P. notoginseng sample 8 0.1625 
Steamed (2h) P. notoginseng  0.0283 
Steamed (6h) P. notoginseng  0.0004 
Steamed (9h) P. notoginseng  0.0003 
P. ginseng sample 1 0.0251 
P. ginseng sample 2 0.0330 
P. ginseng sample 3 0.0212 
P. quinquefolium sample 1 0.0180 
P. quinquefolium sample 2 0.0243 
P. quinquefolium sample 3 0.0192 





In this work, to determine the effects of steaming on P. notoginseng samples, a 
powdered raw sample was steamed for different durations and analysed. It was found 
that when the duration of steaming increased from 2 h to 9 h, the concentration 
decreased from 0.0283% w/w to a negligible amount of 0.0003% w/w. A Student’s-t 
test also showed that the values were significantly decreased (p<0.05) compared to 
the corresponding raw P. notoginseng sample (before steaming). Thus, the greater the 
degree of steaming, the greater is the differences in the concentrations of dencichine 
in raw and steamed samples. The effects of cooking, roasting, autoclaving and 
fermentation on the concentration of dencichine (reported as β-ODAP) in Lathyrus 
sativus were previously studied, and a similar reduction in concentration was reported 
[Akalu et al., 1998]. A higher dencichine concentration in raw P. notoginseng may 
indicate that it has better haemostatic activity than the steamed samples and this is 
desirable for therapeutic uses.  
Low doses of dencichine [Zhao and Wang, 1986], e.g. from the normal 
consumption of P. notoginseng, is unlikely to cause neurotoxicity. The dose of 
dencichine causing neurotoxicity was approximately more than 500 mg/kg in chicks 
(20-60 mg of dencichine was given to 30-40 g chicks) and the lethal dose (LD50) was 
reported to be 1043 mg/kg. Whereas, 0.1 to 1 mg of dencichine was tested for 
haemostasis in 15-20 g mice and this was equivalent to ~5-50 mg/kg [Zhao and Wang, 
1986]. In humans, it was reported that daily chronic consumption of 300 g of grass 
pea seeds (or when a diet consisting of one-third to one-half of peas is consumed) for 
more than 3 months may lead to neurotoxicity and this would be equivalent to 5-125 
mg/kg/day (assuming that the concentration of dencichine in grass pea seeds ranges 
from 0.1-2.5% w/w and the average weight of man is 60 kg) [Akalu et al., 1998]. 
However, to date, there are no human data on the use of dencichine for haemostasis.  
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The present HILIC- MS/MS method was also applied to the analysis of 11 
pairs of raw and steamed P. notoginseng CPMs, and the results are shown in Table 
5.2. Except for two pairs, most of the raw CPM samples were found to contain 0.093-
0.212% w/w of dencichine and the corresponding steamed CPM samples contained 
0.015-0.085% w/w. For pair 10, the dencichine concentrations of raw and steamed 
samples were comparable, showing that the steamed sample may not have been 
steamed sufficiently or was not subjected to heat processing. For pair 11, the raw 
sample was found to contain a low concentration (0.013% w/w) of dencichine, 
comparable to that of most of the steamed samples. This implies that the raw sample 
may in fact have been subjected to some steaming or heat treatment during processing. 
These results correlated with the results from Chapter 3 on the comparison of saponin 
concentrations and chromatographic profiles in raw and steamed P. notoginseng. The 
pairs of products (pairs 10 and 11) were also found to have chromatograms not 
characteristic of their ‘raw’ and ‘steamed’ labels. Except for one pair (pair 10), all the 
steamed samples contained significantly (p<0.05, Student’s-t test) lower amounts (2.5 
to 12 times lower) of dencichine compared to the corresponding raw samples. From 
these results of dencichine concentrations, the varying degrees in which the CPMs are 
processed and its haemostatic activity may also be predicted. 
As for the other Panax species, three sources of P. ginseng roots were found to 
have lower concentrations (0.021-0.033% w/w) of dencichine, while the 
concentrations in the three sources of P. quinquefolium roots were 0.018-0.024% w/w 
(Table 5.1). Therefore, these two species have a much lower content of dencichine (~ 
4 to 16 times lower) compared to raw P. notoginseng roots. This may be one of the 
reasons why raw P. notoginseng has been widely used as a haemostatic agent, but 
haemostatic activity is not the main indication for P. ginseng and P. quinquefolium. A  
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Table 5.2. Concentrations (% w/w, n=3) of dencichine in 11 pairs of raw and steamed 





Product name Brand Concentration of 
dencichine (%w/w) 
1 Pure Raw Pseudoginseng Powder Meihua 0.2052 
 Pure Steamed Pseudoginseng Powder Meihua 0.0171 
2 Raw Tienchi Ginseng Tablet Meihua 0.1297 
 Steamed Tienchi Ginseng Tablet Meihua 0.0195 
3 Yunnan Tienchi Powder (Raw) Nature’s Green 0.2117 
 Yunnan Tienchi Powder (Steamed) Nature’s Green 0.0852 
4 Yunnan Tienchi Tablets (Raw) Nature’s Green 0.1250 
 Yunnan Tienchi Tablets (Steamed) Nature’s Green 0.0509 
5 Tienchi Powder (Raw) Yunfeng 0.2110 
 Tienchi Powder (Steamed) Yunfeng 0.0221 
6 Tienchi Tablets (Raw) Yunfeng 0.1344 
 Tienchi Tablets (Steamed) Yunfeng 0.0151 
7 Tienchi Powder (Raw) Camellia 0.1788 
 Tienchi Powder (Steamed) Camellia 0.0418 
8 Tienchi Tablets (Raw) Camellia 0.0926 
 Tienchi Tablets (Steamed) Camellia 0.0245 
9 Tienchi Tablet (Raw) Yulin 0.1353 
 Tienchi Tablet (Steamed) Yulin 0.0450 
10 Yunnan Tian Qi Powder (Raw) Kiat Ling 0.1117 
 Yunnan Tian Qi Powder (Steamed) Kiat Ling 0.1250 
11 Chinese Yunnan Tien Chi Tablet (Raw) Luen Shing 0.0128 
 Chinese Yunnan Tien Chi Tablet (Steamed) Luen Shing 0.0038 
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previous study [Kuo et al., 2003] also reported that a 3-year-old P. ginseng root 
contained 0.0596% w/w of dencichine. This is slightly higher than the results of this 
study. Differences may be due to the age, quality and source of the ginseng roots. In 
this study, a Korean red ginseng, a type of steamed P. ginseng, was analysed and 
found to contain 0.005% w/w of dencichine, a lower concentration than that in 
Chinese ginseng (white). This result further demonstrated that dencichine 
concentration is decreased on steaming. Long et al. [1996] also mentioned that red 
ginseng has lower dencichine concentration than white ginseng, but the actual 
quantities were not reported. Similarly, by using an amino acid analyser, Zheng and 
Li [1990] found that red ginseng contained less (0.2605% w/w) dencichine compared 
to white ginseng (0.4906% w/w). 
Thermal isomerisation of dencichine to form α-N-oxalyl-L-α,β-
diaminopropionic acid (α-ODAP) (Figure 5.1B) can occur. α-ODAP is non-
neurotoxic unlike β-ODAP. Intramolecular rearrangements involving cyclic 
intermediates such as diketopiperazine types were proposed [De Bruyn et al., 1994]. 
The isomerisation is an equilibrium process whereby a particular equilibrium position 
is reached depending on the conditions used. Studies [Abegaz et al.; 1993, Belay et al., 
1997b; Zhao et al., 1999b] showed that this occurred in acidic conditions and when 
the temperatures were in the range of 55-70˚C. Derivatisation methods that required 
some heating may promote isomerisation. In the preliminary studies, derivatisation by 
adding butanolic HCl, heating at 60˚C and evaporating the solvents with a stream of 
air, to form mono- or di-esters has been attempted. However, the results were not 
reproducible and it may have caused isomerisation of dencichine. Therefore, the 
present method of analysing underivatised dencichine is advantageous to prevent any 
inaccurate results obtained due to isomerisation or degradation. Besides isomerisation, 
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it has been reported that a dencichine solution can also be hydrolysed directly at high 
temperatures, in acidic or basic medium, to give α,β-diaminopropionic acid (DAP) 
(Figure 5.1C) [Akalu et al., 1998; Abegaz et al., 1993; De Bruyn et al., 1994; De 
Bruyn et al., 1993]. This is also the principle behind the analysis of dencichine using 
the ο-phthalaldehyde (OPT) method, in which dencichine is hydrolysed into DAP 
prior to reaction with OPT [Rao, 1978; Briggs et al., 1983]. As high temperatures 
(>100˚C) and long durations are used, the change in dencichine concentration on 
steaming is likely due to thermal hydrolysis. 
In the present work, this hydrolysis was investigated experimentally by 
HILIC/MS/MS monitoring of DAP; MRM transitions of m/z 105 → 87.9 and 105 → 
69.8 were used. The MS/MS instrumental parameters used were similar to those used 
for dencichine, except for the optimal collision energy of 10 eV. Under the same LC 
conditions DAP eluted at 1.40 min, while dencichine eluted at 1.15 min (Figure 5.5). 
Dencichine standard also showed a peak for the MRM transition m/z 105 → 87.9, but 
it appeared at the same retention time (~1.15 min) as that for the transition m/z 177 → 
116, i.e., the protonated DAP determined at 1.15 min is one of the MS product ions of 
dencichine, and did not arise from pre-ionisation decomposition of the dencichine 
standard. Dencichine standard stock solution (1000 ng/µl) was subjected to a 
temperature of 90°C for 14 h. It was then diluted and analysed by HILIC/MS/MS, 
showing both dencichine and DAP peaks after heating. Raw and steamed root 
samples were also analysed for DAP, and it was found that the DAP peak was higher 
in the steamed than in the raw samples. Therefore, these findings showed that 
dencichine was hydrolysed to DAP upon steaming, thus accounting for the differences 


























Figure 5.5. LC/MRM chromatograms of (A) dencichine standard showing ions 
detected for each of the two MRM transitions, m/z 177 → 116 (top) and m/z 105 → 
87.9 (bottom); and (B) diaminopropionic acid (DAP), showing the absence of ions 
detected for MRM transition m/z 177 → 116 (top) and presence of ions detected for 
the transition m/z 105 → 87.9 (bottom). 
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In this chapter, a novel HILIC/ESI-MS/MS method has been successfully 
developed for the analysis of underivatised dencichine in Panax species. Compared to 
other conventional methods, this technique is rapid (5 min), selective, sensitive and 
eliminates the need for sample derivatisation. The method has been validated for 
linearity, accuracy, intra- and interday precision, LOD and LOQ. Results showed that 
steamed P. notoginseng samples contained less dencichine when compared to the raw 
samples, due to the hydrolysis of dencichine to diaminopropionic acid at high 
temperatures. P. ginseng and P. quinquefolium were also found to have lower 
dencichine concentration than P. notoginseng. A higher concentration in raw P. 
notoginseng root may indicate that it has a better haemostatic activity. The method 
developed will be useful for the determination of dencichine for the quality control of 
Panax species, as well as other food crops that may contain this component. 
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CHAPTER 6 
PLATELET AGGREGATION AND BLOOD 
COAGULATION INHIBITORY ACTIVITIES OF PANAX 
NOTOGINSENG, ITS RELATED SPECIES AND ITS 
CHEMICAL COMPONENTS 
6.1 Introduction 
Platelets play a central role in the haemostatic process and are similarly 
involved in the pathological process—thrombosis. They are small discoid cells 
derived from megakaryocytes in the bone marrow and circulate in the blood. Under 
normal conditions, they neither adhere to each other nor other circulating endothelial 
cells. When the blood vessels are damaged, subendothelial cells are exposed and 
platelets adhere to the disrupted surface. This adhesion is mediated by collagen and 
von Willebrand factor (vWF) on the subendothelial surface. After adhesion, platelet 
activation occurs, a process that is stimulated by the interaction of several agonists 
such as ADP, thrombin, epinephrine, with their specific receptors on the platelet 
surface. Phospholipase A2 enzyme is also activated to produce a variety of 
prostaglandins and thromboxane. The adherent and activated platelets will 
subsequently secrete or release various biologically active factors such as ADP, 
serotonin, fibrinogen from their platelet granule content. Release of factors from 
granules, which together with thromboxane A2, can promote further platelet activation, 
recruit other platelets to the site of injury and promote further aggregation to form the 
platelet plug. The aggregation (defined as the adherence of one platelet to another) is 
mediated by fibrinogen or vWF, which connect the platelets by bridging complexes of 
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glycoprotein GPIIb/IIIa on adjacent platelets [Freson et al., 2006]. Therefore, there 
are a variety of platelet agonists and the binding of agonists to specific platelet 
membrane receptors is important to induce adhesion, activation and aggregation 
processes. Inhibition of any of these factors or steps may result in the final inhibition 
of platelet aggregation, i.e. antiplatelet effects. For example, collagen is found in the 
connective tissue of blood vasculature and is considered to be one of the initial 
stimulating factors that the platelet encounters following vascular trauma. The study 
of the platelet response to collagen is important in many platelet aggregation studies. 
The activation of platelets with the exposure of negatively charged 
phospholipids facilitates the assembly of coagulation factors onto the surface and 
activation of the coagulation cascade to generate thrombin and subsequent fibrin 
deposition to stabilise the initial primary platelet plug. This secondary haemostasis 
process is also needed for thrombus growth, development and stability. The 
coagulation cascade is basically divided into the intrinsic, extrinsic and common 
pathways. Intrinsic pathway is activated by surface contact with negatively charged 
phospholipids (provided by activated platelets or platelet activation factors) and 
involves the sequential activation of various factors, Factors XII, XI, IX. Factor X can 
then be activated by Factors IXa and VIII. Extrinsic pathway is initiated by the release 
of tissue thromboplastin which is exposed during vascular injury. Factor VII forms a 
complex with tissue thromboplastin and calcium. This complex rapidly activates 
Factor X to Xa which is needed to activate the final pathway. This common pathway 
is initiated by both the activated intrinsic and extrinsic pathways which produces the 
activated Factor X. Factor Xa, in the presence of Factor V, phospholipid surface and 
calcium, catalyses the conversion of prothrombin (Factor II) to thrombin (Factor IIa) 
which is needed to convert fibrinogen (Factor I) to fibrin (clot). To ensure the 
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physiological balance of haemostasis and avoid massive clot formation, the 
coagulation process is controlled by several mechanisms such as natural inhibitors in 
plasma (e.g. antithrombin III, protein C) and the fibrinolysis system. The fibrinolytic 
pathway involves activation of plasminogen to plasmin, which is needed to degrade or 
split fibrinogen and fibrin into fragments (Fibrin degradation products, FDP). A 
disruption of this fine balance of haemostasis and fibrinolytic system can result in 
bleeding or further thrombosis. The whole coagulation cascade involves a complex 
number of coagulation factors, which are mostly proteins circulating in the plasma 
and are generally synthesised in the liver. A deficiency in any coagulation factors or 
the presence of any circulating or exogenous inhibitors of the factors will thereby 
inhibit the coagulation cascade and prevent the formation of a clot or thrombus. 
As discussed in Section 1.2.1, inhibitions of the platelet function and 
coagulation pathways represent a promising approach for the prevention of 
thrombosis in pathological conditions. A thrombus is a source of thromboembolic 
complications of cardiovascular diseases, and hence antiplatelet and anticoagulation 
agents are used in such diseases. In view of the importance of antithrombotic therapy 
in cardiovascular diseases and the growing number of drugs obtained from botanical 
sources, medicinal herbs and their phytochemicals that prevent thrombosis by 
inhibition of either platelet functions or coagulation pathways are, therefore, of 
special therapeutic interest. 
According to the Chinese Pharmacopoeia, raw P. notoginseng has been 
traditionally used as a haemostatic to arrest internal and external bleeding, reduce 
swelling and pain, as well as to disperse blood clots, eliminate blood stasis and 
promote blood circulation [The State Pharmacopoeia Commission of PR China, 2000]. 
Interestingly, promoting circulation and enhancing haemostasis seems to be of 
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opposite effects scientifically. Studies also showed that raw P. notoginseng has other 
useful pharmacological activities on cardiovascular related diseases such as lower 
blood cholesterol, reduce blood pressure, treatment of coronary heart diseases, cardiac 
infarction, angina pectoris [State Administration of Traditional Chinese Medicine, 
1996; Tang and Eisenbrand, 1992]. However, currently, studies on the antithrombotic 
activities of P. notoginseng are limited. Moreover, the studies on P. ginseng cannot be 
directly postulated to P. notoginseng. In previous chapters, it was found that the 
chemical components in raw and steamed P. notoginseng were different and the 
steamed form contained several unique saponins that were produced during 
processing. Although the chemical components are different, to date, there are no 
scientific studies to show if they have different biological activities. Furthermore, 
several of their unique components have not been tested for antithrombotic activities.  
Therefore, this chapter aims to determine the effects of different forms of P. 
notoginseng and its related species, on blood platelet aggregation and coagulation (in 
vitro and ex vivo). In addition, in vivo bleeding time assays will be carried out to 
investigate their haemostatic effects in the in vivo system. The activities of the 
chemical components of P. notoginseng on blood coagulation and platelet aggregation 
(in vitro) will also be investigated, so as to understand the components that are 








6.2 In vitro platelet aggregation and blood coagulation studies 
6.2.1 Experimental 
6.2.1.1 Materials 
Raw P. notoginseng roots were purchased from different sources in Singapore 
(Samples 1-3) and China (Samples 4-6), as mentioned in Section 3.1.2.1. Several raw 
P. notoginseng roots were also collected from Wenshan (Yunnan, China) (Sample 7, 
WS-7, 4, 5, 11), while reference authenticated raw P. notoginseng (Sample 8) was 
obtained from National Institute for the Control of Pharmaceutical and Biological 
Products (Beijing, China). Four pairs of raw and steamed P. notoginseng CPMs (CPM 
pairs 1, 9, 10 and 11) were bought (Table 3.1, Section 3.1.2.1). P. ginseng, P. 
quinquefolium, Korean red ginseng and reference authenticated red ginseng roots 
were also obtained, as described in Section 3.1.2.1.  
Dencichine, diaminopropionic acid (Section 5.2.1), ginsenosides Rg1, Re, Rb1, 
Rc, Rd and notoginsenoside R1 (Section 3.1.2.1) were purchased. 20S- and 20R-
ginsenoside Rg3 from steamed P. notoginseng were obtained as a gift (Section 4.2.1), 
while 20S-ginsenoside Rh1, 20R-ginsenoside Rh1, ginsenoside Rk3, Rh4, Rk1 and 
Rg5 were isolated in the laboratory as described in Chapter 4 (purity >95%). Water, 
hexane and butanol fractions of steamed P. notoginseng were also obtained by the 
procedures described in Chapter 4. 
Four ml sterile polypropylene tubes (Tapval®) with 0.106 M (3.8%) citrate (1 
part citrate: 9 parts blood) obtained from J.P. Selecta, S.A. (Abrera, Spain), were used 
to collect the blood from rabbits and rats. Ketamine (Ketapex, 100 mg/ml) and 
xylazine hydrochloride (Ilium Xylazil-20, 20 mg/ml) was obtained from Apex 
Laboratories Pty Ltd (NSW, Australia) and Troy Laboratories Pty Ltd (NSW, 
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Australia) respectively. Carboxymethylcellulose (CMC) was from BDH Ltd (Poole, 
UK).  
For platelet aggregation experiments, collagen (1 mg/ml) from equine tendons, 
suspended in isotonic glucose solution of pH 2.7 was purchased from Chrono-Log 
Corporation (Havertown, PA, USA). Phosphate buffered saline (PBS, pH 7.4) 
containing 8 g/L NaCl, 0.2 g/L KCl, 1.44 g/L Na2HPO4 and 0.24 g/L KH2PO4 was 
prepared. Aspirin USP grade was purchased from Sigma-Aldrich (St. Louis, MO, 
USA). 
For blood coagulation experiments, the following reagents were obtained from 
Dade Behring Marburg GmbH (Marburg, Germany): Ci-Trol level 1 (lyophilised 
human plasma with stabilisers and buffers), Thromborel S (Human placental 
thromboplastin containing calcium chloride, stabilisers and preservatives), Actin FSL 
(Liquid purified soy and rabbit brain phosphatides in 0.1 mM ellagic acid activator 
with added buffer, stabilisers and preservatives), Calcium chloride (25 mM), 
Thromboclotin (Bovine thrombin, approximately 2.5 NIH units/ml), Batroxobin (an 
enzyme from the venom of Bothrops atrox), Thrombin (Bovine thrombin, 
approximately 100 NIH units/ml), Owren’s Veronal buffer (pH 7.35), Standard 
human plasma (Pooled citrated human plasma stabilised with 12 g/L hepes buffer and 
lyophilised), Control plasma N (normal values, pooled citrated human plasma 
stabilised with 12 g/L hepes buffer and lyophilised), Control plasma P (pathological 
values, pooled citrated human plasma adjusted to defined factor concentrations, 
stabilised with 12 g/L hepes buffer and lyophilised). Heparin sodium salt (180 USP 
units/mg) from porcine intestinal mucosa was purchased from Sigma-Aldrich (St. 
Louis, MO, USA).  
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6.2.1.2 Sample preparation 
The roots were ground into powder using a laboratory blender. 5 g of each 
powdered sample were accurately weighed and extracted with 50 ml of 70% methanol 
by ultrasonication for 20 min. The extracts were filtered and the ultrasonication 
process was repeated for two additional times. The combined filtrate was evaporated 
to dryness. The residue was weighed and dissolved in appropriate volumes of PBS. 
The mixture was then filtered through a 0.45 µm nylon filter membrane and diluted to 
appropriate concentrations with PBS. Samples of a powdered raw P. notoginseng root 
were steamed at 120°C for 2, 6 and 9 h (Section 3.1.2.3), and extracted using the same 
procedure as described above.  
 
6.2.1.3 Animals for blood collection 
Male New Zealand Whites rabbits (2.5-4 kg) were purchased from Laboratory 
Animal Centre, Singapore, and housed at the Animal Holding Unit of National 
University of Singapore. The care of the animals and collection of blood from rabbits 
were carried out in accordance to internationally accepted guidelines on laboratory 
animal use and the protocols were approved by the Institutional Animal Care and Use 
Committee (IACUC) of National University of Singapore. They were maintained 
healthy in an air-conditioned room at a temperature of 22 ± 1°C and a humidity of 62 
± 2%. The animals were allowed unrestricted access to food (commercial pellet diet 






6.2.1.4 Blood collection  
Fresh whole blood was collected from the ear vein of healthy male rabbits. 
The rabbit was sedated with a mixture of ketamine (20 mg/kg) and xylazine (4 mg/kg), 
given intramuscularly. Blood was dripped from a 22G needle directly into the 4 ml-
citrated tubes and the total volume collected during each session was not more than 
0.67% (if rested for at least 14 days) or 1% of its body weight (if rested for at least 21 
days). To prevent coagulation, the tubes were gently inverted to ensure a good mix of 
citrate and blood. The blood was immediately used after collection. The rabbits were 
rested for at least 14 to 21 days before the next blood collection to ensure sufficient 
recovery of the blood platelets and blood cells.  
 
6.2.1.5 In vitro platelet aggregation assays 
Platelet aggregation experiments were carried out using Chrono-Log model 
570VS four-channels whole blood aggregometer, electrodes and cuvettes obtained 
from Chrono-Log Corporation (Havertown, PA, USA). The whole blood aggregation 
assays were determined by the electrical impedance method [Cardinal and Flower, 
1980]. 450 µl of pre-warmed (37°C) whole blood sample from rabbits was transferred 
into a siliconised plastic cuvette and diluted with an equal volume (1:1) of pre-
warmed (37°C) PBS (pH 7.4). The cuvette was placed in the reaction well of the 
aggregometer which was pre-warmed to 37°C. The diluted blood sample inside the 
cuvette was stirred with a polytetrafluoroethylene-coated magnetic stir bar at a 
constant speed of 1000 rpm throughout the experiment. The diluted blood sample was 
equilibrated for 2 min and once a stable baseline reading was achieved, 20 µl of test 
sample solution (or control) was added into it. The blood and test sample were 
incubated for 2 min, then 2 µl of collagen (to give a final concentration of 2 µg/ml) 
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was added to initiate the aggregation reaction. The platelet aggregation was monitored 
for 5 min by electrical impedance. The results were processed and analysed using 
Aggro/link version 4.75 software. The impedance value (in ohms) was determined 
from the impedance graph, starting from the lowest point after the start of the reaction 
to the time point exactly at the end of the 5 min time interval. The whole blood 
samples were used within 4 h after blood collection and controls were analysed at 
various intervals in between the test samples to ensure adequate activities of the 
platelets. 
 
6.2.1.6 In vitro blood coagulation assays 
Blood coagulation experiments were performed using Sysmex CA-530 blood 
coagulation analyser obtained from Sysmex Corporation (Kobe, Japan). The assays 
carried out include prothrombin time (PT), activated partial thromboplastin time 
(APTT), thrombin time (TT), reptilase time and fibrinogen determination test.  
 
Preparation of plasma sample 
The lyophilised pooled human plasma (Ci-Trol level 1) was reconstituted with 
1 ml of distilled water and left to stand for at least 15 min. It was used within 8 h after 
reconstitution. The plasma mixtures were prepared by mixing 100 µl of plasma with 
50 µl of test sample (2:1 dilution) in a sample cup before performing the following 
assays. For the individual compounds, 3 mM of the samples were prepared to give a 





Prothrombin time (PT) 
Thromborel S was reconstituted with distilled water to the labelled volume. It 
was warmed and maintained at 37°C for at least 30 min before use. 50 µl of the 
plasma mixture was pipetted into a reaction tube and incubated at 37°C for 180 s. 
After incubation for 180 s, 100 µl of Thromborel S reagent was added and the tube 
was vortexed to ensure good mixing of the reagents. The reaction was monitored for 
120 s. Detection was based on light scattering principle, whereby the reaction tube 
was irradiated with light at 660 nm, and the change in scattered light due to turbidity 
change during conversion of fibrinogen to fibrin was detected. The time taken to 
reach 50% change in scattered light was regarded as the clotting time. 
 
Activated partial thromboplastin time (APTT) 
50 µl of the plasma mixture was pipetted into a reaction tube and incubated at 
37°C for 60 s. After incubating for 60 s, 50 µl of Actin FSL reagent was added and 
further incubated for 180 s. 50 µl of calcium chloride was then added and the reaction 
was monitored for 190 s. Detection was based on the same principle as described 
above. 
 
Thrombin time (TT) 
100 µl of the plasma mixture was pipetted into a reaction tube and incubated 
at 37°C for 60 sec. 100 µl of Thromboclotin reagent was then added and the reaction 






50 µl of the plasma mixture was pipetted into a reaction tube and incubated at 
37°C for 60 s. 100 µl of Batroxobin reagent was then added and the reaction was 
monitored for 100 s.  
 
Fibrinogen determination test 
A calibration curve was obtained with various concentrations of standard 
human plasma (100-500 mg/dl) diluted with Owren’s Veronal Buffer (OVB). For the 
analysis of the fibrinogen, 10 µl of the plasma mixture was pipetted into a reaction 
tube and diluted with 90 µl of OVB. It was then incubated at 37°C for 180 s. 50 µl of 
Thrombin reagent was added and the reaction was monitored for 100 s. 
 
6.2.1.7 Statistical analysis 
The experimental results were expressed as mean ± SD. Statistical analyses 
were performed using Student’s t test (for comparisons between two groups) and one-
way analysis of variance (ANOVA) (for comparisons between three or more groups) 
with Tukey-Kramer post hoc test. Data were considered statistically significant when 
p values were <0.05. IC50 values (50% inhibitory concentration) were calculated using 
non-linear regression from Graphpad Prism version 3.00 for Windows (Graphpad 







6.2.2 Results and Discussion 
6.2.2.1 In vitro platelet aggregation assays 
In this study, platelet aggregation assays using whole blood was selected and 
used. Electrical impedance was selected as the measure of platelet aggregations. 
Figure 6.1 shows the typical changes in impedances with time for a typical control 
using PBS. After the addition of test samples or controls, a two min equilibration was 
found to be sufficient to gradually stabilise the baseline prior to the addition of 
collagen. This equilibration was needed to ensure that the blood, PBS and sample 
were thoroughly mixed, to allow the temperature to reach 37°C and to ensure that a 
monolayer of platelets was coated on the electrode. Collagen was then added to 
induce platelet aggregations and the impedance increased to a maximum. Figure 6.1 
also shows the changes in impedances with time for aspirin. After the induction by 
collagen, the increase in impedance was low, as it is known that aspirin inhibits 
platelet aggregations by inhibiting the cyclooxygenase enzyme (Chapter 1). This 
method was capable of detecting antiplatelet activities of aspirin. It served as a 
positive control for comparisons in this study. The absolute degree of platelet 
aggregation was expressed as a percent inhibition (Y), which was calculated using the 
following equation:  
Y (%) = [(A-B)/A] x 100 
where,  A = maximal impedance value (in ohms) of control 
B = maximal impedance value (in ohms) of sample 
The maximal impedance value of the control was regarded as 100% platelet 
aggregation and the impedance values of the samples were compared with the control 
within the same reaction time interval of 5 min. If the added sample inhibits the 







Figure 6.1. Graph showing the effects of (A) control (PBS), (B) aspirin, (C) raw and 
(D) steamed (2 h) P. notoginseng on the changes in electrical impedances in whole 

















final impedance value will be lower than that of the control. The higher the % 
inhibition of platelet aggregation, the greater will be its antiplatelet effects. 
The basic principle [Cardinal and Flower, 1980] behind the whole blood 
platelet aggregometer is that the electrodes will become coated with a monolayer of 
platelets during the initial contact with blood. If no further interactions occur between 
the platelets and electrode, the conductance between the two electrodes will be kept 
constant. However, when platelet aggregation occurs, there will be a gradual 
aggregation of platelets onto the platelet monolayer coated on the electrodes. This 
impairs conduction between the two electrodes and the increased impedance can be 
recorded and measured. This use of whole blood is definitely more reflective of the 
physiological conditions than platelet-rich plasma. Although the Born turbidometric 
optical aggregometer [Born, 1962a; Born, 1962b] was the first device used for 
determining platelet aggregation and it was widely used in research, but its main 
limitation is that it functions only with translucent cell suspensions such as plasma. 
The other components of blood such as the leucocytes can generate anti-aggregating 
agents such as prostacyclin [Cardinal and Flower, 1980], so the determination of 
activities using whole blood will be different from that in platelet-rich plasma. 
Furthermore, during the separation of blood into platelet-rich plasma, some heavier 
platelets may sediment together with the red cells. Preparation of platelet-rich plasma 
will also increase the sample preparation time and labile modulators such as 
thromboxane A2 and prostacyclin may decay. From the above, it is evident that the 
use of whole blood with electrical impedance detection has important advantages over 
platelet-rich plasma with turbidometric detection.  
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In vitro platelet aggregation assays of extracts of P. notoginseng and its related 
species 
When raw and steamed P. notoginseng samples were added, the increase in 
impedance was slower and the maximum was lower as compared to control (Figure 
6.1). As shown in Figure 6.2, raw P. notoginseng samples (sample 2) showed 59.8% 
inhibition (3 mg/ml) of platelet aggregation and the inhibition was dose dependent. 
The values were close to that obtained for the same concentrations of raw P. 
notoginseng reference standard (51.7%). Raw P. notoginseng root samples from the 
same GAP farm and from different sources (Section 6.2.1.1) were found to result in % 
inhibition ranging from 53.4% to 57.8%. The slight variations in their chemical 
contents (as discussed in Chapter 3) did not significantly change their platelet 
inhibitory activities. Thus, the components present predominantly in raw samples do 
not seem to significantly change their overall platelet aggregation activities. 
On the other hand, steamed P. notoginseng samples were found to have a 
significantly higher platelet inhibition activity as compared to the raw samples at both 
concentrations, as shown in Figure 6.2. The percentage inhibition increased with 
increasing duration of steaming. For the raw sample, the IC50 was 3 mg/ml, while the 
value was 1.5 mg/ml for steamed (2 h) samples and less than 1.5 mg/ml for samples 
steamed for more than 2 h. Therefore, steamed P. notoginseng has potentially better 
antiplatelet effects. In Chapters 3, 4 and 5, it was shown that the components were 
changed according to the extent of steaming. Notoginsenoside R1, ginsenosides Rg1, 
Re, Rb1 and Rd were decreased, while 20S and 20R-ginsenoside Rh1, 20S and 20R-
ginsenoside Rg3, ginsenosides Rk3, Rh4, Rk1 and Rg5 were increasingly formed with 
increasing extent of steaming (Figure 3.6 and 3.7). Therefore, these changes in 
chemical compositions may have resulted in an increased in activities and the new 
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components formed after processing may have good inhibitory effects. Four pairs of 
raw and steamed P. notoginseng CPM products, which have been studied in Chapter 3, 
were also investigated for their activities to see whether there was any relationship 
between their differences in chemical profiles and their activities. A pair of raw and 
steamed products, which showed differences in chemical analysis, was found to have 
57.4% and 90.5% inhibition respectively and this was significantly different. Whereas, 
three pairs of raw and steamed products, which have similar chemical profiles, 
showed no significant differences in their activities between raw and steamed 
products. Therefore, this provided clear evidence that the inhibition of platelet 
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Among the three Panax species, P. ginseng and P. quinquefolium were found 
to have lower inhibitory activities (p<0.05) of 46.2% and 37.7% respectively (Table 
6.1), as compared to raw P. notoginseng samples at the same final concentration of 3 
mg/ml. Therefore, P. notoginseng may have the highest antiplatelet action compared 
to its closely related Panax species. Previous studies have been focused on P. ginseng 
and its components, so P. quinquefolium have not been studied for antiplatelet 
activities. Korean red ginseng and red ginseng reference standard were actually P. 
ginseng that have been heat or steamed-treated. Korean red ginseng was previously 
investigated and found to effectively inhibit in vitro platelet aggregations [Yun et al., 
2001b] with an IC50 of 0.32 mg/ml. In this work, the inhibitory activities of Korean 
red ginseng (50.7%) and red ginseng reference standard (52.6%), were found to be 
slightly higher than the Chinese (white) ginseng. Therefore, this was consistent with 
the conclusion obtained for raw and steamed P. notoginseng, i.e. steamed form 
showed greater platelet inhibition. However, unlike the large differences between raw 
and steamed P. notoginseng, the differences between P. ginseng (Chinese) and red 
ginseng were not significant. From the chemical analysis, the extent in which red 










Table 6.1. Platelet inhibitory effects of the various Panax species in vitro as 
compared to control (n≥3) 
 
Sample Final concentration 
(mg/ml) 
% Inhibition 
P. quinquefolium 3.0 37.7 ± 6.8 
P. ginseng 3.0 46.2 ± 5.8 
Korean red ginseng 3.0 50.7 ± 7.2 
Red ginseng reference standard 3.0 52.6 ± 6.2 
Raw P. notoginseng 3.0 59.8 ± 6.2 
Steamed P. notoginseng (9 h) 3.0 100 ± 0.0  
 
 
In vitro platelet aggregation assays of different fractions of P. notoginseng 
The butanolic fraction of steamed P. notoginseng was found to inhibit platelet 
aggregation to the greatest extent, followed by the water and hexane fractions, and in 
a dose-dependent manner (Figure 6.3). Although the non-saponin or lipophilic 
fraction in P. ginseng was also reported to inhibit platelet aggregation in vitro [Park et 
al., 1995] and in vivo [Park et al., 1996], in this work, the majority of the antiplatelet 
components were found to be present in the butanolic fraction of P. notoginseng. 
Chemical analysis of the butanolic fraction using HPLC showed that it contained the 
majority of saponins. Therefore, the saponins were proposed to have good antiplatelet 
activities. This was supported by studies on P. ginseng which showed that the total 
ginsenosides inhibited platelet aggregation, inhibited release of platelet granule 
contents and inhibited morphological changes [Mo et al., 1989]. The 1-butanol 
fraction and diethyl ether fraction of P. ginseng were also reported to suppress the 
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ATP release reaction and inhibit aggregation, with the latter being more potent than 
the former [Kuo et al., 1990]. The P. notoginseng total saponins and panaxatriol 
saponins were found to inhibit platelet aggregation and adhesion [Ma and Xiao, 1998; 
Wang et al., 2004], increase the fluidity of platelet membranes in vitro [Su et al., 1996] 
and inhibit shear-induced platelet aggregation [Liao and Li, 1997]. Isolation of the 
various saponins was subsequently carried out in Chapter 4. These saponins were 
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Figure 6.3. Platelet inhibitory effects of different fractions of steamed P. notoginseng 







In vitro platelet aggregation assays of individual compounds 
 Most of the individual saponins tested have moderate platelet inhibitory 
activities, ranging from 20% to 32% at 100 µM concentration, as shown in Table 6.2. 
Interestingly, 20R-ginsenoside Rh1 and 20R-ginsenoside Rg3 showed no antiplatelet 
activity unlike their corresponding 20S-epimer. On the other hand, ginsenoside Rh4 
inhibited platelet aggregation up to 40%. The strongest activities came from 
ginsenoside Rg5 and 20S-ginsenoside Rg3 which have platelet inhibitory activities 
exceeding 45% at 100 µM. A previous study [Jung et al., 1998] also reported 
ginsenoside Rg3 (IC50 49 µM) and ∆20–ginsenoside Rg3 (IC50 92 µM) to be a new 
class of platelet activating factor (PAF) antagonists which inhibits PAF binding to 
washed platelets. Currently, the antiplatelet effects of various ginsenosides varied 
greatly in different studies. Ginsenosides Ro, Rg1 and Rg2 from P. ginseng [Kuo et 
al., 1990] showed some inhibition of ATP release, but not inhibition of platelet 
aggregation. In another study [Matsuda et al., 1986a], ginsenosides Rg1, Rg2 and Rb1 
inhibited platelet aggregations, but the inhibitions were weak with 10-25% at high 
concentrations of 1 mM. Ginsenoside Rg1 was shown to inhibit platelet aggregation 
and 5-HT release [Kimura et al., 1988]. Panaxynol [Kuo et al., 1990; Teng et al., 
1989], a polyacetylene, isolated from the diethyl ether layer of P. ginseng was found 
to be an active antiplatelet component and its mechanism of action was chiefly due to 
the inhibition of thromboxane formation. Prior to this work, there are still several 
saponins, namely, notoginsenoside R1, 20RS-ginsenoside Rh1, 20R-ginsenoside Rg3, 





Table 6.2. Platelet inhibitory effects of dencichine, diaminopropionic acid and 






Aspirin 100 26.7 ± 2.8 
Notoginsenoside R1 100 22.5 ± 5.8 
Ginsenoside Rg1 100 31.1 ± 6.1 
Ginsenoside Re 100 24.2 ± 7.1 
Ginsenoside Rb1 100 32.6 ± 4.7 
Ginsenoside Rc 100 18.4 ± 3.3 
Ginsenoside Rd 100 29.1 ± 6.4 
20S-ginsenoside Rh1 100 24.7 ± 4.0 
20R-ginsenoside Rh1 100 - 
Ginsenoside Rk3 100 32.3 ± 7.5 
Ginsenoside Rh4 100 40.6 ± 9.5 
Ginsenoside Rk1 100 21.3 ± 6.2 
Ginsenoside Rg5 100 48.2 ± 10.5 
20S-ginsenoside Rg3 100 47.0 ± 12.5 
20R-ginsenoside Rg3 100 - 
Dencichine 100 6.2 ± 1.5 
Diaminopropionic acid 100 21.2 ± 5.9 
Unshaded: Chemical components present in raw and steamed P. notoginseng with the 
steamed form having lower quantities. Shaded: Chemical components present only in 
steamed P. notoginseng  
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The IC50 values of the two most potent saponins, ginsenosides Rg5 and 20S-
Rg3, and aspirin were determined in this work to be 98 µM, 92 µM and 131 µM 
(Figure 6.4) respectively. The IC50 of aspirin was reported to be 139-160 µM [De La 
Cruz et al., 2002; Yun et al., 2001b] for collagen-induced platelet aggregations, which 
were closed to the results obtained in this study. Aspirin, which inhibits 
cyclooxygenase enzyme, is an antiplatelet drug widely used for prophylaxis of 
thrombosis. Another clinically used antiplatelet drug, ticlopidine, which prevents the 
activation of glycoprotein IIb/IIIa complex by platelet ADP, has a reported IC50 value 
of 513 µM [De La Cruz et al., 2002] for collagen-induced platelet aggregation. 
Therefore, these two ginsenosides, isolated from steamed P. notoginseng, 
demonstrated more potent platelet inhibitory effects than some of the clinically used 
drugs. The good antiplatelet effects of ginsenosides Rg5 and Rh4 have not been 
previously reported.  


















Figure 6.4. Dose response curves for aspirin, ginsenosides Rg3 and Rg5, showing the 
changes in percentage platelet inhibition with concentration (І: represents the standard 
deviations). 
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As discussed in Chapter 5, dencichine is a bioactive amino acid component 
present in raw P. notoginseng and it is reported to be responsible for P. notoginseng’s 
haemostatic activity. However, it is not previously known if dencichine has any 
effects on platelet aggregation. The current results show that it has no effects on 
platelet aggregation. This was not unexpected as dencichine is known to have 
haemostatic activity (Table 6.2). The mechanism for haemostasis is still largely 
unknown. It has been reported to increase the platelet number in a study [Zhao and 
Wang, 1986], but it is not known if this is one of its main mechanism for its 
haemostatic effects. The content of dencichine was greatly reduced in steamed P. 
notoginseng samples (Chapter 5). Furthermore, diaminopropionic acid, a hydrolysed 
product from dencichine, was present in the steamed samples and it was found to be 
3.4 times more active than dencichine, and with slightly less activity than aspirin at 
the same concentration. This may also be one of the reasons contributing to the higher 
inhibition activity seen in the steamed samples.  
 
6.2.2.2 In vitro blood coagulation assays 
 The PT measures the activity of factors of the extrinsic pathway including 
Factors II (prothrombin), V, VII, X and I (fibrinogen). Complementarily, the APTT 
screens for abnormalities of the intrinsic coagulation pathway, including Factors I 
(fibrinogen), II (prothrombin), V, VIII, IX, X, XI, XII, prekallikrein, and high 
molecular weight kininogen (HMWK). Thrombin time (TT) measures the direct 
conversion of fibrinogen to fibrin in the common coagulation pathway by the addition 




In vitro blood coagulation assays of extracts of P. notoginseng  
The extracts of raw P. notoginseng were found to significantly prolong PT at 
the various concentrations used in the study and to significantly prolong APTT at 
higher concentration (6.7 mg/ml), as shown in Table 6.3. The changes were 
concentration dependent. Twelve different sources (Section 6.2.1.1) of raw P. 
notoginseng have also been investigated. The reference raw P. notoginseng standard 
was found to prolong PT (20.6 s) and APTT (44.4 s) to similar values as the other raw 
samples at the same concentration (5 mg/ml). The ranges of PT and APTT for various 
sources of roots were found to be 20.1 to 22.6 s and 42.3 to 50.8 s respectively. 
Despite some differences in the quantities of some chemical components (Chapter 3), 
various sources of raw P. notoginseng samples gave comparable results, suggesting 
that the variations in contents of notoginsenoside R1, ginsenosides Rg1, Re, Rb1, Rc 
and Rd did not significantly affect anticoagulant effects. 
Extracts of steamed P. notoginseng were found to prolong both PT and APTT 
significantly in a concentration dependent manner (Table 6.3). With increasing extent 
of steaming from 2 to 9 h, the PT and APTT for the steamed samples were increased 
significantly. Comparisons of raw and steamed samples showed that the PT and 
APTT for steamed samples were significantly longer than the raw samples at the 
various concentrations (p<0.05) tested. These results were further verified when a 
typical pair of P. notoginseng CPM, which have different chromatographic profiles 
(Chapter 3), were investigated. The steamed CPM was found to have prolonged PT 
(27 s) and APTT (81 s) as compared to the PT (21 s) and APTT (44 s) in the 
corresponding raw sample. On the other hand, for an atypical pair of CPM which gave 
similar chromatographic profiles, both PT and APTT were not significantly different 
between the two forms. In view of these results, the differences in the different types 
 168
of chemical components present in raw and steamed P. notoginseng have affected 




Table 6.3. Effects of extracts of raw and steamed P. notoginseng on PT and APTT in 
human blood plasma in vitro (n≥3) 
 
Sample Final conc. 
(mg/ml) 
PT (s) APTT (s) 
Control - 15.1 ± 0.7 42.2 ± 1.5 
Raw P. notoginseng 3.3 17.7 ± 1.3* 44.4 ± 0.7 
Steamed P. notoginseng (2h) 3.3 20.3 ± 1.3* 51.0 ± 3.6* 
Steamed P. notoginseng (6h) 3.3 25.9 ± 0.9* 64.1 ± 4.0* 
Steamed P. notoginseng (9h) 3.3 27.1 ± 0.8* 76.1 ± 4.0* 
Raw P. notoginseng 5.0 20.6 ± 0.8* 43.7 ± 1.0 
Steamed P. notoginseng (2h) 5.0 22.0 ± 1.5* 60.7 ± 5.0* 
Steamed P. notoginseng (6h) 5.0 33.3 ± 1.8* 135.9 ± 1.9* 
Steamed P. notoginseng (9h) 5.0 40.6 ± 1.8* NC 
Raw P. notoginseng 6.7 23.4 ± 1.0* 47.0 ± 1.3* 
Steamed P. notoginseng (2h) 6.7 29.5 ± 0.5* 81.1 ± 4.2* 
Steamed P. notoginseng (6h) 6.7 41.4 ± 1.3* NC 
Steamed P. notoginseng (9h) 6.7 58.1 ± 6.7* NC 
NC: no coagulation 
*: p<0.05 compared to control 
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The APTT values for steamed samples were equivalent to various 
concentrations (0.017-0.167 U/ml) of heparin, which served as a positive control. 
Heparin, a clinically used anticoagulant drug, binds to antithrombin III (AT-III), 
which results in its enhanced affinity to several activated forms of factors, namely 
Factors IIa (thrombin), Xa, IXa, and this binding renders the factors inactive. 
Therefore, heparin was found to prolong APTT, but PT was only prolonged at much 
higher concentrations of heparin (Figure 6.5). This observation was also found in 
another study [Yun et al., 2001b]. The observation that both PT and APTT were 
prolonged by raw and steamed P. notoginseng suggested that the samples may act on 
a multitude of different factors in both the intrinsic and extrinsic pathways or they 
may affect the factors in the common coagulation pathway such as Factors II, V, X, 
fibrinogen.  
A determination of thrombin time (TT) was further carried out for all the 
samples used in this study. Heparin showed an increase in TT with increasing 
concentrations. Furthermore, the extracts of P. notoginseng generally prolonged TT in 
a concentration dependent manner (Figure 6.6). Similar to the results of PT and APTT, 
the same trend whereby steamed samples gave longer TT than the raw samples, was 
observed. Earlier, it was shown that steamed samples prolonged PT and APTT more 
than raw samples. Likewise, steamed samples were found to prolong TT to a greater 






















































Figure 6.6. Graph showing the effects of raw and steamed P. notoginseng on 
thrombin time in vitro (n≥3). 
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In view of the above results, the effects of P. notoginseng may seem similar to 
high concentration of heparin, whereby all three of the above parameters were 
prolonged. Reptilase time can be used for the differential diagnosis of a prolonged TT. 
Presence of prolonged TT and normal reptilase time is usually used for the detection 
of exogeneous anticoagulant such as heparin. As supported by this study, the six 
different concentrations (0.017-0.167 U/ml) of heparin did not significantly change 
the reptilase time as compared to control (18.0 ± 0.5 s). Similar to heparin, the 
reptilase time was not significantly (p>0.05) prolonged using the same concentrations 
of P. notoginseng samples as in the TT assays. The results indicated that P. 
notoginseng samples did not affect the ability of fibrinogen to be cleaved by Bothrops 
atrox toxin, resulting in the formation of fibrin. Therefore, the samples may be 
directly or indirectly affecting the thrombin or have heparin-like effects. Presence of 
fibrinogen degradation products (FDP) from fibrinolysis will also increase TT and 
reptilase time. Since reptilase time was not prolonged, fibrinolysis may not have 
occurred. For further confirmation, the determination of fibrinogen in the plasma was 
carried out. A standard curve was developed and used for the determination of 
fibrinogen in P. notoginseng, its fractions, P. ginseng and P. quinquefolium. All the 
results showed that the concentration of fibrinogen did not change significantly 
(p>0.05) as compared to control (Table 6.4). Therefore, this confirmed that the 







Table 6.4. Effects of extracts of raw and steamed P. notoginseng on fibrinogen 
concentration in plasma (n≥3) 
 
 
Sample Fibrinogen (mg/dl) 
Control 171.3 ± 6.2 
Raw P. notoginseng 166.1 ± 4.3 
Steamed P. notoginseng (2h) 159.9 ± 7.5 
Steamed P. notoginseng (6h) 160.6 ± 9.6 
Steamed P. notoginseng (9h) 175.1 ± 9.8 
Butanol fraction 169.0 ± 2.8 
Water fraction 165.4 ± 5.1  
Hexane fraction 159.3 ± 6.7 
Standard raw P. notoginseng 164.0 ± 8.4 
P. ginseng 166.1 ± 2.6 
P. quinquefolium 162.9 ± 8.5 
Korean red ginseng 156.0 ± 8.5 




In vitro blood coagulation assays of extracts of different Panax species 
For the other related Panax species, namely P. ginseng (Chinese), P. 
quinquefolium and red ginseng reference standard, PT was slightly prolonged 
compared to controls, but the PT were shorter than those obtained from raw P. 
notoginseng at the same concentration (Table 6.5). TT of these samples also showed 
some prolongation. Previous study has reported that red ginseng prolonged PT and 
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APTT [Yun et al., 2001b]. In addition, it was found to have an inhibitory effect 
against experimental disseminated intravascular coagulation in rats, and promoted 
fibrinolytic system in fibrin plates [Matsuda et al., 1986a; 1986b]. The active 
component was subsequently found to be ginsenoside Ro [Matsuda et al., 1986a; 
1986b]. Ginsenoside Ro was not studied in this work as it has not been detected in P. 
notoginseng. In general, this study found that both raw and steamed P. notoginseng 




Table 6.5. Effects of extracts of various Panax species on PT and APTT of human 






PT (s) APTT (s) 
P. quinquefolium 5.0 17.3 ± 1.0 40.9 ± 0.4 
P. ginseng 5.0 16.6 ± 1.1 41.4 ± 0.3 
Korean red ginseng 5.0 14.6 ± 0.5 40.1 ± 0.8 
Red ginseng reference standard 5.0 16.4 ± 0.9 40.3 ± 2.5 
Raw P. notoginseng 5.0 20.6 ± 0.8* 43.7 ± 1.0 
Steamed P. notoginseng (9 h) 5.0 40.6 ± 1.8* NC 






In vitro blood coagulation assays of fractions of P. notoginseng 
The fractions of steamed P. notoginseng were screened to determine the most 
active fraction for future identification of active compounds. Butanolic fraction 
prolonged both PT and APTT in a concentration dependent manner, as shown in 
Table 6.6. The water fraction did not prolong PT but prolonged APTT slightly (49.9 s) 
at a higher concentration (3.33 mg/ml). On the other hand, the hexane fraction did not 
prolong PT, but prolonged APTT significantly and to a greater extent than butanolic 
fraction. This may imply that the active components for anticoagulation activities are 
likely to be less polar components present in the hexane fraction and butanol fraction. 
These results were in agreement with a study on P. ginseng which found that the 




Table 6.6. Effects of fractions from steamed P. notoginseng on PT and APTT of 
human blood plasma in vitro (n≥3) 
 
Fractions PT (s) at different concentrations  APTT (s) at different concentrations 
 0.8 mg/ml 1.7 mg/ml 3.3 mg/ml 0.8 mg/ml 1.7 mg/ml 3.3 mg/ml 
Butanol 19.4 ± 0.2 35.7 ± 2.3 53.6 ± 2.7  45.9 ± 0.4 56.9 ± 0.3 NC 
Water 14.5 ± 0.1 14.5 ± 0.3 16.4 ± 0.3  40.6 ± 0.4 46.2 ± 1.3 49.9 ± 1.1 
Hexane 14.5 ± 0.3 15.1 ± 0.3 16.9 ± 0.8  69.6 ± 1.7 108.2 ± 1.7 NC 





In vitro blood coagulation assays of individual compounds 
Sixteen pure components present in raw and steamed P. notoginseng were 
evaluated for their effects on blood coagulation. The results are shown in Table 6.7. 
The shaded components are only present in the steamed samples. Ginsenosides Rk1 
and Rg5 were found to prolong PT, while 20S-ginsenoside Rh1 prolonged APTT at a 
final concentration of 333 µM. In addition, these three ginsenosides were present only 
in the steamed samples. Individually, most of the other chemical components did not 
prolong PT and APTT, suggesting that these saponins were not the components 
responsible for the anticoagulation effects or the concentration was still insufficient. 
Another reason may be the lack of synergistic effects when the components were 
tested individually. Therefore, this work provided the first information on the 
anticoagulation activities of raw and steamed P. notoginseng extracts, fractions and 
pure components, so that future studies may further explore if there are other 













Table 6.7. Effects of some chemical components in raw and steamed P. notoginseng 
on the PT and APTT in human blood plasma in vitro (n≥3) 
 
Sample Final conc. 
(µM) 
PT (s) APTT (s) 
Control - 15.1 ± 0.7 42.2 ± 1.5 
Notoginsenoside R1 333 15.1 ± 0.1 42.5 ± 0.5 
Ginsenoside Rg1 333 15.2 ± 0.2 42.2 ± 0.5 
Ginsenoside Re 333 15.5 ± 0.2 42.7 ± 0.2 
Ginsenoside Rb1 333 15.6 ± 0.6 40.7 ± 0.4 
Ginsenoside Rc 333 16.7 ± 0.3* 43.7 ± 1.3 
Ginsenoside Rd 333 14.5 ± 0.3 40.6 ± 1.4 
20S-ginsenoside Rh1 333 15.7 ± 0.2 45.5 ± 1.1* 
20R-ginsenoside Rh1 333 15.4 ± 0.2 43.2 ± 1.9 
Ginsenoside Rk3 333 15.7 ± 0.1 43.1 ± 0.9 
Ginsenoside Rh4 333 15.6 ± 0.2 43.2 ± 0.7 
Ginsenoside Rk1 333 16.5 ± 0.4* 41.6 ± 1.0 
Ginsenoside Rg5 333 16.1 ± 0.8* 42.8 ± 1.3 
20S-ginsenoside Rg3 333 15.7 ± 0.6 42.5 ± 1.6 
20R-ginsenoside Rg3 333 15.1 ± 0.2 42.8 ± 1.2 
Dencichine 333 15.0 ± 0.4 42.5 ± 1.7 
Diaminopropionic acid 333 14.8 ± 0.4 42.6 ± 1.1 
Unshaded: Chemical components present in raw and steamed P. notoginseng with the 
steamed form having lower quantities. Shaded: Chemical components present in 
steamed P. notoginseng only. 
*: p<0.05 compared to control 
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6.3 In vivo and ex vivo studies 
6.3.1 Experimental 
6.3.1.1 Materials 
The raw P. notoginseng roots (sample 2) were obtained from Singapore 
(Section 3.1.2.1). Dencichine and aspirin were purchased (as mentioned in Section 
5.2.1 and 6.2.1.1). All materials used for blood collection, platelet aggregation and 
blood coagulation experiments were also described in Section 6.2.1.1. 
 
6.3.1.2 Animals 
Male Sprague-Dawley rats (200-300 g) were purchased from Laboratory 
Animal Centre, Singapore. The care of the animals and the experiments carried out on 
the rats were in accordance to internationally accepted guidelines on laboratory 
animal use and the protocols were approved by the Institutional Animal Care and Use 
Committee (IACUC) of National University of Singapore. They were housed in an 
air-conditioned room (temperature of 22 ± 1°C and a humidity of 62 ± 2%) at the 
Animal Holding Unit of National University of Singapore. The rats were allowed 
unrestricted access to food (commercial rat pellet diet) and water and they were 
acclimatised for at least a week before any experimentation. 
 
6.3.1.3 Sample preparation 
Five g of each powdered sample were accurately weighed and extracted with 
50 ml of 70% v/v methanol by ultrasonication for 20 min. The extracts were filtered 
and the ultrasonication process was repeated for two additional times. The combined 
filtrate was evaporated to dryness. The residue was weighed and suspended in 
appropriate volumes of 0.5% carboxymethylcellulose (CMC) solution. Steamed P. 
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notoginseng samples were steamed at 120°C for 9 h, using the method described in 
Section 3.1.2.3, before extraction by ultrasonication. 
 
6.3.1.4 In vivo bleeding model 
The samples were suspended in 0.5% CMC. The rats were divided into five 
groups: control (0.5% CMC), aspirin (25 mg/kg), dencichine (25 mg/kg), raw P. 
notoginseng (500 mg/kg) and steamed P. notoginseng (500 mg/kg). Each group 
consisted of at least 7 rats. The rats were fed with the appropriate sample solution by 
oral gavage. The concentration of samples was adjusted appropriately so that the total 
volume was not more than 3 ml for each rat. After 90 min, they were anaesthetised 
with a mixture of 75 mg/kg ketamine and 10 mg/kg xylazine intraperitoneally. The 
tail bleeding model was modified from those of White et al. [2001] and Beviglia et al. 
[1993]. The tail was initially warmed for 3 min in a 0.9% saline solution which was 
previously warmed and maintained at 37°C. Bleeding was induced by transection of 
the rat tail at 5 mm from the tip. The distal portion of the tail (3 cm) was immersed 
vertically into the 0.9% saline solution at 37°C. The time between the start of 
transection to bleeding cessation was recorded as the bleeding time. Bleeding 
cessation was considered to be the time when blood flow stopped for at least 30 s. If 
the bleeding was not ceased by 15 min, the experiment was stopped and pressure was 
applied to stop the bleeding.  
 
6.3.1.5 Ex vivo platelet aggregation assays 
The rats were orally fed with the sample solutions and they were divided into 
five groups, each with at least 7 rats, similar to the above bleeding assays. After 110 
min, 4 ml of blood was collected intra-cardiacally (by cardiac puncture) from the 
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anaesthetised rats into the citrated tube. A portion of the collected blood was used in 
platelet aggregation assays while the rest was reserved for blood coagulation assays. 
The platelet aggregation assays were performed as described in Section 6.2.1.5, 
except that no test sample solution was added to the blood samples. After 
equilibrating the blood sample with PBS for 2 min, the reaction was immediately 
induced with collagen. 
 
6.3.1.6 Ex vivo blood coagulation assays 
 The rats were orally fed with the sample solutions and they were divided into 
four groups (control, dencichine, raw and steamed P. notoginseng), each with at least 
7 rats. After 110 min, 4 ml of blood was collected intra-cardiacally (by cardiac 
puncture) from the anaesthetised rats into the citrated tubes. A portion of the blood 
was centrifuged at 3000 g for 10 min to obtain the platelet poor plasma (PPP). It was 
ensured that the plasma was minimally contaminated with lysed red blood cells by 
slowly drawing the blood into the syringe. The blood coagulation assays (PT and 
APTT) were performed as described in Section 6.2.1.6, except for the direct use of the 
rats’ plasma instead of pooled human plasma and no test sample solution was further 
added into the rats’ plasma.  
 
6.3.1.7 Statistical analysis 
The experimental results were expressed as mean ± SD and statistical analyses 
were performed using Student’s t test (for comparisons between two groups) and one-
way analysis of variance (ANOVA) (for comparisons between three or more groups) 
with Tukey-Kramer post hoc test. Data were considered statistically significant when 
p values were <0.05. 
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6.3.2 Results and Discussion 
6.3.2.1 Bleeding time assays 
A bleeding time (haemorrhagic) model was optimised and used in this study. 
Using this model, seven control rats were given CMC and the average tail bleeding 
time was 196.4 ± 44.7 s. This tail bleeding time of rats determines the time taken for 
the formation of a haemostatic plug in which platelets, plasma factors and blood 
vessel walls are all involved in the haemostasis process. It has often been used as a 
haemorrhagic model for determining primary haemostasis, detection of platelet 
disorders and the testing of antiplatelet drugs. The design of these models has been 
studied and many experimental factors will affect the bleeding times [Dejana et al., 
1982]. These include the location, size, depth of the lesion, position of the tail 
(horizontal or vertical), environment, temperature and type of anaesthesia. Therefore, 
careful standardisation of the method is needed. Template bleeding models used 
specific small lesions on the dorsal part of the rat tail but it was unable to detect 
aspirin-induced platelet dysfunction [Dejana et al., 1982]. On the other hand, the 
bleeding model employing the transection of tail tip will involve the larger blood 
vessels in addition to the small ones in the dermis and subcutaneous tissues. Therefore, 
this bleeding time will be sensitive to both platelet function and coagulation defects 
and this latter model was more widely established than the former. There are 
numerous factors which can affect these pathways and some may have opposing or 
synergistic effects. Therefore, this bleeding time (haemorrhagic) model provides a 
measure for screening the overall platelet aggregation and blood coagulation effects in 
vivo. 
Aspirin, being an antiplatelet drug, was used as a positive control for 
comparison with the sample-treated rats. Dosages of 10 to 200 mg/kg have been 
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employed in other in vivo studies [Matsuda et al., 1986b; Su et al., 1996; Dejana et al., 
1982]. Preliminary studies with 10-50 mg/kg of aspirin in this rat bleeding model 
showed that aspirin positively prolonged the bleeding times in a dose-dependent 
manner. It prolonged the bleeding time to 605 s (p<0.05) at 25 mg/kg, which was 
significantly different from negative control. A dosage of 50 mg/kg prolonged the 
bleeding time to more than 15 min.  
The bleeding time for rats given dencichine was slightly shorter but not 
significantly different from that obtained for control rats. This further supported the 
findings [Zhao and Wang, 1986] that dencichine was one of the haemostatic 
components that can reduce bleeding time in P. notoginseng. The ED50 for 
haemostasis was reported to be 35 mg/kg [Ishida et al., 1989] but all the previous 
haemostatic studies on dencichine were carried out using intraperitoneal 
administration. The different routes of administration and bleeding models may also 
result in some differences in bleeding times. The oral route was used in this study, as 
these herbs are usually orally consumed by humans. As found in Chapter 5, raw P. 
notoginseng contained more dencichine than the steamed form, so the raw form may 
have greater haemostatic effects.  
As shown in Table 6.8, both raw and steamed P. notoginseng significantly 
prolonged the bleeding times to 397 s and 529 s respectively, as compared to the 
control. The bleeding times for the whole extract of steamed P. notoginseng and 
aspirin were not significantly different. Steamed P. notoginseng (oral administration 
of 500 mg/kg) effects on the prolongation of bleeding were comparable to that of 
aspirin (25 mg/kg), implying that it has good anti-haemostatic effects in vivo in a 
mammalian physiological system. At the same dosage, the bleeding times of raw and 
steamed P. notoginseng were further found to be significantly different from each 
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other. Steamed P. notoginseng has more potent anti-haemostatic effects than the raw 
form, as seen from the longer bleeding times. Due to the different potency or degree 
of haemostatic effects, it is therefore important to differentiate the raw and steamed 
forms. The saponins have antiplatelet effects as seen earlier from the in vitro studies 
and may play a role in prolonging the bleeding time in vivo. Dencichine, however, 
was found to have opposing effects and shorten bleeding times in vivo. Herbs may 
contain many components which may have different, opposing, cumulative or 
synergistic effects. The therapeutic effects of herbs would therefore depend on the 
concentration of the individual components and their complex effects on each other 
when mixed together in different proportions in the herb. For P. notoginseng, this 
study showed that the extracts of the herb administered orally resulted in significant 
anti-haemostatic effects in vivo. Sophora japonica is another example which was 
found [Ishida et al., 1989] to have an anti-haemostatic component (isorhamnetin) 
which can specifically suppress the haemostatic component (quercetin). The parched 
(heated on hot plate, 200°C, 2h) and unparched Sophora japonica also showed 
differences in haemostatic effects. Therefore, it is not uncommon to have both anti-
haemostatic and haemostatic components present in the same herb and their complex 
mechanisms are largely not known.  
There were two previous reports [White et al., 2000; White et al., 2001] on the 
effects of raw P. notoginseng on bleeding times using a haemorrhagic rat model. 
Contrary to our results, the alcoholic extracts of P. notoginseng were found to result 
in the shortest bleeding times, followed by the hydrophilic (water) extracts and 
lipophilic (hexane) extracts. Haemostatic effects were significant compared to placebo 
(wheat flour) for the alcoholic extract (which contains mainly saponins), but the other 
extracts were not significantly different from the placebo. The mechanisms of 
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haemostasis for P. notoginseng were not exactly clear. For both studies, the authors 
investigated its effects by applying the extracts externally or topically. This may have 
resulted in the different effects as compared to oral administration. The effects of oral 
administration of the steamed extract on bleeding times have not been previously 
reported. This may also explain why P. notoginseng has been traditionally used for 
cessation of bleeding, as well as for improving blood circulation and removing blood 
stasis - two seemingly opposing effects - but may be important in maintaining the 
overall balance and homeostasis of the blood system.  
 
 
Table 6.8. Effects of oral administration of aspirin, dencichine, raw and steamed P. 
notoginseng on rats’ tail bleeding time (in vivo) (n=7) 
 
Treatment groups Dosage (mg/kg) Bleeding time (seconds) 
Control (0.5% CMC) - 196.4 ± 44.7  
Aspirin 25 604.9 ± 84.0* 
Dencichine 25 189.3 ± 43.9 
Raw P. notoginseng 500 397.1 ± 38.2* 
Steamed P. notoginseng 500 529.1 ± 78.7* 








6.3.2.2 Ex vivo platelet aggregation assays 
 The inhibitions of platelet aggregation after oral administration of samples into 
Sprague-Dawley rats are shown in Table 6.9. The results were consistent with the in 
vitro results. Dencichine resulted in low inhibition of platelet aggregation, while 
aspirin showed a 64% inhibition. Steamed P. notoginseng resulted in significantly 
higher % inhibition of platelet aggregation as compared to raw P. notoginseng. The 
percentage inhibition due to steamed sample at a dose of 500 mg/kg was also not 
significantly different from aspirin (25 mg/kg), implying that its effect was close to 
that of a commonly used antiplatelet drug. Therefore, steamed P. notoginseng may 
have potentially useful clinical effects which warrant further research. In this study, 
the dosages of aspirin administered were in the effective dose ranges that have been 
previously reported for platelet studies. The dosages of the extracts administered were 
also chosen based on the dose ranges that have been commonly used in other 
pharmacological studies. The above results showed that the inhibitors of platelet 
aggregations were able to reach the blood stream after oral administration and 
produced the effects similar to that obtained in vitro.  
Based on the in vitro results, several of the individual saponins gave good 
activities, and their effects can be synergistic or cumulative when they were present 
together in the extracts. They were the likely components responsible for the ex vivo 
antiplatelet activities. This was further supported by studies which showed inhibition 
of platelet aggregations by P. notoginseng total saponins [Ma and Xiao, 1998] and P. 
notoginseng panaxatriol saponins [Su et al., 1996] given intraperitoneally to rats. A 
clinical study [Wang et al., 2004] in patients showed that raw P. notoginseng total 
saponins (Xuesaitong capsule) (120 mg twice daily for 4 weeks) reduced platelet 
activation, adhesion and aggregation, prevented thrombosis and improved 
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microcirculation. Its therapeutic effect on clinical syndrome was more effective than 
aspirin (50 mg once daily for 4 weeks). Mixtures of P. notoginseng and Salvia 
miltiorrhiza (danshen) of different ratios were also reported for its ex vivo platelet 
aggregation effects [Liu et al., 2002]. Among the various proportions of Salvia 
miltiorrhiza and P. notoginseng tested, it was found that a ratio of 10:3 was the best, 
while raw P. notoginseng extract alone gave less effect on rabbits’ platelet 
aggregation. However, raw P. notoginseng alone could markedly inhibit platelet 
adhesion. Therefore, it is proposed that P. notoginseng may act through multiple 
components and multiple pathways. 
 
 
Table 6.9. Effects of oral administration of aspirin, dencichine, raw and steamed P. 
notoginseng on platelet aggregations in rats ex vivo (n≥7) 
 
Treatment groups Dosage (mg/kg) % inhibition 
Aspirin 25 66.9 ± 19.9 
Dencichine 25 8.0 ± 1.9 
Raw P. notoginseng 500 36.8 ± 10.6 









6.3.2.3 Ex vivo blood coagulation assays 
 The PT and APTT in rats’ plasma after oral administration of the samples are 
shown in Table 6.10. PT and APTT were not significantly changed in the rats that 
were given dencichine, raw and steamed P. notoginseng, as compared to control rats. 
The results did not agree with the in vitro results obtained in Section 6.2.2.2. There 
may be a few possible reasons for the observation. The bioavailability of the 
components responsible for anticoagulation activities may be low, so the 
concentration reaching the blood stream may not be sufficient enough to prolong the 
coagulation times in vivo. The dosage of the extracts administered to the rats, which 
contain a mixture of numerous components, may not be sufficiently high to overcome 
the low bioavailability. Alternatively, the active compounds may be metabolised by 
enzymes or rendered inactive in the physiological system. Pharmacokinetics of some 
saponins in P. ginseng such as ginsenosides Rg3, Rg1, Rb1, had been previously 
studied and they were found to have relatively low absorption and were metabolised 
upon oral administration [Xu et al., 2003; Tawab et al., 2003]. The pharmacokinetics 
of most components in P. notoginseng are still largely unknown. From this study, 
three ginsenosides (20S-Rh1, Rk1 and Rg5) were shown to have some anticoagulation 
effects in vitro. However, besides saponins, there may be other active components 
that may contribute to the anticoagulation effects. To add to the complexity, like most 
herbal medicines, the various components may work together synergistically to give 
its overall effects. Ex vivo coagulation studies on P. notoginseng have not been 
reported prior to this work. From the results of this study, for the same concentration 
of raw and steamed P. notoginseng, the in vivo bleeding times for both were 
significantly prolonged and antiplatelet effects were observed ex vivo, but ex vivo 
anticoagulant effects were not apparent. This demonstrated that the in vivo 
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prolongation of bleeding time in rats may be contributed by the antiplatelet effects 




Table 6.10. Effects of oral administration of dencichine, raw and steamed P. 
notoginseng on plasma coagulation parameters in rats ex vivo (n≥7) 
 
Treatment groups Dosage (mg/kg) PT (s) APTT (s) 
Control (0.5% CMC) - 8.4 ± 0.2 17.7 ± 1.9 
Dencichine 25 8.5 ± 0.2 18.4 ± 0.2 
Raw P. notoginseng 500 8.4 ± 0.3 18.6 ± 0.8 
















The raw and steamed P. notoginseng roots were found to have antiplatelet (in 
vitro and ex vivo) and anticoagulation (in vitro) activities, with the steamed samples 
having significantly higher activities than the raw samples. These activities were also 
seen in other Panax species such as P. ginseng and P. quinquefolium, but to a lesser 
extent. Most of the saponins were found to have varying degrees of antiplatelet 
activities. The antiplatelet activities of steamed P. notoginseng were likely due to the 
cumulative effects of the saponins present. The IC50 values of ginsenoside Rg5 and 
20S-ginsenoside Rg3 for the inhibition of collagen-induced platelet aggregation 
showed that these two ginsenosides were more potent than aspirin. They may serve as 
potential leads for antiplatelet drugs and further research is warranted. 
In vivo bleeding times of rats orally-fed with the extracts were prolonged 
significantly and these were likely to be due to their antiplatelet effects. This study 
showed that P. notoginseng is a useful medicinal herb with antithrombotic activities, 
especially the steamed form which may have potential for further development of 
antithrombotic drugs. In addition, these results highlighted the impact of steam 
processing on P. notoginseng and the importance of standardising this process for 
consistent antithrombotic activities. 
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CHAPTER 7 
CONCLUSIONS AND FUTURE PROSPECTS 
Chapter 1 gives an overview of the importance, safety, efficacy and quality of 
herbal medicines, as well as the importance of antithrombotic and haemostatic 
therapies in cardiovascular diseases. Furthermore, many prescription drugs have 
botanical origin and plants are good sources of lead compounds. The root of P. 
notoginseng is an important and highly regarded Chinese medicinal herb, available in 
both raw and steamed forms. Their traditional uses differ and the ability to 
differentiate them is important. Prior to this work, there is a general lack of studies on 
the chemical and biological differences between the two forms. 
Chapter 2 describes the rationale, hypotheses and objectives of this work. The 
main objectives are to develop methods for the quality control of P. notoginseng, and 
to study the effects of processing, namely, the chemical and biological differences 
between raw and steamed P. notoginseng.  
Several new methods for the quality control of P. notoginseng are developed 
and discussed in Chapter 3. A HPLC-DAD analytical method (Section 3.1) was 
successfully developed for the simultaneous analysis of six saponins, namely, 
ginsenosides Rb1, Rc, Rd, Re, Rg1 and notoginsenoside R1. This method was 
applicable to the differentiation of the two different forms of P. notoginseng, as well 
as differentiating it from two other Panax species, namely, P. ginseng and P. 
quinquefolium. The entire extraction and analytical method has been optimised and 
validated for linearity, precision, specificity, LOD and LOQ. Coupled with 
hierarchical clustering analysis, the different species were distinctly clustered into 
different groups. Raw P. notoginseng samples from different sources were found to 
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have similar profiles but their saponins concentrations may vary considerably. It was 
also discovered that the individual roots from a single GAP source had several 
outliers with slightly different profiles and varying ratios of notoginsenoside R1, 
ginsenosides Rb1 and Rd. From the chemical studies, it was found that the 
concentrations of the analysed saponins were decreased upon steaming and additional 
components were formed. The differences increased significantly with increasing 
duration of steaming. Prior to the work, raw and steamed P. notoginseng have not 
been compared or analysed quantitatively using advanced analytical techniques. The 
chemical studies were extended to eleven pairs of raw and steamed P. notoginseng 
CPMs and discrepancies were found in three pairs, showing the current lack of quality 
control and standardisation of the process. The method developed will be useful for 
routine quality control of P. notoginseng samples. 
In addition to assaying the saponins, another quality control measure is 
chromatographic fingerprinting. In Section 3.2, a novel HPLC method coupled with 
chromatographic pattern matching analysis was first developed to quantitatively 
compare the chromatograms of raw and steamed P. notoginseng samples. The average 
pattern match standard deviation values for identical samples were found to be below 
0.0006. The pattern match standard deviation values increased with the duration of 
steaming and were statistically higher than that obtained for identical samples. These 
values gave useful quantitative indications of the similarity of the sample pairs and 
served as a similarity or match index. From these, the degree in which the raw root 
samples were changed by the steaming process was successfully deduced. This 
method was capable of detecting inconsistencies in the CPMs. This is the first 
application of the pattern matching method for differentiating herbs or complex 
samples based on their chromatographic profiles. The degree of similarity between 
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samples can be determined quantitatively and it is useful for standardising herbal 
processing. The HPLC method coupled with chromatographic pattern matching 
analysis is a potentially useful tool in ensuring quality of complex herbal samples. 
In Chapter 4, major potential markers that play key roles in the differentiation 
of raw and steamed P. notoginseng were successfully isolated and purified. Their 
identities were confirmed using NMR and MS. Their purities were determined by 
HPLC and found to be >95% for all compounds. 20S-ginsenoside Rh1, 20R-
ginsenoside Rh1, 20S-ginsenoside Rg3, 20R-ginsenoside Rg3, ginsenosides Rk3, Rh4, 
Rk1 and Rg5 were identified. They were found to be predominantly present in the 
steamed form and their concentrations increased with increasing extent of steaming. 
To date, this is the first study of the detection and isolation of ginsenosides Rk1 and 
Rk3 from P. notoginseng roots, as well as the first separation and identification of 
these fourteen saponins in a single HPLC chromatogram of steamed P. notoginseng. 
Several constituents (20S-ginsenoside Rh1, 20R-ginsenoside Rh1, 20S-ginsenoside 
Rg3, 20R-ginsenoside Rg3, ginsenosides Rk3, Rh4, Rk1 and Rg5) were not detected 
in the raw samples. From the determination of their structures and the corresponding 
reduction in the concentrations of some saponins in raw P. notoginseng upon 
steaming, it was apparent that the new components were formed from some saponins 
in the raw form. The new components were postulated to be formed by hydrolysis and 
loss of the glycosyl moieties, isomerisation and dehydration at C-20. Of the eight 
marker components, ginsenosides Rh1, Rg3, Rg5 and Rh4, have been individually 
reported in other studies to have anticancer effects, therefore implying that the 
steamed form may have different activities compared to its raw form. However, to 
date, the biological activities of ginsenosides Rk1 and Rk3 have not been reported. 
These constituents warrant further research as they are present in significant quantities 
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in steamed samples. Future studies should explore the minor saponins, as well as the 
other classes of compounds present in steamed P. notoginseng. The determination of 
the isolated compounds can also be done in the future to standardise their amounts in 
the steamed samples. In view of the differences in components and activities, it is 
evident from the results that the steaming process has an important impact on P. 
notoginseng and standardisation of the process is critical in ensuring consistent 
quality and efficacy of steamed products. 
Besides saponins in P. notoginseng, dencichine is another important 
constituent, reported to be responsible for raw P. notoginseng’s main haemostatic 
indication. In Chapter 5, a novel HILIC/ESI-MS/MS method was developed for the 
analysis of underivatised dencichine in Panax species. This is the first report of 
analysis of dencichine using LC-MS/MS. Being a small polar amino acid derivative, 
its retention on various reversed-phase columns is difficult without derivatisation and 
its analysis by LC-MS is challenging. This novel use of HILIC separation method was 
found to be suitable for retaining underivatised dencichine and for coupling with MS. 
The developed method was rapid (5 min), selective, sensitive and did not require any 
sample derivatisation. Elution time was about 1 min. The method was validated for 
linearity, accuracy, intra- and interday precision, LOD and LOQ, and applied to the 
analyses of raw and steamed P. notoginseng root samples and such products. The 
method is useful for the determination of dencichine in the quality control of Panax 
species, and it will also be applicable to other complex food crops that may contain 
dencichine.  
The dencichine concentrations in various raw P. notoginseng roots were found 
to range from 0.134 to 0.293% w/w. When taken in normal recommended dose, the 
amount of dencichine is safely below the neurotoxic dose. Results also showed that 
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when the duration of steaming increased from 2 to 9 h, the concentration of 
dencichine in P. notoginseng decreased significantly to a negligible amount. The 
change was monitored and determined to be due to the hydrolysis of dencichine to 
diaminopropionic acid. 
Eleven pairs of raw and steamed P. notoginseng CPM products were also 
analysed for their dencichine concentration. Consistent with the above results on 
steamed P. notoginseng roots, most of the CPM steamed products had lower 
concentrations of dencichine than their corresponding raw products, but their 
differences varied according to the different extents of steaming. This further 
emphasised the importance of standardising the steaming process to ensure consistent 
concentration of dencichine. A higher dencichine concentration in raw P. notoginseng 
root indicated that it may have better haemostatic activity than the steamed samples. P. 
ginseng (0.021-0.033% w/w) and P. quinquefolium (0.018-0.024% w/w) were also 
found to have significantly lower dencichine concentrations than raw P. notoginseng. 
This may provide an explanation as to why the related Panax species and steamed P. 
notoginseng are not traditionally indicated for haemostasis. Therefore, this work 
provided a scientific basis for the haemostatic use of raw P. notoginseng. However, 
the detailed mechanism of action of dencichine’s haemostatic activity has to be 
further elucidated in the future. The results from all the chemical studies support the 
hypothesis that processing of raw P. notoginseng by steaming changes the 
concentration and composition of chemical constituents in P. notoginseng. The 
chemical profiles of both forms can be differentiated from each other and from its 
closely related species, using various qualitative and quantitative methods.  
Chapter 6 describes the biological studies on platelet aggregation and blood 
coagulation in vitro and ex vivo, in order to explore if the differences in chemical 
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components result in different biological activities. The raw and steamed P. 
notoginseng roots were found to inhibit collagen-induced platelet aggregations in a 
dose dependent manner. The steamed samples were significantly more potent than the 
raw samples and the percentage inhibition increased with the extent of steam 
processing. Related Panax species such as P. ginseng and P. quinquefolium were 
found to have lower activities. Red ginseng (i.e. processed P. ginseng) also 
demonstrated slightly higher inhibitory activities as compared to P. ginseng. The 
butanolic fractions of steamed P. notoginseng resulted in the greatest inhibition of 
platelet aggregation as compared to the hexane and water fractions, implying that the 
butanolic fraction contained most of the active constituents.  
The individual saponins were studied and found to exhibit varying degrees of 
inhibition of platelet aggregation. The IC50 values for the two most active 
ginsenosides, namely, ginsenoside Rg5 and 20S-ginsenoside Rg3, were 98 µM and 92 
µM respectively. They were found to be more potent than aspirin (IC50 131 µM), thus 
they may serve as potential leads for the development of antiplatelet drugs. As most 
of the saponins studied in this work showed some platelet inhibition activities, the 
overall antiplatelet activities of steamed P. notoginseng may be due to the cumulative 
effects of all the saponins present. The detailed mechanisms for platelet aggregations 
of these active compounds and extracts have to be further explored in order to 
understand their mechanism of action. 
Further ex vivo platelet aggregation studies were carried out, confirming the 
platelet inhibitory activities of both raw and steamed P. notoginseng. This result is 
consistent with that found in the in vitro studies. The inhibitory effects of the steamed 
samples were also demonstrated to be comparable to that of aspirin. This is the first 
study for the comparison of inhibition of platelet aggregation activities in raw and 
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steamed P. notoginseng, together with related Panax species. Several individual 
saponins, such as notoginsenoside R1, 20RS-ginsenoside Rh1, 20R-ginsenoside Rg3, 
ginsenosides Rk3, Rh4, Rk1 and Rg5, were also studied individually for the first time. 
For coagulation studies, it was found that the extracts of raw and steamed P. 
notoginseng prolonged PT and APTT in a dose dependent manner and the coagulation 
times were significantly increased with the extent of steaming. For P. ginseng, P. 
quinquefolium and red ginseng (steamed P. ginseng), the resulting coagulation times 
were significantly shorter than that from raw P. notoginseng at the same concentration, 
showing that P. notoginseng has a better anticoagulation effect than the other Panax 
species. From the results obtained from the different fractions of P. notoginseng, it 
was found that the active components with anticoagulation activities were likely to be 
the less polar components present in butanol and hexane fractions. The individual 
saponins were tested and most were found to show weak or no activities. These 
results indicated that the saponins may not be the main components causing the 
anticoagulant effects. Other components present in P. notoginseng inhibiting blood 
coagulation should be further explored.  
Preliminary assessment on the potential mechanisms of anticoagulation action 
was carried out by determining the thrombin time, reptilase time and fibrinogen, using 
various P. notoginseng extracts. The samples appeared to affect both the intrinsic and 
extrinsic coagulation pathways. However, they neither caused degradation of 
fibrinogen nor promoted the fibrinolytic system, but may have heparin-like effects. 
The detailed mechanisms of the extracts could be further explored. Raw and steamed 
P. notoginseng did not prolong the coagulation times ex vivo, nevertheless, this is the 
first study on their coagulation effects and future studies need to further investigate 
their pharmacokinetics after oral administration. 
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An in vivo haemorrhagic rat model was used to determine the overall 
haemostatic ability. This model provided a measure for screening the overall in vivo 
platelet aggregation and blood coagulation effects. Dencichine was found to shorten 
bleeding time, hence demonstrating in vivo haemostatic activity. Bleeding times were 
prolonged significantly by orally administered raw and steamed P. notoginseng 
extracts when compared to negative controls. Results demonstrated that the steamed 
form was significantly a stronger anti-haemostatic than the raw form, and its effect 
was comparable to that of aspirin at a dosage of 25 mg/kg. This was consistent with 
the results that the raw form contained a higher concentration of dencichine, a 
haemostatic agent. These results indicate that there are many components present in P. 
notoginseng which may have complex and opposing effects. However, from this 
study, the overall effects after oral administration of raw and steamed P. notoginseng 
extracts were found to be anti-haemostatic in vivo. 
The biological studies carried out supported the hypothesis that the changes in 
chemical constituents upon steam processing have significant effects on the biological 
activities, such as platelet aggregation, blood coagulation and haemostasis. These 
studies showed that P. notoginseng, especially the steamed form, would be a useful 
medicinal herb with promising overall antithrombotic activities that may prevent 
thrombosis in patients. The two potent saponins (ginsenoside Rg5 and 20S-
ginsenoside Rg3) may also be promising leads which warrant further detailed 
mechanistic studies. In view of these results, the presence of any important herb-drug 
interactions with clinically used antithrombotic agents would need to be evaluated. 
Healthcare professionals should be cautious about these potential interactions which 
may occur in patients consuming P. notoginseng together with other antithrombotic 
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drugs. Besides antithrombotic activities, other activities such as anticarcinogenic or 
chemopreventive activities may also be worth exploring in the future.  
In conclusion, the quality control of P. notoginseng to ensure proper 
differentiation between its raw and steamed forms is important, as steam processing 
has important implications on its activities. The work in this thesis is one step towards 
understanding botanical medicine. The chemical and biological differences between 
the two different forms of P. notoginseng and related species have been scientifically 
evaluated. Further scientific studies can be carried out to further understand their 
traditional uses, explore other potential new uses for this traditional herb, elucidate the 
mechanism of action and to discover potential new drugs.  
The methods developed in this work can also be extended to the quality 
control of other botanical medicine, to enhance the quality, safety and efficacy of such 
natural remedies. With further understanding of the effects of processing on the 
chemical components and biological activities, the full benefits of botanical medicine 
can be potentially reaped by ensuring high quality and safety, to meet unmet 
therapeutic needs.  
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